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Abstract  
Nicotinic acetylcholine receptors (nAChRs) are a complex class of ligand gated ion 
channels consisting of multiple subtypes with different stoichiometries. Of these, the two 
most commonly found in the brain are the α7 and α4β2 nAChRs. The binding site of 
agonists and competitive antagonists at nAChRs is well established. However, the binding 
site of many allosteric modulators remains unknown. Additionally, despite their 
importance in brain function, the role of specific subtypes and stoichiometries is largely 
unknown. This thesis deals with the synthesis of alkaloid derivatives that can be used to 
establish the binding sites of allosteric modulators and study the role of specific subtypes 
and stoichiometries in the brain. Such information can be used to develop better drugs and 
drug targets for the treatment of neurological diseases. 
Galanthamine and codeine are reported to be positive allosteric modulators at nAChRs. In 
order to establish their binding site, thiol reactive analogues of galanthamine, codeine and 
the structurally similar alkaloid, morphine, were synthesised for use as probes in covalent 
trapping experiments. The α,β-unsaturated ketone derivatives of each alkaloid; narwedine, 
codeinone and morphinone were synthesised along with the codeine mustard and a 
protected derivative of the benzyl chloride analogue of codeine. While the chlorinated 
derivatives were too unstable for use as probes, the α,β-unsaturated ketone derivatives 
were stable in aqueous solution and their reactivity towards thiols was assessed by 
monitoring their reaction with a cysteine derivative. All of the α,β-unsaturated ketone 
derivatives displayed sufficient reactivity for use as thiol reactive probes.  
Methyllycaconitine (MLA) is an antagonist at nAChRs that is known to bind at the α7–α7 
interface of α7 nAChRs and at the α4–α4 and α4–β2 interfaces of α4β2 nAChRs. Small 
bicyclic ester analogues of MLA were synthesised with functional groups targeting key 
residues that are unique to the binding sites at the α4–α4 and α4–β2 interfaces of α4β2 
nAChRs. Esters with the pyridine moiety were synthesised to target an aspartic acid 
residue in the α4–β2 binding site via salt bridge interactions. Esters with the acetamide 
moiety were synthesised to target a tryptophan residue in the α4–α4 binding site via 
hydrogen bonding interactions. Preliminary screening of the esters with both moieties for 
inhibition at α7 and α4β2 nAChRs revealed them to be inhibitors at α4β2 nAChRs, 
particularly (α4)3(β2)2 nAChRs which contain the α4–α4 binding site. 
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Chapter 1: Introduction 
1.1. Nicotinic Acetylcholine Receptors – Structure, Location and Function: 
1.1.1. General Structure: 
Nicotinic acetylcholine receptors (nAChRs) are a class of pentameric ligand-gated ion 
channels composed of five homologous subunits organised around a central pore1-3. They 
are involved in neuron-muscle and neuron-neuron communication. The first nAChR 
subtype studied extensively was isolated from the electric organ of Torpedo marmorata 
consisting of four subunits assigned α, β, γ and δ in order of increasing apparent molecular 
weight4. The receptor structure could be broken down into three domains (Figure 1.1); a 
large extracellular domain (E) consisting of β-strands organised into a β-barrel 
configuration, a membrane spanning domain and a smaller intracellular domain (I) 
consisting of an α-helix from each subunit2,5. Each subunit has four α-helix trans-
membrane domains (M1–M4) arranged such that the M2 domain forms the wall of the 
central pore. An excess of negatively charged groups lines the extracellular and 
intracellular surfaces resulting in a cation stabilising environment that repels anions5. 
 
Figure 1.1: Structure of the muscle nAChR viewed from above (left) and in the  
plane of the cell membrane (right); α, β, γ and δ are the subunits of the muscle  
nAChR, E is the extracellular domain and I is the intracellular domain5 
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Subunits are classed as either α-type or non α-type based on the presence or absence of a 
pair of adjacent cysteine residues, crucial to the formation of the agonist binding site1,2.  
Studies of the Torpedo nAChR by electron microscopy in the closed and open states 
revealed that the α-type subunits exist in a ‘distorted’ state, when compared to the non  
α-type subunits, when the channel was closed2,5. However, binding of agonists such as 
acetylcholine (ACh) causes a local disturbance along with a larger scale conformational 
change to a ‘relaxed’ conformation. The inner M2 domain changes shape, widening the 
pore and allowing the flow of ions.   
The agonist binding site, located at the interface between an α-subunit and an adjacent 
subunit, is made up of a total of 6 loops (A–F) containing the residues that interact with 
agonists6. Three of these loops (A–C) are found on the α-type subunit termed the 
‘principal’ subunit, while the remaining three loops (D–F) are found on the adjacent 
subunit, termed the ‘complementary’ subunit. In addition to the crucial pair of adjacent 
cysteine residues, found at the apex of loop C, five aromatic amino acids are also found in 
the agonist binding site forming what is known as the ‘aromatic cage’. These include three 
tyrosines (Tyr) and one tryptophan (Trp) from the ‘principal’ subunit and one tryptophan 
from the ‘complementary’ subunit (Trp). Acetylcholine and related agonists such as 
carbamoylcholine are able to interact with these residues through cation-π interactions 
between the quaternary ammonium ion and the electron-rich aromatic rings (Figure 1.2). 
 
Figure 1.2: Five aromatic amino acids forming the ‘aromatic cage’; three tyrosines (Tyr) 
and two tryptophans (Trp), carbamylcholine is also shown in white, image generated from 
X-Ray crystallography data7, Lymnaea stagnalis AChBP, PDB Code 1UV6, using PyMol  
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Further insight into the structure of the agonist binding site was obtained with the 
discovery of the ACh binding protein (AChBP) isolated from snails (Lymnaea stagnalis) 
and sea slugs (Aplysia californica). The AChBP is a soluble homopentamer released by 
these species in response to increased ACh levels in the synaptic cleft. It resembles the 
extracellular domain of nAChRs providing a good model for the agonist binding site of 
nAChRs2,6. It is most closely related to the human α7 nAChR, sharing 24% sequence 
identity in the ligand binding domain. 
The binding site of the AChBP is found in cavities at the interface between subunits 
formed from three loops on the ‘principal’ face of one subunit and three loops on the 
‘complementary’ face of the adjacent subunit. There are five of these cavities per 
pentamer, located close to the outer edge of the ring (Figure 1.3)6. The key residues, 
including those that constitute the ‘aromatic cage’ and the pair of adjacent cysteine 
residues, are conserved between the agonist binding site of nAChRs and the binding site of 
the AChBP. As such, the AChBP exhibits similar ligand specificity to that of nAChRs 
binding known agonists such as ACh and nicotine as well as antagonists such as 
methyllycaconitine (MLA)6.  
 
Figure 1.3: Structure of the agonist binding site  
in the AChBP, adapted from Brejc, K. et. al.6 
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1.1.2. Muscular vs. Neuronal nAChRs: 
Since the analysis of nAChRs from Torpedo marmorata, a total of 17 distinct subunits 
have been identified. Different combinations of subunits give rise to differing functionality 
and affinity for certain agonists and antagonists. The different nAChRs that result can be 
classified based on their location in the body, as muscular or neuronal. 
 
Figure 1.4: Muscle nAChRs at the neuromuscular junction, adapted from Physioweb8 
Muscular nAChRs are found in skeletal muscles at the neuromuscular junction (Figure 1.4) 
where they mediate neuromuscular transmission by allowing the passage of ions to 
generate an action potential9. This action potential is propagated along the muscle fibres 
causing the muscle to contract. There are two subtypes of muscular nAChRs (Figure 1.5), 
foetal and adult. Foetal muscular nAChRs, like the Torpedo nAChRs, consist of two α1 
subunits and one each of β1, γ and δ subunits2-4,9. In adult muscular nAChRs the γ subunit 
is replaced with a ε subunit.   
 
Figure 1.5: The two subtypes of muscular nAChRs, foetal (left) and adult (right) 
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Neuronal nAChRs are found in the central and peripheral nervous systems as well as in 
some non-neuronal tissues. Neuronal nAChR subtypes are composed of different subunits 
and are denoted by their composition, for example α7. Unlike muscular nAChRs, there are 
a significant number of different neuronal nAChR subtypes owing to the many subunits 
expressed. There are twelve known neuronal nAChR subunits, nine α-type (α2–α10) and 
three non α-type (β2–β4). Two different classes of receptor (Figure 1.6) can be formed 
from these subunits, namely homomeric and heteromeric pentamers2-4,9,10. Homomeric 
pentamers are made up of five of the same α-type subunit (α7, α9 or α10). Heteromeric 
pentamers are made up of α-type (α2 – α6) and non α-type subunits usually of the form 
(αx)2(βy)33. By far the most common subtypes found in the brain are the homomeric α7 and 
the heteromeric α4β2 nAChRs. These receptors are commonly differentiated by their 
affinity for different ligands with α4β2 nAChRs characterised by high affinity for nicotine 
and α7 characterised by high affinity for α-bungarotoxin (α-BTX). 
 
Figure 1.6: The two types of neuronal nAChRs, heteromeric (left) and homomeric (right) 
The role of neuronal nAChRs in the body is not as well understood as muscular nAChRs, 
because of the significant number of different receptor subtypes and the lack of subtype 
specific agonists and antagonists to study them10. However, they are believed to modulate 
the release of neurotransmitters and influence physiological functions including sleep, 
anxiety and several cognitive functions10. As a consequence of the diversity of neuronal 
nAChR subtypes and their roles they are implicated in a variety of neurological conditions9 
including addiction, schizophrenia, Alzheimer’s disease and epilepsy.  
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1.1.3. Ligand Binding: 
Nicotinic acetylcholine receptors can exist in three distinct states; resting, active and 
desensitized (Figure 1.7). Receptors alternate between these three states via conformational 
changes in response to ligand binding. In the absence of an agonist such as acetylcholine, 
receptors are predominantly in the resting state. In this state the ion channel is closed but 
the receptor is responsive to the application of an agonist. When an agonist is bound to the 
receptor the proteins are stabilised in a conformation in which the ion channel is open. If 
the agonist is allowed to remain for too long, the receptor undergoes a conformational 
change to the desensitized state in which the ion channel is again closed but the agonist 
remains bound. When the agonist is removed the receptor eventually reverts to the resting 
state. The equilibria between the resting, active and desensitised states can be shifted by 
binding of allosteric modulators. For example positive allosteric modulators, discussed 
later in this chapter, can cause a shift in the equilibrium from the closed states to the active 
state in the presence of an agonist.  
 
Figure 1.7: The three states of nAChRs 
  
6 
 
                                                                                                                                 Chapter 1 
 
The equilibrium established when a ligand (L) binds to a receptor (R) to generate a 
complex (L•R) is defined as follows: 
L + R L R  
The equilibrium constant (Kd) for the reverse reaction is commonly used to describe the 
affinity of that ligand for the receptor (i.e. how well the ligand binds to the receptor). A 
low value for Kd corresponds to a high affinity. It has units of concentration and is 
calculated as follows: Kd = [L ∙ R][L][𝑅𝑅] 
Where [L], [R] and [L•R] are concentrations of the ligand, receptor and ligand-receptor 
complex respectively. The value of Kd also corresponds to the ligand concentration at 
which half the receptor population will be occupied (i.e. [R] = [L•R]). The affinity of a 
ligand for a receptor is commonly measured by carrying out direct binding assays 
(measuring Kd) or competition binding assays (measuring the inhibition constant, Ki) with 
radiolabelled ligands. Because desensitisation is fast relative to the time-scale of binding 
assays, the affinity measured in this manner reflects binding in the desensitised state rather 
than the active state. The values estimated by binding assays will generally also be lower 
than those corresponding to binding in the active state because the desensitised state has a 
higher affinity for agonists.   
The response a receptor has to binding of a ligand can be described in terms of efficacy 
and potency. Efficacy is the maximum possible response that a ligand can elicit from the 
receptor. Potency is a measure of the concentration of ligand required to elicit a response 
of a given magnitude. Potency is generally quantified as the agonist concentration required 
to elicit half of the maximum response (EC50), or the antagonist concentration required for 
50% inhibition (IC50). The EC50 value for an agonist is generally much lower than the Kd 
or Ki value estimated from binding assays, sometimes by orders of magnitude, reflecting 
the fact that EC50 values correspond to binding in the active state. This binding perturbs the 
equilibrium between resting and active states leading to a functional response that can be 
detected.   
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1.2. Agonists, Antagonists and Allosteric Modulators: 
1.2.1. Acetylcholine: 
O
N
O
 
Figure 1.8: Chemical structure of ACh 
Acetylcholine (ACh) is an endogenous neurotransmitter acting on nicotinic (nAChR) and 
muscarinic (mAChR) acetylcholine receptors in the central and peripheral nervous system. 
As the name suggests it is the ester formed between choline and acetic acid (Figure 1.8). It 
is synthesised in nerve cells via reaction between choline and acetyl coenzyme A, 
catalysed by the enzyme choline acetyl transferase. Acetylcholine is then released from 
nerve cells into the extracellular space where it can interact with nAChRs on nearby cells. 
It is later removed from the extracellular space by acetylcholinesterase (AChE) catalysed 
hydrolysis back to choline, which is then transported back into the nerve. 
When ACh acts on a homogenous receptor population consisting of a single type of 
binding site, a monophasic response is observed and a plot of this response to ACh against 
the dose follows a sigmoidal curve (Figure 1.9). Alternatively, when ACh acts on a 
receptor population consisting of two different types of binding site, a biphasic response 
may be observed and a plot of this response to ACh against the dose gives rise to a curve 
with two sigmoidal regions corresponding to the two different binding sites. This can occur 
when the receptor population is heterogeneous, consisting of two different receptors or 
when the population is homogenous where the receptors contain two different binding 
sites. The effect is only clearly seen if there is a significant difference in the potency of the 
agonist at the two binding sites leading to a difference in their sensitivity to agonist 
binding.     
 
Figure 1.9: Monophasic and biphasic response curves 
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Figure 1.10: The stoichiometries of α4β2 receptors, (α4)2(β2)3 (left) and (α4)3(β2)2 (right) 
Of the two predominant nAChR subtypes present in the nervous system, the α4β2 receptors 
display the most interesting response to ACh. It is known that α4β2 receptors exist in two 
stoichiometries, and both appear to be naturally expressed in the human brain11. These are 
the high sensitivity (α4)2(β2)3 form and the low sensitivity (α4)3(β2)2 form (Figure 1.10). 
As a result, when studying the response of α4β2 receptor populations to ACh, a biphasic 
dose-response curve is observed reflecting, in part, these mixed populations.  
 
Figure 1.11: Dose-response curves for α4β2 receptor populations of the (α4)2(β2)3 form 
(white squares) and (α4)3(β2)2 form (black squares), adapted from Harpsoe, K. et. al.11 
The response of individual nAChR stoichiometries can also be studied by controlling 
receptor expression in vitro. While receptor populations consisting solely of the (α4)2(β2)3 
form give rise to a monophasic response, receptor populations of the (α4)3(β2)2 form give 
rise to a biphasic response (Figure 1.11) suggesting that this form contains high and low 
sensitivity binding sites11. In addition to the two high sensitivity ACh binding sites found 
at the α4-β2 interfaces, the (α4)3(β2)2 form has a low sensitivity ACh binding site at the 
α4-α4 interface. Activation of the α4-α4 in addition to the α4-β2 binding sites gives rise to 
a higher response but this is not evident in the dose-response curves since the responses are 
normalised (Figure 1.11). It has been hypothesised that the lower sensitivity of the 
(α4)3(β2)2 form results from the need for agonist binding at the α4-α4 interface to fully 
activate the receptor11. By targeting the α4-α4 interface, ligands could be developed that 
selectively inhibit or modulate agonist activity at α4β2 receptors of the (α4)3(β2)2 
stoichiometry.   
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1.2.2. Agonists: 
An agonist is any compound that binds to a receptor to elicit a response. An agonist is a 
full agonist if it elicits the maximal possible response from the receptor, defined relative to 
an agonist such as ACh. Alternatively, it is a partial agonist if it elicits a fraction of the 
maximal response. In general, agonists of nAChRs contain common key features which 
have enabled the development of a pharmacophore model. The initial model developed by 
Beers and Reich 12 was based on the structure of ACh and compared the structures of other 
agonists and antagonists. Two key features were identified, a cationic nitrogen involved in 
cation–π interactions with the previously discussed ‘aromatic cage’, and a hydrogen bond 
acceptor separated by a distance of approximately 5.9 Å (Figure 1.12). 
 
Figure 1.12: Pharmacophore model developed by Beers and Reich12 
 applied to nicotine (left) and ACh (right) 
More recently, Nicolotti et al.13 analysed a selection of 11 agonists with sufficient 
structural variation to develop an updated pharmacophore model. The two key features 
identified by Beers and Reich are included in the model along with a hydrophobic centre 
generally occupied by aliphatic rings. The hydrogen bond acceptor identified by Beers and 
Reich is defined in this model as the lone pair of either a pyridyl nitrogen or a carbonyl 
oxygen. It has recently been determined that this hydrogen bond is formed with a backbone 
-NH, often through a water molecule14. A selection of nAChR agonists, both natural and 
synthetic, is shown in Figure 1.13 on the following page. 
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Figure 1.13: Selection of natural and synthetic nAChR agonists 
Nicotine (1) is the main alkaloid in tobacco responsible for its addictive effects, and is the 
prototypic agonist of nAChRs15,16. It acts on all subtypes of nAChRs, although of the two 
most prominent subtypes it has a significantly greater binding affinity at α4β2 receptors  
(Ki = 1–11 nM) where it is a potent full agonist (EC50 = 1 μM)16. Long-term exposure of 
α4β2 receptors to nicotine (1) results in an increase in the number of receptors in a process 
known as upregulation2,17. Additionally, the exposure causes a shift in assembly from the 
(α4)3(β2)2 form to the (α4)2(β2)3 form18. Varenicline (2), a smoking cessation aid sold 
under the tradename Champix, is a partial agonist (45% efficacy) with significantly higher 
binding affinity at α4β2 receptors (Ki = 110–170 nM) than other nAChR subtypes19.   
Epibatidine (3), a toxin secreted by various species of poison dart frogs, is the most potent 
nAChR agonist known. It is approximately 100 times more potent than ACh at α4β2 
receptors (EC50 = 4–20 nM)16. Like ACh, the dose-response curve obtained for brain α4β2 
receptor populations is biphasic suggesting mixed populations and differences in its action 
on the two stoichiometries expressed20. The upregulation effect seen after exposure to 
nicotine (1) is not found after exposure to epibatidine (3). While it is also an agonist at α7 
receptors, it has greater binding affinity at α4β2 receptors (Kd = 19 pM)16.  
  
11 
 
Chapter 1  
 
Other natural agonists such as cytisine (4) and anatoxin-A (5) generally show this same 
trend in binding affinity16. One natural agonist which doesn’t conform to the same trend in 
binding affinity is choline (6), a selective agonist for the α7 receptor21. It has 10-fold lower 
potency than ACh at the α7 receptor (EC50 = 1.6 mM)16 but is a full agonist. This suggests 
that the carbonyl oxygen of ACh may not be necessary for agonist binding at the α7 
receptor.  
The synthetic compound AR-R17779 (7), a conformationally restricted analogue of ACh, 
is another agonist that is selective for the α7 receptor. It has more than 100 times greater 
binding affinity at the α7 receptor (Ki = 92 nM) than at the α4β2 receptor22. Studies on 
analogues of AR-R17779 (7) reveal that replacement of the proton on the carbamate 
nitrogen with an alkyl group dramatically increased the binding affinity at α4β2 receptors 
whilst simultaneously decreasing the binding affinity at the α7 receptor. This suggests a 
lipophilic pocket may be present in the binding site of the α4β2 receptor that is not present 
in the α7 receptor binding site. 
Sazettidine-A (8), is a synthetic nAChR agonist, selective for the α4β2 receptor. It was 
originally thought of as a ‘silent desensitiser’ causing desensitisation of receptors without 
activating them23. However, more recent studies have revealed it is an agonist at α4β2 
receptors with different activity at the two stoichiometries. It is a full agonist on the 
(α4)2(β2)3 form, but only a partial agonist on the (α4)3(β2)2 form (6% efficacy)24. The same 
upregulation effect noted after exposure to nicotine (1) is also found after exposure to 
sazettidine-A (8)23. 
In addition to the agonists discussed here there are numerous other agonists of nAChRs 
and these have been reviewed extensively in the literature13-16,25.   
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1.2.3. Antagonists: 
 
Figure 1.14: Dose-Response curves reflecting the effect of competitive antagonists (left) 
and non-competitive antagonists (right) on the response to agonist binding. 
An antagonist is any compound that binds to a receptor without eliciting a response, but in 
doing so it blocks the response elicited by an agonist. Antagonists can be either 
competitive or non-competitive depending on their effect on agonist binding  
(Figure 1.14). Competitive antagonists (surmountable) are those which can be overcome 
by increasing the agonist dose. Non-competitive antagonists (insurmountable) are those 
which cannot be overcome by increasing the agonist dose. In the case of competitive 
antagonists the effect on the dose-response curve is a shift to the right such that the agonist 
maintains efficacy at higher doses. In the case of non-competitive antagonists the effect is 
a shift downward such that the agonist shows lower efficacy. In general, competitive 
antagonists bind at the same site as agonists and therefore conform to the agonist 
pharmacophore model. As non-competitive agonists generally bind at a different site to 
agonists they do not conform to the agonist pharmacophore model.  
Some of the most potent and selective nAChR antagonists are peptide based neurotoxins 
found in venoms including α-bungarotoxin from the Taiwanese Banded Krait and the  
α-conotoxins from Conus snails15,16,26. α-Bungarotoxin, consisting of 75 amino acids, is a 
selective antagonist at the α7 nAChR that does not appear to interact with heteromeric 
nAChRs such as the α4β2 subtype. Similarly, the α-conotoxins, consisting of 14-17 amino 
acids, are selective towards specific subtypes of receptor. For example, α-conotoxin ImI is 
a selective antagonist of the α7 nAChR. Some non-peptidic antagonists are shown in 
Figures 1.15 and 1.16. 
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Figure 1.15: Selection of competitive nAChR antagonists  
Dihydro-β-erythroidine (DHBE, 9) and erysodine (10) are alkaloids found in the seeds of 
Erythrina species26,27. Erysodine (10) is a more selective antagonist of neuronal nAChRs 
over muscle nAChRs when compared with DHBE (9)27. Erysodine (10) has greater 
binding affinity than DHBE (9) at α4β2 receptors (Ki = 5 nM vs 35nM) and, to a lesser 
extent, at α7 receptors (Ki = 4 μM vs 9 μM)26. Strychnine (11), a potent convulsant known 
for its action as a glycine receptor antagonist, is a potent competitive antagonist at the α7 
nAChR (IC50 = 1.9 μM, Ki = 1.1 μM)), and a non-competitive antagonist at the α4β2 
nAChR (IC50 = 118 μM)28. d-Tubocurarine (12), an alkaloid from the bark of the 
Chondodendron tomentosum plant used as an arrow poison, is a non-selective antagonist 
active at muscle and neuronal nAChRs26. Methyllycaconitine (MLA, 13) from the 
Delphinium brownii plant is one of the most potent competitive antagonists at the α7 
nAChR (IC50 = 140 pM, Ki = 1 nM)15,29 that also acts as an antagonist at the α4β2 
receptor26. A more detailed analysis of MLA and its analogues is covered in chapter 3. 
Lobelline (14), an alkaloid found in Indian tobacco, was originally considered an nAChR 
agonist as it stimulates the release of dopamine26,30. However, more recent evidence shows 
that this stimulation is not nAChR mediated and it acts as an nAChR antagonist.  
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Figure 1.16: Selection of non-competitive nAChR antagonists 
Mecamylamine (15), originally developed as a ganglionic blocker to treat hypertension, is 
the archetypal non-competitive antagonist for neuronal nAChRs15,16,31. It inhibits activity at 
most subtypes of neuronal nAChRs functioning as an open channel blocker as evidenced 
by its voltage-dependent antagonism31. The upregulation effect noted following chronic 
exposure to nicotine (1) also occurs following chronic exposure to mecamylamine (15)32. 
Other compounds, originally designed as ganglionic blockers for the treatment of 
hypertension, also function as non-selective non-competitive antagonists at nAChRs and 
include hexamethonium (16) and chlorisondamine (17)15,16. Racemic bupropion (18), 
originally developed as an antidepressant and now used as a smoking cessation aid, is a  
non-competitive antagonist at α4β2 and α7 nAChRs that does not appear to act within the 
channel pore15,16,33. Additionally, dissociative anaesthetics such as phencyclidine (19) and 
(S)-ketamine (20) and steroids such as progesterone (21) and testosterone (22) have also 
been reported as non-competitive antagonists at neuronal nAChRs15,16. 
  
15 
 
Chapter 1  
 
1.2.4. Allosteric Modulators: 
Allosteric modulators are compounds that bind to sites other than the agonist binding site 
to alter the response to agonist binding. Positive allosteric modulators (PAMs) increase the 
response at a given agonist concentration, while negative allosteric modulators (NAMs) 
decrease the response. They can alter the efficacy of the agonist resulting in an upward 
(PAM) or downward (NAM) shift in the dose-response curve. Alternatively, they can alter 
the affinity of the agonist for the receptor resulting in a shift in the dose-response curve to 
the left (PAM) or right (NAM). Non-competitive antagonists, discussed in the previous 
section, are negative allosteric modulators that affect the efficacy of the agonist without 
affecting the affinity. Negative allosteric modulators that affect the affinity of the agonist 
have a similar effect to competitive antagonists but can be distinguished from these based 
on the fact that they do not compete with the agonist for binding. A selection of positive 
allosteric modulators of nAChRs, both natural and synthetic, is shown in Figure 1.17 
below. 
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Figure 1.17: Selection of nAChR positive allosteric modulators 
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Galanthamine (23) and physostigmine (24) are AChE inhibitors that are reported to act as 
positive allosteric modulators of α4β2 and α7 nAChRs15,16,34. They increase the affinity of 
ACh for the receptors without affecting the efficacy35. Despite interest in their activity at 
nAChRs the binding site remains unknown. A more detailed analysis of the effect of 
galanthamine on nAChRs is covered in Chapter 2. Codeine (25), an opioid with a chemical 
structure similar to that of galanthamine has the same effect on nAChRs without the 
inhibition of acetylcholinesterase15,16,35. Desformylflustrabromine (26) is a positive 
allosteric modulator, selective for the α4β2 receptor, which acts to increase the maximum 
response that can be elicited by acetylcholine36. It has the opposite effect at α7 nAChRs 
where it acts as an inhibitor. 5-Hydroxyindole (27), a metabolite of serotonin, is a positive 
allosteric modulator that is selective for the α7 receptor, increasing the efficacy of 
acetylcholine37. The synthetic compound, NS9283 (28), selectively modulates heteromeric 
nAChRs, including the (α4)3(β2)2 receptor, but not the (α4)2(β2)3 receptor38,39. Like 
galanthamine and physostigmine, it increases the affinity of acetylcholine without affecting 
the efficacy. While the majority of naturally synthesised steroids act as antagonists of 
neuronal nAChRs, estradiol (29) is a positive allosteric modulator at the α4β2 receptor34,40. 
Its effects on α7 nAChRs have not been established.  
Nicotinic acetylcholine receptors are a complex class of receptors consisting of multiple 
subtypes with different stoichiometries. While the binding site of agonists and competitive 
antagonists at nAChRs has been studied extensively, the binding sites of allosteric 
modulators such as those described in this section generally remains unknown. Chapter 2 
of this thesis deals with work developing analogues of galanthamine (23) and codeine (25) 
that can be used to establish their binding site at nAChRs. An understanding of the role of 
specific subtypes and stoichiometries in the brain requires subtype and stoichiometry 
specific ligands. Chapter 3 of this thesis deals with work developing ligands that bind 
selectively to either the (α4)2(β2)3 or the (α4)3(β2)2 stoichiometry of the α4β2 nAChR.   
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Chapter 2: Investigating the binding site of Codeine and Galanthamine 
2.1. Introduction: 
2.1.1. Galanthamine:  
Galanthamine (23) is an alkaloid present in many plant species from the Amaryllidaceae 
family including Galanthus, Narcissus and Leucojum. It was first isolated by Proskurnina 
and Yakovlena in 1952 from the Caucasian snow drop (Galanthus woronowii)41. The 
chemical structure was determined, with the incorrect stereochemistry, by Uyeo and 
Kobayashi in 195642. The structure was confirmed, and the stereochemistry was corrected, 
when galanthamine (23) was synthesised for the first time by Barton and Kirby43 in an  
8-step synthesis culminating in the reduction of (–)-narwedine (30) to a separable mixture 
of (–)-galanthamine (23) and (–)-epigalanthamine (31) with lithium aluminium hydride 
(Scheme 2.1). Since then there have been numerous attempts to improve upon this 
synthesis such that it would be viable to prepare (–)-galanthamine (23) on an industrial 
scale44. The reduction of narwedine (30) can be completed stereoselectively to afford 
galanthamine (23) as the sole product using L-selectride45. 
O
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HO30 23
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HO 31
+LiAlH4
 
Scheme 2.1: Reduction of (–)-narwedine to (–)-galanthamine and (–)-epigalanthamine 
During initial studies into the synthesis of galanthamine (23) by Barton and Kirby43 an 
interesting method to obtain enantiomerically pure narwedine (30) was discovered. When 
crystallising (–)-narwedine (30) prepared from (–)-galanthamine (23) the sign and 
magnitude of the optical rotation of the material obtained was dependent on the solvent 
used. When crystallising from acetone a product with a negative optical rotation was 
obtained corresponding to (–)-narwedine (30). However, when crystallising from ethanol a 
positive optical rotation was obtained, corresponding to (+)-narwedine (30a).  
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Figure 2.1: Racemisation of narwedine (30) via an intermediate dienone 
In protic solvents such as ethanol, narwedine (30) can racemise via an intermediate 
dienone as shown in Figure 2.1 above. It was therefore hypothesised that during 
crystallisation from ethanol narwedine (30) racemised completely. This hypothesis was 
confirmed by crystallising racemic narwedine (30 + 30a) from ethanol with  
(–)-galanthamine (23) in a 2:1 ratio to obtain pure (+)-narwedine (30a). As crystallisation 
proceeded, traces of (–)-galanthamine (23) remaining after oxidation induced separation of 
(+)-narwedine (30a) from the racemate giving crystals of (+)-narwedine (30a)43. This is 
believed to result from (–)-galanthamine (23) interacting with (–)-narwedine (30) 
preventing it from crystallising. It has since been demonstrated that only traces of either 
enantiomer of galanthamine (23) are needed to obtain high yields of enantiomerically pure 
narwedine (30 or 30a)45 by a dynamic kinetic resolution process. Furthermore, racemic 
narwedine (30 + 30a) can be seeded with a small amount (1%) of the desired enantiomer of 
narwedine (30 or 30a) instead of galanthamine (23) as in the industrial synthesis 46. In this 
process, crystallisation of the added enantiomer is induced in preference to the other 
enantiomer. Galanthamine (23) is currently obtained either industrially46, or isolated from 
Narcissus or Leucojum species in addition to the original Galanthus species. 
Galanthamine (23) was initially used in Eastern European countries as a curare reversal 
agent in anaesthetic practice and to assist in recovery from paralysis associated with 
poliomyelitis and other neuromuscular disorders47-49. Once it was established that 
galanthamine (23) could penetrate the blood-brain barrier its use in the treatment of 
neurological disorders associated with decreased cholinergic transmission, particularly 
Alzheimer’s disease, was investigated. Galanthamine (23) is currently approved to treat the 
symptoms of Alzheimer’s disease in many countries world-wide, including Australia50.   
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Galanthamine (23) is reported to have a dual mode of action on the cholinergic system 
with the overall effect of increasing nAChR activity44,47. It increases ACh levels by 
competitively inhibiting AChE, the enzyme responsible for breaking down ACh  
(IC50 ≈ 3 μM)51. At low concentrations (0.02-2 μM), it is also reported to act as a positive 
allosteric modulator increasing the response of neuronal nAChRs to ACh. Galanthamine 
(23) binds to pre-synaptic and post-synaptic nAChRs increasing their sensitivity to ACh. 
Since pre-synaptic nAChRs are involved in the release of neurotransmitters, including 
ACh, galanthamine (23) has the additional effect of enhancing the release of 
neurotransmitters such as ACh. At higher concentrations (>10 μM) galanthamine (23) acts 
as an inhibitor at nAChRs52. 
The binding site of galanthamine (23) on the AChE enzyme is well established. As a 
competitive inhibitor it binds in the same location as ACh. Crystal structures have been 
obtained for galanthamine (23) bound to Torpedo californica acetylcholinesterase 
(TcAChE)53 and recombinant human acetylcholinesterase (rhAChE)54 demonstrating that it 
interacts with the choline binding site and the acyl-binding pocket to prevent ACh from 
binding to the enzyme. However, since galanthamine (23) acts as a positive allosteric 
modulator at nAChRs, its binding site at these receptors is more difficult to locate. While 
there have been numerous studies into potential binding sites of galanthamine (23) at 
nAChRs a definitive binding site has not yet been determined.   
An X-ray crystal structure of galanthamine (23) bound to the AChBP has been obtained, 
demonstrating that galanthamine (23) binds in the same region as ACh55. However, it was 
noted that galanthamine (23) did not interact with the pair of adjacent cysteine residues in 
the C-loop of the binding site that are crucial for agonist binding. Mutants of the AChBP, 
with these cysteine residues replaced by alanine or serine, were prepared and binding 
studies were carried out with agonists and allosteric ligands, including galanthamine (23). 
While agonists like ACh showed a significant reduction in binding affinity for these 
mutants when compared with the wild type, there was no change observed with allosteric 
ligands. Based on these findings it was suggested that galanthamine (23) and other 
allosteric ligands may bind at interfaces not containing the principle face of the α-subunit 
of heteromeric nAChRs55. The residues that galanthamine (23) was found to interact with 
are still present at these interfaces but the pair of cysteine residues are not.  
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Blind docking experiments have also been used to gain insight into potential binding sites 
for galanthamine (23) and other allosteric modulators at nAChRs. Studies on the AChBP 
identified three potential binding sites for galanthamine (23), physostigmine (24) and 
codeine (25), within the channel pore56. Two were located close to the agonist binding site 
(I and II), the third was located further down in a region corresponding to just above the 
transmembrane domain in functional receptors (III) as shown in Figure 2.2 below.  
 
Figure 2.2: Location of potential binding sites of galanthamine identified by blind  
docking studies on the inner (left) and outer (right) surfaces of two adjacent residues  
of the AChBP. ACh is shown in the agonist binding site in black. Image generated  
from X-Ray crystallography data57 PDB Code 3WIP, using PyMol 
Following further modelling studies on the AChBP and the extracellular domain of human 
α7 and α4β2 nAChRs another two potential binding sites on the outer surface were 
identified in addition to the agonist binding site58. Both sites were at the interface between 
two subunits, one was above the agonist binding site (IV), the other was below (V) as 
shown in Figure 2.2 above. Based on studies with an antibody known to inhibit the binding 
of galanthamine (23) and other nAChR allosteric modulators59, the lower binding site on 
the outer surface of the protein (V) was identified as the most likely binding site of those 
identified by blind docking experiments.  
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More recently, photolabelling studies with [3H]galanthamine and [3H]physostigmine were 
employed to directly identify amino acids contributing to their binding sites on the  
muscle-type Torpedo nAChR60. Based on these studies three binding sites were identified 
for galanthamine (23) and physostigmine (24) in the presence of agonist  
(Figure 2.3). These were at the δ-β interface at a site equivalent to the benzodiazepine 
binding site in GABAA receptors (I) and at the α-γ interface in the entry to the agonist 
binding site (II) and within the ion channel near the level of the agonist binding site (III). 
Additionally, in the absence of agonist, these ligands were found to bind in the α-δ agonist 
binding site (IV). 
 
Figure 2.3: Location of binding sites of galanthamine (23) and physostigmine (24)  
on the muscle-type Torpedo nAChR, physostigmine (24) is shown in pink at each  
binding site, adapted from Hamouda, A.K. et.al.60 
While the results of these studies provide some insight into the binding site locations of 
galanthamine (23) and other nAChR positive allosteric modulators they do not definitively 
establish the binding site at neuronal nAChRs, especially the α7 and α4β2 receptors. 
Identification of the binding site at these receptors would aid in the development of a 
proposed mechanism of allosteric modulation and allow for the design of more effective 
allosteric modulators. Photoaffinity labelling, as applied in the study of the muscle type 
Torpedo nAChR60, is limited by the fact that photoreactive ligands only photolabel certain 
residues. For example, [3H]galanthamine only photolabeled tyrosine and cysteine residues. 
A more promising method is covalent trapping which is an extension of the substituted 
cysteine accessibility method. The technique has already been successfully applied to 
identify the binding site of small analogues of MLA (13) at nAChRs61,62, and to 
demonstrate that MLA (13) binds at the α7-α7 interface of α7 nAChRs62 and at the α4-α4 
interface of α4β2 nAChRs29.      
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2.1.2. Substituted Cysteine Accessibility Method: 
The substituted cysteine accessibility method (SCAM) is a technique for studying protein 
structure that was originally developed to locate the residues lining the ion channel of 
nAChRs within the membrane spanning segment of the receptor63. Consecutive residues in 
the protein are mutated, in turn, to cysteine and the resulting mutants are exposed to small, 
hydrophilic, thiol reactive compounds such as 2-aminoethylmethanethiosulfonate 
(MTSEA, 32). When these thiol reactive compounds encounter a cysteine residue, they 
form a covalent bond with the thiol as shown in Figure 2.4.  
S
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O
O
NH3
S S S
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O
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32   
Figure 2.4: Reaction of MTSEA (32) with ionised cysteine residues 
In a membrane-embedded channel protein, the cysteine residues introduced will be in one 
of three regions: the water accessible surface, the lipid accessible surface or the protein 
interior. The lining of the channel is part of the water accessible surface and in the 
membrane spanning domain it is the only water accessible surface. At the lipid accessible 
surface and within the protein interior, deprotonation of the thiol is suppressed as a result 
of the low dielectric constant of these environments64. Since the thiol reactive compounds 
are generally electrophilic, the reaction is significantly faster with the ionised form of the 
thiol (-S–) than with the non-ionised form (-SH). This, in combination with the partitioning 
of the generally charged reagents within water rather than the lipid region, results in a 
significantly greater rate of reaction at the water accessible surface.  
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The formation of a covalent bond is generally detected as an irreversible change in the 
function of the receptor64,65. In the case of residues lining the channel pore a decrease in 
response to agonist binding is often observed, as detected by electrophysiology 
experiments, resulting from the introduced bulk attached to the cysteine residue restricting 
the flow of ions through the channel (Figure 2.5). However, it is theoretically possible that 
the covalent attachment does not induce a measurable effect on receptor function. 
Therefore the fact that receptor function remains unchanged following exposure to the thiol 
reactive compound is not necessarily an indication that the mutated residue is not in the 
water accessible region.  
 
Figure 2.5: Blocking effect of the increased bulk introduced within the channel as  
a result of the reaction between cysteine residues in the channel and MTSEA (32)  
Endogenous cysteine residues located in the water accessible regions of a protein may also 
impact on the results of experiments with cysteine mutagenesis. If covalent attachment of 
thiol reactive compounds to endogenous cysteine residues results in a measurable change 
in receptor function it may be necessary to engineer a pseudo wild-type protein with the 
endogenous cysteine residues replaced with a suitable, less reactive residue such as alanine 
or serine64,65. 
Since each substitution can have significant effects on the structure and function of a 
receptor it is necessary to assay the function of mutant receptors prior to experiments with 
thiol reactive compounds. If a mutant has near wild-type functionality it is likely that the 
3D structure of the mutant receptor is close to that of the wild-type receptor. It is then 
assumed that the introduced cysteine is in nearly the same location in 3-dimensional space 
as the original residue.  
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The technique can also be extended to determine residues within ligand binding sites65. 
When a covalent bond is formed at a cysteine residue within a ligand binding site, the 
introduced bulk associated with the covalent attachment will generally prevent ligand 
binding through steric blockade. In this manner an irreversible change to the binding of a 
ligand to a receptor indicates that the mutated residue is likely to reside in the binding site 
of that ligand. However, binding of the thiol reactive compound in a different region to the 
ligand can lead to a conformational change that reduces ligand binding. If the ligand is 
already in the binding site when the thiol reactive compound is introduced, the ligand will 
protect any cysteine residues in the binding site preventing covalent attachment. While a 
protecting effect resulting from ligand binding may indicate that a particular residue 
resides in the binding site, the possibility that allosteric effects associated with the ligand 
binding at some distance from a particular cysteine residue result in that residue being 
obscured cannot be ruled out65. Ligands may protect residues located deep within a binding 
pocket by binding above the residues blocking entry of thiol reactive compounds. 
Alternatively, binding of the ligand may result in a conformational change in the protein 
that obscures the residue of interest.  
Residues contributing to the binding site of a ligand can be more reliably determined by 
using thiol reactive analogues of the ligand. If the analogue is close enough in structure to 
the ligand it will bind in the same location as the ligand and may even retain the same 
biological effect. Once bound, the analogue can react with appropriately placed cysteine 
residues forming a covalent bond that traps the analogue within the binding site. To 
effectively distinguish cysteine residues within the binding site from those in other water 
accessible regions of the protein the analogue must not react too quickly. If the reaction is 
too fast the analogue will react with water accessible cysteine residues before it has the 
chance to bind in the ligand binding site. As a result the analogue may be trapped by a 
cysteine residue that is nowhere near the binding site of the original ligand. However, this 
is more of an issue in the traditional application of SCAM where higher concentrations of 
the methanethiosulfonate reagents (in the mM range) are required. For thiol reactive ligand 
analogues, their affinity for the receptor binding site allows for much lower concentrations 
to be used thereby limiting the non-selective reaction. 
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Figure 2.6: Covalent trapping of MLA maleimide 33 with cysteine. 
This covalent trapping technique has been applied to demonstrate that MLA (13) binds at 
the agonist binding site of α7 nAChRs62, and at the α4–α4 binding site of α4β2 nAChRs29, 
a binding site that had not previously been proposed for MLA (13). Reactivity towards 
thiols was induced by replacing the succinimide ring with a maleimide ring giving 
analogue maleimide 33. Mutants of the α7 and α4β2 nAChRs with a free cysteine residue 
in the respective binding sites were exposed to a solution of analogue maleimide 33. The 
free cysteine residue reacted with analogue maleimide 33 via conjugate addition  
(Figure 2.6) trapping it within the binding site. This was observed as an irreversible 
reduction in the current elicited by ACh applied to the receptors after removal of any 
unreacted analogue maleimide 33. Using the same principles, it was demonstrated that the 
small, bicyclic MLA analogue 34 shown in Figure 2.7 also binds at the agonist binding site 
of α7 nAChRs62.  
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Figure 2.7: Structure of bicyclic MLA analogue 34, the  
structure of MLA is shown on the left for comparison. 
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2.1.3. Project Aims: 
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Figure 2.8: Structures of the alkaloids that are the focus of this  
study; codeine (25), morphine (35) and galanthamine (23) 
It is clear from the available literature that the mechanism of allosteric modulation of 
nAChRs is not fully understood and the binding site of allosteric ligands such as those in 
Figure 2.8 has not been located with certainty. Covalent trapping provides a promising 
solution to the problem but requires thiol reactive analogues of the positive allosteric 
modulators. To ensure that the analogues bind in the same location as the original ligand, 
the modifications to the ligand structure must not be so drastic as to alter the binding 
properties of the ligand. To this end, the conjugated ketone analogues of codeine (25), 
morphine (35) and galanthamine (23), namely codeinone (36), morphinone (37) and 
narwedine (30) were targeted as thiol reactive probes. Additionally the chlorinated 
derivatives of codeine (25); mustard 38 and benzyl chloride 39 were also targeted. The 
structures of all target analogues are shown in Figure 2.9 below.   
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Figure 2.9: Structures of the targeted analogues of  
galanthamine (23), codeine (25), and morphine (35) 
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These target analogues have been designed such that a single minor adjustment is made to 
the structure of the ligand. In the case of the α,β-unsaturated ketones, this adjustment is an 
oxidation of the allylic alcohol. As shown in the space filling models of codeine (25) and 
codeinone (36) in Figure 2.10 the two compounds are virtually indistinguishable in terms 
of the spacial arrangement of atoms. As a result, the two compounds are likely to have 
similar binding properties and bind in the same location on mutant nAChRs. However, it 
should be noted that conversion of the hydrogen bond donor (OH) to a hydrogen bond 
acceptor (C=O) may alter the binding properties. The modifications to the structure of 
codeine (25) to generate chlorinated analogues 38 and 39 are slightly more significant. 
However, the spacial arrangement of atoms is largely conserved and although the 
introduction of chlorine may have an effect on binding affinities the location of the binding 
site should still be the same. Although the binding site is likely to remain unchanged for 
the target analogues, their mode of action may change. For example, while codeine (23) is 
a positive allosteric modulator, its analogues may be inhibitors.    
 
Figure 2.10: Space-filling models of codeine (25, left) and codeinone  
(36, right) viewing from the bottom face of the aromatic ring 
Once the analogues had been prepared their reactivity towards thiols was evaluated in the 
first instance by studying the kinetics of the conjugate addition reaction with a protected 
cysteine derivative in solution. Additionally, the mode of reaction of the analogues with 
free cysteine was established by isolating and fully characterising the products of their 
reaction with the protected cysteine derivative.  
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2.2. Synthesis of α,β-Unsaturated Ketones:  
2.2.1. Codeinone:  
A number of different conditions were trialled to oxidise codeine (25) to codeinone (36) 
and these are summarised in Table 2.1 below. Of the four oxidising agents tested,  
Dess-Martin periodinane (DMP) was found to be the most suitable forming the cleanest 
product in the highest yield. The chromium based reagents, pyridinium chlorochromate 
(PCC) and CrO3, required multiple applications of flash chromatography to successfully 
remove all of the chromium residues and the overall yields of the desired product suffered 
as a result. Additionally, CrO3 failed to completely oxidise codeine further limiting the 
overall yield of the product. When MnO2 was used as the oxidising agent codeinone (36) 
was oxidised further generating 14-hydroxycodeinone (40) as the major product, identified 
by comparison of 1H-NMR data with the literature66. 
Table 2.1: Conditions trialled for the oxidation of codeine (25) to codeinone (36) 
O
O
HO
N
Conditions
O
O
O
N
H H
25 36
O
O
O
N
OH
40
+
5
86
5
86
 
Conditions Conversion Yield Product PCC / DCM Reflux Complete 51% 36 CrO3 / H2SO4 / Acetone 0 °C – RT Incomplete 31% 36 DMP / DCM RT Complete 81% 36 MnO2 / DCM RT Incomplete 38% 40 
 
An added advantage of the oxidation with DMP was that when pure DMP was used and 
the reaction allowed to proceed to completion, pure codeinone could be obtained without 
the need for flash chromatography. Instead, the oxidising agent and its by-products were 
converted to water soluble salts by stirring vigorously with 2 M aq NaOH. These were 
removed during the subsequent extraction. If freshly prepared DMP was not used a small 
portion of the codeinone (36) was oxidised further, generating 14-hydroxycodeinone (40). 
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Oxidation of the allylic alcohol to afford codeinone (36) was confirmed by analysis of the 
1H-NMR and 13C-NMR spectra. In addition to the absence of the H6 peak around 4.2 ppm, 
the H5 peak changes from a doublet to a singlet indicating the removal of H6. The H8 peak 
shifts further downfield to a position characteristic of the β-proton in an α,β-unsaturated 
ketone. A peak also appears in the 13C-NMR spectrum at 194.6 ppm which can be 
attributed to the ketone. In general, the 1H-NMR and 13C-NMR data were in agreement 
with literature data67.  
In addition to simplifying the purification of codeinone (36), the ability to isolate the 
product without flash chromatography allowed an unwanted side reaction to be avoided. 
Under acidic conditions, codeinone (36) can isomerise via double bond migration to 
neopinone (41) as shown in Figure 2.11. This product is inseparable from codeinone (36). 
Following protonation of the ketone, the γ-proton is lost to form the intermediate dienol. 
This can then tautomerise to neopinone (41). It has been demonstrated that the 
isomerization described above can occur in aqueous solutions under acidic, basic or neutral 
conditions68,69. Under these conditions, codeinone (36) and neopinone (41) exist in an 
equilibrium favouring codeinone (36) which is the more stable compound due to 
conjugation of the alkene with the ketone. The effect of this equilibrium on the kinetics 
studies will be discussed later in this chapter. 
O
O
O
N
O
O
O
N
H
36
O
O
O
N
O
O
HO
N
41
H
-H+
Tautomerism
H
H
  
Figure 2.11: Mechanism of double bond migration of codeinone (36) 
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The presence of neopinone (41) in samples of codeinone (36) was readily apparent in the 
1H-NMR spectrum with duplicate methyl peaks at 3.90 ppm and 2.47 ppm corresponding 
to the O-methyl and N-methyl protons respectively, along with a number of small doublets. 
An assignment of the peaks in the 1H-NMR spectrum of a sample of codeinone (36) 
contaminated with neopinone (41) is given in Table 2.2. Regions where peaks 
corresponding to the two isomers overlap are highlighted in bold. Literature data for a 
mixture of the two isomers70 was used to aid in the assignment.   
Table 2.2: 400 MHz 1H-NMR data for codeinone (36) and neopinone (41) 
O
O
O
N
1
2
33a
4
5
6
7
8
9
10
11
12
13
14
15
16
17
17a
H
O
O
O
N
1
2
33a
4
5
6
7
8
9
10
11
12
13 14
15
16
17
17a
36 41  
 Codeinone (36) Neopinone (41) 
1 6.58-6.71 (m) 6.58-6.71 (m) 
2 6.58-6.71 (m) 6.58-6.71 (m) 
3a 3.83 (s) 3.90 (s) 
5 4.69 (s) 4.99 (s) 
7 6.07 (dd, J = 10.4, 2.8) 3.30 (d, J = 17.2) 2.74 (dd, J = 17.2, 6.4) 
8 6.58-6.71 (m) 5.49 (d, J = 6.0) 
9 3.44 (m) 3.63 (d, J = 6.4) 
10 3.10 (d, J = 18.4) 2.25-2.35 (m) 
3.19-3.26 (m) 
2.53-2.66 (m) 
14 3.19-3.26 (m) - 
15 2.08 (td, J = 12.4, 4.8) 1.81-1.92 (m) 
2.25-2.35 (m) 
1.81-1.92 (m) 
16 2.53-2.66 (m) 2.25-2.35 (m) 
2.53-2.66 (m) 
2.25-2.35 (m) 
17a 2.46 (s) 2.47 (s) 
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2.2.2. Morphinone:  
Initial attempts to oxidise morphine (35) directly to morphinone (37) resulted in 
decomposition and morphinone (37) could not be isolated from the reaction mixture. 
Considering the success with the oxidation of codeine (25) it was believed that a route 
involving protection of the phenol may prove more successful (Scheme 2.2). To this end,  
morphine (35) was protected at the phenolic position with TBDMS-OTf and triethylamine 
(NEt3) in DCM to afford compound 42 in 30% yield. The allylic alcohol was then oxidised 
using DMP to generate the corresponding unsaturated ketone 43 in 88% yield. This was 
deprotected with a 1:1 mixture of 1 M aq HCl and methanol to give morphinone (37) after 
basic work-up in a yield of 70%.  
HO
O
HO
N
TBDMSO
O
HO
N
H
35
HO
O
O
N
TBDMSO
O
O
N
37
H
42
43
TBDMS-OTf / NEt3
DCM RT
Yield = 30%
Dess-Martin periodinane
DCM RT
Yield = 88%
aq HCl / MeOH (1:1) RT
Yield = 70%
HH
 
Scheme 2.2: Synthesis of morphinone (37) from morphine (35) 
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The low yield in the first step of the synthesis can be explained by the fact that  
TBDMS-OTf is highly reactive and selectivity for the phenol was difficult to achieve even 
under the weakly basic conditions afforded by triethylamine. As a result, a mixture of the 
mono protected product 42, and bis protected product 44 was obtained along with some 
unreacted starting material in a ratio of 2:1:1 (Scheme 2.3). However, these were readily 
separated by flash chromatography. The product resulting from selective protection of the 
allylic alcohol was not observed. Selective protection of the phenolic OH of morphine (35) 
has previously been achieved in reasonably high yields with minimal formation of the bis 
protected product using TBDMS-Cl instead of TBDMS-OTf71. However, initial attempts to 
replicate this synthesis failed to produce significant amounts of the desired product. 
HO
O
HO
N
TBDMSO
O
HO
N
H
35
H
42
TBDMS-OTf / NEt3
DCM RT
TBDMSO
O
TBDMSO
N
H
44
+
 
Scheme 2.3: Mixture of products obtained in the TBDMS protection of morphine (35) 
Protection of the phenol of morphine (35) was accompanied by an increased solubility in 
the reaction mixture resulting from the decreased polarity. For the purified product, 
incorporation of a single TBDMS protecting group was indicated by the presence of a 
singlet at 0.98 ppm integrating for 9 protons and two singlets at 0.19 ppm and 0.16 ppm 
integrating for 3 protons each. These correspond to the t-butyl and methyl protons 
respectively. While protection of the allylic alcohol instead of the phenol is possible, the 
success of the subsequent oxidation step suggests this was not the case. Oxidation of 
protected morphine 42 was confirmed by NMR analysis. As with codeinone (36), a peak in 
the 13C-NMR spectrum at 194.4 ppm suggested the presence of the ketone. Additionally, 
the H5 peak changes from a doublet to a singlet indicating the removal of H6 and the H6 
peak around 4.2 ppm is absent. The H8 peak also shifts further downfield to a position 
characteristic of the β-proton in an α,β-unsaturated ketone. Additionally, the 1H-NMR data 
for both compounds were in agreement with the literature72; literature 13C-NMR data were 
not available but are reported as part of this work. 
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The subsequent deprotection proceeded without major difficulty aside from two minor side 
reactions generating the side products shown in Figure 2.12. Since the deprotection is 
carried out under acidic conditions, approximately 10% of the morphinone (37) underwent 
acid catalysed deconjugation in a similar manner to codeinone (36) generating the 
analogous deconjugated isomer 45. As with codeinone (36), this deconjugated isomer was 
unable to be separated from morphinone (37). Additionally, if methanol from the reaction 
mixture was not completely removed prior to basic extraction a product with an extra  
O-methyl group was obtained, consistent with a conjugate addition to generate methoxy 
compound 46. The product was extracted from aqueous solution (pH 9) with a 3:1 mixture 
of chloroform and isopropanol. At this pH, the phenol is expected to be protonated  
(pKa ≈ 10) and the tertiary amine is expected to be deprotonated (pKa ≈ 8). 
HO
O
O
N
45
HO
O
O
N
46
H
OMe
  
Figure 2.12: Structures of the side products generated  
during the deprotection of compound 43  
Deprotection to afford morphinone (37) was readily apparent with the absence of peaks 
below 1 ppm corresponding to loss of the TBDMS group in the 1H-NMR of the product. 
While literature NMR data were not available for morphinone (37), the 1H-NMR spectrum 
of the product was nearly identical to that of codeinone (36) except for the absence of the  
O-methyl peak. The phenolic proton was not observed in the 1H-NMR spectrum in CDCl3, 
possibly due to environmental exchange. However, the presence of a very broad absorption 
(3600-2400 cm–1) corresponding to the H-bonded O–H stretch of the phenol was observed 
in the IR spectrum.   
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2.2.3. Narwedine: 
Dess-Martin periodinane
DCM RT 2 h
O
O
N
HO
O
O
N
O
Yield = 71%
23 30
8
6
8
6
 
Scheme 2.4: Oxidation of galanthamine (23) 
The oxidation of galanthamine (23) was performed using DMP to afford narwedine (30) in 
71% yield (Scheme 2.4). However, galanthamine (23) appeared to be significantly more 
resistant to oxidation, requiring 2.8 equivalents of DMP to fully oxidise the alcohol instead 
of the standard 1.4 equivalents. Additionally, the oxidising agent had to be added in two 
separate batches to ensure complete oxidation of galanthamine (23). As a result of the 
basic conditions required during work-up, the product racemises via the mechanism shown 
in Figure 2.13 below. Following a base promoted elimination reaction the resulting 
phenoxide can add to either of the two alkenes to regenerate either enantiomer of 
narwedine (30 or 30a). The result is a product with an optical rotation of –7° corresponding 
to an almost 1:1 mixture of the two enantiomers45. 
O
O
N
O
O
N
O
O
30 30a
O
N
O
O
H
Base
BaseH Base  
Figure 2.13: Mechanism of racemisation of narwedine (30)  
Oxidation of galanthamine (23) was confirmed by analysis of the 1H-NMR and 13C-NMR 
spectra. In the 1H-NMR spectrum there is a significant downfield shift in the H8 peak to a 
region characteristic of the β-proton in an α,β-unsaturated ketone. Additionally, the peak 
around 4.1 ppm corresponding to the H6 proton is absent. A peak at 194.6 ppm in the  
13C-NMR spectrum suggested the presence of a ketone. In general, the 1H-NMR and  
13C-NMR data were in agreement with the literature73. 
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An enantioenriched sample of narwedine (30) was obtained by oxidising with MnO2 
instead of DMP, eliminating the need for a basic work-up and therefore minimising the 
racemisation process. Instead, the oxidising agent is separated from the product by 
filtration giving narwedine (30) in 77% yield. The product obtained by this method had an 
optical rotation of –237° corresponding to an approximately 4:1 mixture of  
(–)-narwedine (30) and (+)-narwedine (30a)45. The racemisation of narwedine (30) in 
methanol was studied by monitoring the change in optical rotation of a solution over time. 
Using this method, the half-life of racemisation was estimated at approximately 25 
minutes.  
L-Selectride
THF -78oC
O
O
N
O
O
O
N
HO
(±)-30 (±)-23
Yield = 63%
 
Scheme 2.5: Stereoselective reduction of racemic narwedine ((±)-30) 
To explore whether the modulatory effect of galanthamine (23) results from the unnatural 
enantiomer, a sample of racemic galanthamine ((±)-23) was prepared from a racemic 
sample of narwedine ((±)-30). Using L-Selectride, narwedine could be stereoselectively 
reduced to galanthamine (23) in 63% yield (Scheme 2.5). The stereochemical outcome of 
the reaction is largely controlled by the furan ring which sterically blocks the bulky  
L-Selectride from attacking at the si face of the cyclohexanone ring (Figure 2.14). 
O
N
O
O
B
s-Bu
s-Bus-Bu
H
H
ON
O
O
H
H
- (s-Bu)3B
    
 Figure 2.14: Steric effect of the furan ring blocking  
attack at the si face of the cyclohexanone ring   
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2.3. Synthesis of Chlorinated Derivatives of Codeine:  
2.3.1. Codeine Mustard:  
O
O
HO
N
O
O
HO
NH
H H
38 47
O
O
HO
N
H
25
Cl
 
Scheme 2.6: Retrosynthetic strategy for the synthesis of the codeine mustard (38) 
Codeine mustard 38 could be prepared in two steps from codeine (25) as shown in  
Scheme 2.6. Mustard 38 could be obtained by an alkylation of norcodeine (47), which in 
turn could be obtained by N-demethylation of codeine (25). Two methods were trialled for 
the N-demethylation. In each case, N-demethylation was primarily indicated by a loss of 
the N-methyl peak at 2.5 ppm in the 1H-NMR spectrum. Additionally, the 1H-NMR and 
13C-NMR data were in agreement with the literature74. 
The N-demethylation of codeine (25) was initially attempted using a modified Polonovski 
reaction75,76 (Scheme 2.7). Codeine (25) was first oxidised with meta-chloroperbenzoic 
acid (m-CPBA) to afford codeine-N-oxide (48) in quantitative yield. Codeine-N-oxide (48) 
was then reduced with ferrocene generating norcodeine (47) in 22% yield along with  
codeine (25) as the major by-product. The yield was only marginally improved by 
replacing ferrocene with ferroceneacetic acid.   
O
O
HO
N
H
48
O
O
HO
N
H
25
m-CPBA
O
O
HO
NH
H
47
ferrocene
CHCl3
 - 5 oC CHCl3
 
/ HCl 50 oC
O
 
Scheme 2.7: Polonovski-type N-demethylation of codeine (25) 
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The proposed mechanism for the Polonovski-type N-demethylation is shown in Figure 2.15 
below. Following protonation at the oxygen the N-oxide is reduced to the intermediate 
radical cation with loss of the oxygen as water. The intermediate can then either be reduced 
further to generate the methyl amine or a proton can be lost followed by oxidation to 
generate an imine which can be hydrolysed during work-up to give the N-demethylated 
product. Based on this mechanism it is clear that reduction of starting material can also 
compete with product formation.  
R1
R2
N
CH3
O R1
R2
N
CH3
OH
R1
R2
N CH2
R1
R2
N CH2
Fe(II) Fe(III)
R1
R2
N CH3
R1
R2
NH
+ (H2O)CH2O+
R1
R2
N CH3
Fe(II) Fe(III)Fe(II) Fe(III)
+ (H+)
- (H+)
- (H2O)
+ (H+)
 
Figure 2.15: Proposed mechanism of the Polonovski-type N-demethylation77 
Better results were achieved using α-chloroethyl chloroformate (ACE-Cl) to generate 
intermediate carbamate 49 which was hydrolysed in methanol to afford norcodeine (47) in 
82% yield over two steps (Scheme 2.8). In the absence of base, the initial reaction with 
ACE-Cl was very slow and the reaction was still incomplete after three days. This is 
believed to result from the acidic nature of ACE-Cl which can be hydrolysed by moisture 
generating HCl as a by-product. Under acidic conditions the amine is far less nucleophilic 
and therefore unable to react with ACE-Cl. Addition of base to the reaction mixture 
resulted in a significant increase in the rate of reaction and complete conversion was 
achieved in one day. The added base had to be removed prior to hydrolysis with methanol 
otherwise a different product, believed to be the methyl carbamate, was formed instead. 
O
O
HO
N
H
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O
O
HO
N
H
25 O
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47
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DCE Reflux Reflux
  
Scheme 2.8: N-Demethylation of codeine (25) using ACE-Cl and methanol  
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Figure 2.16: Mechanism of formation of intermediate carbamate 49  
The proposed mechanism of N-demethylation with ACE-Cl and methanol involves initial 
formation of a carbamate with loss of the methyl group as chloromethane as shown in 
Figure 2.16. Nucleophilic substitution of carbamate 49 with methanol affords the  
α-methoxy carbamate which breaks down to the carbamic acid and acetaldehyde dimethyl 
acetal. The carbamic acid is unstable and rapidly undergoes decarboxylation generating 
norcodeine (47) with loss of carbon dioxide (Figure 2.17).   
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Figure 2.17: Mechanism of break down of intermediate carbamate 49  
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Scheme 2.9: Reductive alkylation of norcodeine (47) 
Of the numerous methods trialled to alkylate norcodeine (47) only reductive alkylation 
with chloroacetaldehyde and sodium triacetoxyborohydride was successful (Scheme 2.9) 
generating mustard 38 in 85% yield of sufficient purity for characterisation. The reactions 
were monitored using liquid chromatography – mass spectrometry (LCMS). A set of two 
peaks (m/z = 348 and 350) in a ratio of 3:1 were detected corresponding to the two isotopes 
of chlorine in the protonated mustard. A peak corresponding to the aziridinium ion 50 
(m/z = 312, Figure 2.18) was also detected. Formation of mustard 38 was confirmed by 
examination of the 1H-NMR spectrum. A new triplet at around 3.6 ppm was assigned to 
the methylene protons adjacent to the chlorine (H17b) and a set of multiplets centred around 
2.9 ppm was assigned to the methylene protons adjacent to the amine (H17a). 
O
O
HO
N
H
50
Cl
O
O
HO
N
H
38
Cl
 
Figure 2.18: Aziridinium ion 50 formation 
Aziridinium ion 50 forms from an intramolecular cyclisation under basic or neutral 
conditions as shown in Figure 2.18 above. The formation of this ion is believed to give rise 
to the reactivity of mustard 50 that led to difficulties with other attempted synthetic 
strategies. When the more basic sodium cyanoborohydride was used as a reducing agent, a 
product with a mass spectrum consistent with the ethyl bridged dimer 51 (Scheme 2.10) 
was formed as the sole product (m/z = 598). Attempts to carry out alkylation with  
1-bromo-2-chloroethane under basic conditions led to the same product.     
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Aziridinium ion 50 reacts rapidly with nucleophiles generating alkyl derivatives of codeine 
(Scheme 2.10). During synthesis under basic conditions aziridinium ion 50 can react 
rapidly with a second molecule of norcodeine (47) to afford the ethyl bridged dimer 51. In 
aqueous solutions, aziridinium ion 50 is rapidly hydrolysed generating the hydroxy 
derivative 52. The half-life of this reaction in buffer, estimated by analysing a solution of 
mustard 38 by LCMS at regular intervals, was approximately 30 minutes at a concentration 
of 10 μg/mL. In methanol, the methoxy derivative 53 is rapidly generated. A 1H-NMR 
spectrum of a 10 mg/mL solution of pure mustard 38 in deuterated methanol obtained  
2 hours after preparing the solution indicated that only half of mustard 38 remained. This 
suggested that the half-life of hydrolysis is approximately 2 hours. Since covalent trapping 
studies are carried out in aqueous solution, mustard 38 was deemed too reactive to be 
useful as a thiol-reactive probe and a study of its reaction kinetics with cysteine was not 
performed.  
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Scheme 2.10: By-products formed during the alkylation of norcodeine (47)  
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2.3.2. Benzyl Chloride Derivative: 
A protected analogue of targeted benzyl chloride derivative 39 was prepared in  
5 steps from morphine (35) as shown in Scheme 2.11. Selective triflation at the phenolic 
position with N-phenyltriflamide and NEt3 in DCM gave morphine-3-triflate (54) in 82% 
yield. The remaining allylic alcohol was then protected with TBDMS-OTf and 2,6-lutidine 
to afford protected triflate 55 in 90% yield. Protected triflate 55 then underwent 
carbonylative coupling catalysed by Pd(dppf)Cl2 in a mixture of DMF and methanol in a 
sealed tube generating methyl ester 56 in 72% yield. Reduction of the ester with LiAlH4 in 
THF gave benzyl alcohol 57 in 84% yield, which was converted to protected benzyl 
chloride 58 in 86% yield using thionyl chloride (SOCl2) in DCM. 
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Scheme 2.11: Synthesis of the protected benzyl chloride analogue (58) from morphine (35)   
Selective triflation proceeded without major issues. By exploiting the acidic nature of the 
phenol and using a weak base (NEt3), morphine-3-triflate (54) was formed as the sole 
product. Triflation of the phenol was accompanied by an increase in the solubility of the 
product in dichloromethane. Generation of the triflate was demonstrated by the 
introduction of a quartet (J = 319 Hz) centred around 188.8 ppm corresponding to the CF3 
carbon coupling with the three bonded fluorine atoms. Additionally, the 1H-NMR and  
13C-NMR data were in agreement with the literature78.     
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The subsequent TBDMS protection also proceeded without major difficulty aside from the 
fact that crystallisation of the product only occurred when all traces of 2,6-lutidine were 
removed. Samples contaminated with 2,6-lutidine formed a viscous oil instead. Although 
the presence of 2,6-lutidine did not affect later steps in the synthesis, it could be removed 
by drying the product under reduced pressure overnight prior to flash chromatography.  
Incorporation of the TBDMS protecting group was indicated by the presence of a singlet at 
0.93 ppm integrating for 9 protons and two singlets at 0.14 ppm and 0.11 ppm integrating 
for 3 protons each in the 1H-NMR spectrum. These correspond to the t-butyl and methyl 
protons respectively. In general, the 1H-NMR and 13C-NMR data were in agreement with 
literature data79. 
Carbonylative coupling proved to be more of a challenge and initial attempts to carry out 
the reaction led to, at most, 67% conversion. While the unreacted triflate (55) could be 
separated from products later in the synthesis, some of the starting material reacted in 
subsequent steps to generate new impurities which could not be separated from the desired 
products. Since triflate 55 and ester 56 could not be efficiently separated by standard 
purification techniques the reaction was optimised to proceed to completion prior to 
carrying out the subsequent steps in the synthesis. The reaction could be repeated with the 
crude product to convert any of the remaining triflate 55 leading to complete conversion 
over two treatments. Alternatively, increasing the volume of the sealed tube from twice the 
volume of the reaction mixture to 5 times the volume, thus increasing the total amount of 
carbon monoxide in the reaction vessel, enabled the complete conversion in one step.  
Ester formation was supported by examination of the NMR spectra. In the 1H-NMR 
spectrum a new singlet appears around 3.9 ppm corresponding to the O-methyl group of 
the ester. There is also a significant downfield shift in the C2 proton consistent with the 
change from an electron donating triflate substituent at C3 to the electron withdrawing ester 
substituent. In the 13C-NMR spectrum a peak appeared at 166.6 ppm which was attributed 
to the ester carbonyl.  
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Figure 2.19: Mechanism of the palladium catalysed carbonylative coupling 
The mechanism of the carbonylative coupling reaction is shown in Figure 2.19 above. 
First, triflate 55 undergoes oxidative addition with the palladium complex Pd(0)(dppf), 
formed from the reduction of the pre-catalyst (Pd(II)(dppf)Cl2), generating intermediate 59. 
Carbon monoxide then inserts into the Pd-C bond generating the intermediate acyl 
palladium species 60, which undergoes ligand exchange with methoxide to give the second 
intermediate acyl palladium species 61. Reductive elimination of palladium from this 
intermediate regenerates the initial palladium complex along with the target ester 56.  
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Figure 2.20: Chemical structure of dppf 
Reduction of the ester with LiAlH4 to generate benzyl alcohol 57 proceeded without major 
difficulty when starting ester 56 was contaminated with dppf (Figure 2.20). However, 
when ester 56 was sufficiently clean the allylic silyl ether was also deprotected to afford 
diol 62 (Figure 2.21). Deprotection is believed to result from Li+ chelation followed by 
reduction by the nucleophilic hydride ion. It is believed that dppf prevents the deprotection 
of the allylic alcohol by preferentially reacting with LiAlH4. Attempts to replace LiAlH4 
with the less reactive LiBH4 failed in generating benzyl alcohol 57. 
O
HO
N
H
HO
62   
Figure 2.21: Chemical structure of diol 62  
Ester reduction to give benzyl alcohol 57 was confirmed by examination of the 1H-NMR 
spectrum, with the appearance of a set of doublets at 4.5 ppm and 4.7 ppm corresponding 
to the benzylic protons adjacent to the OH group. Additionally, there is a significant 
upfield shift in the C2 proton consistent with the change to an electron donating 
hydroxymethyl substituent at C3. Reduction of the ester is also supported by the absence of 
peaks above 160 ppm in the 13C-NMR spectrum. 
Of the reagents trialled for the chlorination of benzyl alcohol 57, only thionyl chloride was 
able to generate the desired benzyl chloride 58 in sufficient yield and purity.  
N-Chlorosuccinimide failed to generate any of the desired product and only traces of the 
desired product were detected following treatment with triphenylphosphine in carbon 
tetrachloride. The chlorination reactions were monitored by LCMS with a set of two peaks 
(m/z = 348 and 350) in a ratio of 3:1 indicating formation of benzyl chloride 58. The  
1H-NMR and 13C-NMR spectra were very similar to those of benzyl alcohol 57.  
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Figure 2.22: 1H-NMR spectrum of benzyl chloride 58  
taken after 20 minutes in CDCl3 solution 
The product was found to be unstable in solution and clean NMR spectra could not be 
obtained. The 1H-NMR spectrum shown in Figure 2.22 was taken 20 minutes after 
dissolving the sample in CDCl3. In the aromatic region of the spectrum there are four 
doublets (1a, 1b, 2a and 2b) with roughly equal integrations consistent with the formation 
of a dimer. It is proposed that benzyl chloride 58 reacts via nucleophilic substitution at the 
amine (Scheme 2.12) generating dimer 63. The significant downfield shift in the C2a proton 
can be accounted for based on the inductively electron withdrawing nature of the 
quaternary ammonium ion. Additionally, when a solution of the sample was analysed by 
LCMS a set of two peaks (m/z = 827 and 829) in a ratio of 3:1 were detected in the mass 
spectrum corresponding to dimer 63. A cluster of peaks around m/z = 415 corresponding to 
the protonated (and doubly charged) dimer were also detected.   
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Scheme 2.12: Proposed dimerisation of the benzyl chloride (58)   
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In nucleophilic solvents such as water or methanol benzyl chloride 58 rapidly reacted with 
the solvent generating benzyl alcohol 57 or methyl ether 64 respectively (Figure 2.23). 
Attempts to determine the half-life of the reaction with water were unsuccessful and when 
solutions of compound 58 in buffer were prepared hydrolysis to form alcohol 57 appeared 
to be complete within 1 minute at concentrations as low as 10 μM.  Based on these results 
it was determined that the deprotected benzyl chloride derivative 39 would not be suitable 
for use in covalent trapping experiments. 
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Figure 2.23: Structures of the products of the reaction of the  
benzyl chloride 58 with water (left) and methanol (right) 
The instability of benzyl chloride 58 also proved problematic for the deprotection step and 
attempts to deprotect the allylic silyl ether failed to cleanly generate the desired product 
(Scheme 2.13). Deprotection with aqueous HCl, as was applied in the synthesis of 
morphinone (37), led to complete hydrolysis of the benzyl chloride along with the 
deprotection generating the diol 62 (Figure 2.21) as the sole product. Fluoride based 
deprotection using tetrabutylammonium fluoride (TBAF) led to a complex mixture of 
products that could not be adequately separated or characterised by standard laboratory 
purification techniques. Analysis of the mixture by LCMS revealed peaks corresponding to 
the protonated forms of benzyl fluoride derivative 65 (m/z = 302, Scheme 2.14) and  
diol 62 (m/z = 300, Figure 2.21) in addition to the set of two peaks (m/z = 318 and 320) 
corresponding to benzyl chloride 39. 
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Scheme 2.13: Attempted deprotection of benzyl chloride 58 
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Scheme 2.14: Synthesis of benzyl fluoride 65  
Based on these results, and the fact that benzyl chloride 39 was deemed too unstable for 
use in covalent trapping experiments, the synthesis of benzyl chloride 39 was abandoned. 
However, it was hypothesised that benzyl fluoride 65 may be a suitable alternative as it 
was likely to be more stable. Given the generation of significant quantities of benzyl 
fluoride 65 as a side product in the deprotection with TBAF, attempts were made to force 
the reaction to favour formation of benzyl fluoride 65 by using a large excess of TBAF 
(Scheme 2.14). While the reaction was successful in generating benzyl fluoride 65 the 
large excess of TBAF made purification difficult on the small scale that the reaction was 
performed. Due to time constraints the synthesis of benzyl fluoride 65 was not pursued 
further.   
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2.4. Reaction Kinetics: 
2.4.1 Solution Kinetics: 
Reactions of the thiol-reactive probes with a protected analogue of cysteine were 
monitored in solution as a means of evaluating their suitability for use in covalent trapping 
studies. The data obtained provides useful information regarding the relative reactivity of 
probes and, when combined with the results of covalent trapping studies, can be used to aid 
in the design of new reactive probes. However, care should be taken when extrapolating 
the results of kinetics studies in solution with the performance of the thiol-reactive probes 
in covalent trapping experiments.  
The reaction of a thiol-reactive probe (P) with a cysteine derivative (C) in solution is a 
second-order reaction (Scheme 2.15a) in which the rate of reaction is dependent upon the 
concentration of the probe (P) and the cysteine derivative (C). The rate constant (k) gives a 
measure of the absolute reactivity of the probe (P) towards cysteine residues. In covalent 
trapping experiments, an equilibrium is established between unbound probe (P),  
receptor (R) and the probe-receptor complex ([P•R]). The probe-receptor complex then 
reacts via covalent bond formation (Scheme 2.15b). The rate of covalent bond formation 
depends upon the first order rate constant (k2) and the concentration of the probe-receptor 
complex, which is in turn determined by the affinity of the probe for the receptor.  
P + C P C
k
a)
P + R P R
k+1
b) P R
k2
k-1  
Scheme 2.15: a) Second-order addition reaction of a probe (P) with a  
cysteine derivative (C) in solution; b) Kinetic scheme for covalent  
trapping of a probe (P) by a cysteine mutant receptor (R) 
The rate of covalent bond formation is also related to the absolute reactivity of the probe 
towards cysteine residues. However, the second-order rate constant (k) measured in 
solution is not directly comparable to the first order rate constant (k2) for covalent bond 
formation in the probe-receptor complex. The formation of the complex influences the rate 
of reaction through proximity effects. For example, if the cysteine residue in the mutant 
receptor is in a favourable position relative to the probe, the rate of covalent bond 
formation may be significantly greater than would be expected based on studies of its 
reaction in solution.  
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The reaction of a thiol-reactive probe (P) with a cysteine derivative (C) in solution is a 
bimolecular reaction. As such the rate of reaction at a given time is directly proportional to 
the concentration of each reagent. This relationship is represented by the following 
equation: 
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 = −𝑑𝑑[𝑃𝑃]
𝑑𝑑𝑅𝑅
= 𝑘𝑘[𝑃𝑃][𝐶𝐶] 
If the cysteine derivative (C) is in significant excess its concentration does not change 
significantly over time and the rate is directly proportional to the concentration of the thiol-
reactive probe (P). The reaction is said to be pseudo-first order and the equation can be 
simplified to the following: 
−
𝑑𝑑[𝑃𝑃]
𝑑𝑑𝑅𝑅
= 𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜[𝑃𝑃]            𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜 = 𝑘𝑘[𝐶𝐶] 
The above equation can be rearranged to generate a differential equation which can be 
integrated as follows, where [P]0 is the initial concentration of the probe (P): 
�
1[𝑃𝑃]𝑑𝑑[𝑃𝑃][𝑃𝑃][𝑃𝑃]0 = � −𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜𝑑𝑑𝑅𝑅𝑡𝑡𝑡𝑡0  
𝑙𝑙𝑙𝑙[𝑃𝑃] − 𝑙𝑙𝑙𝑙[𝑃𝑃]0 = −𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜𝑅𝑅 
𝑙𝑙𝑙𝑙
[𝑃𝑃][𝑃𝑃]0 = −𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜𝑅𝑅 
This equation can be solved for [P] to obtain a relationship between the concentration of 
the thiol-reactive probe (P) and reaction time: [𝑃𝑃][𝑃𝑃]0 = 𝑅𝑅−𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜𝑡𝑡  [𝑃𝑃] = [𝑃𝑃]0𝑅𝑅−𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜𝑡𝑡 
Therefore, a plot of the concentration of the limiting reagent with time will follow a 
standard exponential decay curve.  
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Following initial trials monitoring the reaction of codeinone (36) with various protected 
derivatives of cysteine, N-acetyl-L-cysteine methyl ester (66) was chosen as the cysteine 
derivative to assess the reactivity of the thiol-reactive analogues with cysteine residues. 
Free cysteine could not be used as side reactions at the amine or carboxylic acid functional 
groups would likely complicate the results of kinetic studies.   
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O  
Scheme 2.16: Synthesis of N-acetyl-L-cysteine methyl ester (66) 
N-Acetyl-L-cysteine methyl ester (66) was synthesised from N-acetyl-L-cysteine (67) by 
esterification with SOCl2 in methanol (Scheme 2.15). When SOCl2 was added to the 
reaction mixture at room temperature, a significant amount of the product was oxidised 
generating disulfide dimer 68 (Figure 2.24). However, this oxidation was inhibited 
significantly by cooling the reaction mixture to 0 °C prior to adding SOCl2. Attempts to 
prepare N-acetyl-L-cysteine methyl ester (66) by acetylating L-cysteine methyl ester (69) 
with acetic anhydride failed with generation of thioacetate 70 as the major product 
(Scheme 2.16). 
H
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Figure 2.24: Structure of disulfide dimer 68 formed via  
oxidation of N-acetyl-L-cysteine (67) by SOCl2 
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2.4.2. Synthesis of Adducts: 
A pure sample of the compound resulting from the reaction between codeinone (36) and  
N-acetyl-L-cysteine methyl ester (66) was prepared to establish the mode of reaction of 
free cysteine with codeinone (36). A mixture of codeinone (36) and two equivalents of  
N-acetyl-L-cysteine methyl ester (66) in methanol was left to react overnight  
(Scheme 2.16), generating adduct 71 in 94% yield.   
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Scheme 2.17: Synthesis of the codeinone N-acetyl-L-cysteine methyl ester adduct 71 
The structure was assigned as that shown in Scheme 2.12 based on NMR analysis. The 
peaks in the 1H-NMR spectrum, shown in Figure 2.25, were fully assigned by combining 
COSY, NOESY and HSQC data. The peaks in the 13C-NMR spectrum were assigned by 
correlation of the 1H-NMR assignments with HSQC and HMBC data.  
 
Figure 2.25: 1H-NMR spectrum of the codeinone  
N-acetyl-L-cysteine methyl ester adduct 71 
52 
 
                                                                                                                                 Chapter 2 
 
The absence of peaks corresponding to the alkene protons in codeinone (36) suggests that 
the cysteine has added across the double bond as expected. A strong HMBC correlation 
between C8 and H2a’ places the amino acid side chain at C8, consistent with a conjugate 
addition. The stereochemistry at C8 can be predicted based on steric arguments.  
Codeinone (36) adopts a T-shape conformation as shown in Figure 2.26, with the 
piperidine and cyclohexenone rings perpendicular to the furan and phenyl rings. As a 
result, the rate of reaction at the bottom face (indicated with an arrow) is likely to be 
significantly greater than at the top face due to the steric bulk of the furan and phenyl rings. 
Reaction at the bottom face leads to the 8S-diastereomer shown in Scheme 2.17.    
N
O
O
O
R-SH
N
H
O
O
MeOR =
H8
RS H5
O
H7αH14
H7βN
O
O
 
Figure 2.26: Stereochemical outcome of the conjugate addition  
to codeinone (36), key nOe interactions are indicated in red  
The stereochemistry was confirmed by consideration of coupling constants and nOe 
interactions of protons in the cyclohexanone ring. The C8 proton appeared as a triplet of 
doublets with two large coupling constants (~13 Hz) and one small coupling constant  
(2.4 Hz). This is consistent with the structure above in which the C8 proton would exhibit 
axial-axial coupling with H14 and H7α with large coupling constants and axial-equatorial 
coupling with H7β with a small coupling constant. In the alternative stereochemistry, small 
coupling constants would be expected for the C8 proton corresponding to axial-equatorial 
and equatorial-equatorial coupling. The key nOe interactions observed for the protons of 
the cyclohexanone ring (Figure 2.26) were also consistent with the proposed structure. An 
nOe interaction was detected between H5 and H7α, between H8 and H7β, and between H7α 
and H7β. Because the H8 peak is so close to the H10β peak any nOe interaction would be 
masked by the diagonal autorelaxation peaks and could not be detected. For the same 
reason, nOe interactions could not be detected between H14 and H7α. Additionally, since 
the H14 peak was overlapping with the N-methyl peak, nOe interactions with H14 were 
difficult to distinguish from those with the N-methyl protons. 
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A preparation of compound 71 has been reported in the literature previously, reacting 
codeinone (36) with N-acetyl-L-cysteine methyl ester (66) in acetonitrile under mildly 
basic conditions80. However, the NMR data reported differed considerably from that 
obtained for compound 71 prepared via the method described in this section. A comparison 
of the NMR data is given in Table 2.3 below. Significant differences between the two sets 
of data are highlighted in bold.  
Table 2.3: Comparison of 400 MHz 1H NMR and 100 MHz 13C-NMR data  
obtained for compound 71 with literature NMR data (same field strengths) 
 Compound 71 Literature Compound 80 
1H-NMR 13C-NMR 1H-NMR 13C-NMR 
1 6.68 (d, J = 8.0) 120.4 6.63 (d, J = 7.9) 114.7 
2 6.70 (d, J = 8.0) 115.0 6.80 (d, J = 7.9) 120.1 
3 - 143.1 - 142.7 
3a 3.89 (s) 57.0 3.54 (s) 52.5 
4 - 145.2 - 144.8 
5 4.69 (s) 91.5 4.72 (s) 91.1 
6 - 204.8 - 204.6 
7 2.53 (t, J = 13.2) 2.70 (dd, J = 13.2, 2.4) 47.5 2.20-2.54 (m) 51.3 
8 2.30 (td, J = 12.8, 2.4) 41.6 2.91 (dd, J = 5.1, 2.7) 41.2 
9 3.63 (s, br) 56.9 3.99 (m) 56.6 
10 2.34 (dd, J = 18.4, 5.2) 3.01 (d, J = 18.8) 19.3 
2.20-2.54 (m) 
2.96-3.14 (m) 19.0 
11 - 126.5 - 126.1 
12 - 126.8 - 126.4 
13 - 47.2 - 46.9 
14 2.44-2.49 (m) 47.4 2.69-2.87 (m) 44.1 
15 1.82 (d, br, J = 12.0) 2.06 (td, J = 12.0, 4.0) 35.7 
1.91 (m) 
2.20-2.54 (m) 35.2 
16 2.20 (td, J = 12.0, 2.8) 2.57 (d, br, J = 11.6) 47.3 
2.20-2.54 (m) 
2.69-2.87 (m) 47.1 
17a 2.44-2.49 (m) 43.0 2.20-2.54 (m) 42.6 
1’ - 170.9 - 170.6 
1a’ 3.46 (s) 52.6 3.66 (s) 52.3 
2’ 4.81 (m) 52.3 4.82 (m) 52.1 
2a’ 2.98 (dd, J = 14.0, 4.0) 3.04 (dd, J = 14.0, 4.4) 31.5 2.96-3.14 (m) 31.1 
3’ 6.32 (d, br, J = 6.8 Hz) - 6.38 (s, br) - 
3a’ - 169.9 - 169.7 
3b’ 1.97 (s) 23.2 2.06 (s) 22.8 
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A key difference between the two spectra is in the peak corresponding to the C8 proton. 
Not only is there a significant difference in the chemical shift (2.30 ppm vs. 2.91 ppm), the 
splitting pattern and coupling constants are different. As previously discussed, the C8 
proton of compound 71 appears as a triplet of doublets with a large coupling constant 
corresponding to coupling with H14 and H7α and a significantly smaller coupling constant 
corresponding to coupling with H7β. However, the C8 proton of the literature compound 
appears as a doublet of doublets with two small coupling constants. This data is more 
consistent with the 8R isomer 71a (Figure 2.27), not the 8S stereochemistry as was 
reported in the literature. 
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Figure 2.27: Proposed structure of the literature compound 80 
In addition to the differences in NMR data, the optical rotation observed for compound 71 
was significantly smaller and of the opposite sign to that reported in the literature. 
Attempts to replicate the literature procedure80 to generate compound 71a for further 
characterisation failed. The optical rotation and 1H-NMR data of the compound prepared 
by literature methods were similar to those obtained for compound 71 prepared in MeOH. 
Reasons for this discrepancy remain unclear and attempts to contact the authors of the 
study were unsuccessful. 
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Since morphinone (37) proved too polar for purification by standard flash chromatography, 
synthesis of a pure sample of its adduct (72) with N-acetyl-L-cysteine methyl ester (66) 
would likely require more time consuming purification techniques and was not pursued. 
Codeinone (36) differs from morphinone (37) only in the substitution on the phenyl ring 
and this is unlikely to influence reaction at the cyclohexenone ring to any significant 
extent. Therefore the product of the reaction between morphinone (37) and cysteine 
derivative 66 was expected to have the structure shown in Figure 2.28 below by analogy. 
This is supported by the fact that during kinetics studies, only one product was detected.  
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Figure 2.28: Proposed structure of the compound formed when 
 N-acetyl-L-cysteine methyl ester (66) reacts with morphinone (37) 
When narwedine (30) reacted with N-acetyl-L-cysteine methyl ester (66), two products 
were generated and isolated by flash chromatography in a total yield of 81%. Unlike 
codeinone (36), neither face of the cyclohexenone ring in narwedine (30) is unhindered 
(Figure 2.29). The bottom face is sterically hindered by the azepane ring and the top face is 
sterically hindered by the furan and phenyl rings. Further, narwedine (30) forms a racemic 
mixture in methanol and products resulting from reaction with both enantiomers will be 
present. Therefore, if reaction occurred at both faces a total of four products would be 
present. Due to the stereocenter in N-acetyl-L-cysteine methyl ester (66), products of its 
reaction with each enantiomer of narwedine (30 and 30a) will be diastereomers and should 
be different by 1H-NMR and 13C-NMR analysis. 
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Figure 2.29: 3D-structure of narwedine (30) 
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Figure 2.30: 1H-NMR spectrum of the two products resulting from the  
reaction of narwedine (30) with N-acetyl-L-cysteine methyl ester (66) 
The 1H-NMR spectra obtained for the two fractions are shown in Figure 2.30 above. As 
with the codeinone N-acetyl-L-cysteine methyl ester adduct 71, the peaks were fully 
assigned with the aid of COSY, NOESY and HSQC data. The absence of peaks 
corresponding to the alkene protons in narwedine (30) suggests that the cysteine has added 
across the double bond. A strong HMBC correlation between C8 and H2a’ suggests addition 
at C8, consistent with a conjugate addition.  
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Based on examination of the 1H-NMR and 13C-NMR spectra, each fraction appears to 
contain a single diastereomer. The peaks appear sharp and there is no doubling of peaks, 
even within the 800 MHz 1H-NMR, that might suggest more than one stereoisomer is 
present. Additionally the 1H-NMR and 13C-NMR spectra are very similar, the only 
significant differences are associated with C8 / H8 and the cysteine side chain. This 
suggests that the enantiomerically pure cysteine derivative 66 adds to only one face of the 
cyclohexenone ring of racemic narwedine (30) generating two diastereomers. Coupling 
constants and nOe interactions of the protons in the cyclohexenone ring were examined in 
an attempt to establish at which face of the ring the cysteine derivative 66 reacts.  
In both spectra the C8 proton appears as a broad singlet suggesting that the coupling 
constant for any coupling is very small. Additionally, the C4a proton appears as a triplet 
with very small coupling constants (2.8 Hz) in both spectra. Such coupling constants are 
consistent with gauche relationships in which the C8 or C4a proton bisects the two adjacent 
protons when viewed along the C–C bond. Proposed conformers resulting from addition at 
either face of the cyclohexenone ring, with C8 and C4a protons gauche to their adjacent 
protons, are shown in Figure 2.31 below. 
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Figure 2.31: Proposed conformers of the two possible stereoisomers resulting  
from addition of cysteine at C8 with the cysteine facing up (left) or  
down (right) when the molecule is viewed as shown in the centre  
The key nOe interactions observed for protons in the cyclohexenone ring were an nOe 
between H5α and one of the C9 protons and an nOe between one of the C7 protons and the 
protons of the cysteine side chain. These interactions can be rationalised for either 
diastereomer in Figure 2.31 and therefore cannot be used to determine at which face 
cysteine derivative 66 reacts. An nOe between the C5 and C7 protons would only be 
expected for the chair-like conformation (Figure 2.31, right). Since this was not detected it 
may be tempting to conclude that the isomer corresponding to the alternate conformation is 
the product. However, the absence of an nOe cannot be reliably used as evidence to 
eliminate a possible isomer. 
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While the 1H-NMR data were not sufficient to determine at which face N-acetyl-L-cysteine 
methyl ester (66) reacts, the most likely face can be tentatively assigned based on steric 
arguments. The furan and phenyl rings are conformationally constrained and form a flat 
surface which is sterically undemanding81. Conversely, the azepane ring is not as restricted 
and does not form a flat surface. Therefore the top face is slightly less sterically hindered 
than the bottom face (Figure 2.32) and reaction is more likely to occur at the top face. 
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Figure 2.32: Proposed intermediates for the Michael addition to narwedine (30)  
resulting from attack at the bottom face (left) and top face (right)  
Additionally, in the conjugate addition reaction, the nucleophile approaches a plane 
defined by the alkene substituents. As a result, addition at the bottom face gives rise to a 
boat-like intermediate (Figure 2.32)82,83. Addition at the top face leads to the more stable 
chair-like intermediate, further supporting the suggestion that addition from the top face is 
more likely. Based on these arguments, the likely structures of the compounds formed 
when N-acetyl-L-cysteine methyl ester (66) reacts with racemic narwedine (30 and 30a) are 
those of adducts 73a and 73b in Figure 2.33. However, in the absence of further structural 
information such as X-ray crystal structures, these could not be assigned to their respective 
fractions. 
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Figure 2.33: Proposed structures of the two products formed when N-acetyl-L-cysteine 
methyl ester 66 reacts with racemic narwedine (30 and 30a) 
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2.4.3. Codeinone and Morphinone: 
The kinetics of the reaction between codeinone (36) or morphinone (37) and  
N-acetyl-L-cysteine methyl ester (66) were monitored under conditions as close as possible 
to those employed in SCAM studies (Scheme 2.18). The reaction was carried out at room 
temperature and the reaction mixture was buffered to pH 7.5 with HEPES. Samples of the 
reaction mixture were taken at regular intervals and analysed by LCMS to quantify the 
amount of unreacted ketone remaining in the sample.   
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Scheme 2.18: Reaction of codeinone (36) or morphinone (37)  
with N-acetyl-L-cysteine methyl ester (66)  
As outlined in the previous section, when N-acetyl-L-cysteine methyl ester (66) is in 
significant excess, the concentration of codeinone (36) or morphinone (37) should follow a 
standard exponential decay relationship with time. However, due to the equilibrium 
discussed in section 2.2.1 a small amount of the deconjugated isomer (41 or 45), which 
was unreactive towards thiols, was present in the stock solutions of codeinone (36) or 
morphinone (37). Although a pure sample of codeinone (36) could be prepared, 
isomerisation was observed following preparation and storage of the stock solutions. Since 
these isomers appeared to co-elute with the α,β-unsaturated ketones under the liquid 
chromatography conditions employed, and the masses of their molecular ions were 
identical their presence contributed to the measured concentration of the α,β-unsaturated 
ketone. Furthermore, reaction of the conjugated enone appeared fast relative to the 
equilibration of the deconjugated enone. As a result the measured total enone concentration 
can never reach zero and the exponential decay relationship has a non-zero asymptote. 
Therefore the relationship between the total enone concentration and time is given by the 
following equation where [A]0 is the initial concentration of the α,β-unsaturated ketone and 
[B] is the concentration of the deconjugated isomer: 
𝑇𝑇𝑇𝑇𝑅𝑅𝑅𝑅𝑙𝑙 𝐸𝐸𝑙𝑙𝑇𝑇𝑙𝑙𝑅𝑅 𝐶𝐶𝑇𝑇𝑙𝑙𝐶𝐶𝑅𝑅𝑙𝑙𝑅𝑅𝐶𝐶𝑅𝑅𝑅𝑅𝐶𝐶𝑇𝑇𝑙𝑙 = [𝐴𝐴]0𝑅𝑅−𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜𝑡𝑡 + [𝐵𝐵]  
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The area of the peak corresponding to a particular compound in the LCMS chromatogram 
is proportional to the number of ions detected for that compound in the range monitored. 
Theoretically, this is directly proportional to the concentration of the compound and a 
linear relationship between the concentration of the compound and its peak area should be 
observed. However, if the concentration of ions is too high, the detector can become 
saturated and the relationship is no longer linear. 
 
Figure 2.34: Calibration curve of the correlation between the area of the peak 
corresponding to codeinone (36) and the concentration 
During initial attempts to study the kinetics of the reaction of codeinone (36) with  
N-acetyl-L-cysteine methyl ester (66) a non-linear relationship was observed for the 
concentration range required for kinetics analysis. However, by switching from single ion 
monitoring to scanning over a narrow range the detector sensitivity was reduced enough 
that a linear relationship between peak area and concentration was observed over the 
required concentration range (Figure 2.34). This drop in sensitivity results from the 
detector having to scan a range of m/z ratios and not sensing ions when it is tuned to other 
m/z ratios in the range. The same technique was applied to obtain a calibration curve for 
morphinone (37). This calibration curve can be found in Appendix A along with the 
kinetics data not described in this section.  
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A plot of the concentration of codeinone (36) measured, in triplicate, at regular time 
intervals during the reaction with N-acetyl-L-cysteine methyl ester (66) is shown in  
Figure 2.35 below. The starting concentration of codeinone (36) was 25 μM and the 
concentration of N-acetyl-L-cysteine methyl ester (66) was 500 μM. As is evident by the 
R2 value of 0.9929 the data agree well with an exponential decay equation with a non-zero 
asymptote. The observed pseudo-first order rate constant (kobs) is (2.0 ± 0.1) × 10–3 s–1, 
corrected for the error propagated from the line of best fit in the calibration curve. The 
corresponding second order rate constant (k) is 4.0 ± 0.2 M–1 s–1. 
 
Figure 2.35: Total enone concentration over time during the reaction of codeinone (36) 
with N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 25 μM 
Based on the equation the initial concentration of codeinone (36) was 26 ± 1 μM and the 
initial concentration of neopinone (41) was 1.2 ± 0.2 μM, corrected for the error 
propagated from the line of best fit in the calibration curve. The sum of these values,  
27 ± 1 μM, is reasonably close to the expected value of 25 μM. The discrepancy could 
result from differences in the relationship between peak area and concentration for the two 
compounds. Additionally, the percentage of the deconjugated isomer present in the sample 
measured by 1H-NMR was approximately 5% corresponding to an initial concentration of 
1.25 μM, almost exactly the value obtained from curve fitting.  
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A similar plot was generated for the reaction of morphinone (37) at a concentration of  
25 μM with a 20-fold excess of N-acetyl-L-cysteine methyl ester (66) as shown below in 
Figure 2.36. The data fit well to an exponential decay equation with a non-zero asymptote 
as evidenced by the R2 value of 0.9948. The observed pseudo-first order rate constant (kobs) 
is (1.8 ± 0.1) × 10–3 s–1 corrected for the error propagated from the line of best fit in the 
calibration curve. This corresponds to a second order rate constant (k) of 3.6 ± 0.2 M–1 s–1 
which is very close to the rate constant obtained for codeinone (36). This is unsurprising 
considering the structural similarity between the two compounds. 
 
Figure 2.36: Total enone concentration over time during the reaction of morphinone (37) 
with N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 25 μM 
From the equation above, the initial concentration of morphinone (37) was 21 ± 1 μM and 
the concentration of the deconjugated isomer 45 is 1.3 ± 0.2 μM when corrected for the 
error in the calibration curve. The sum of these values, 22 ± 1 μM, is slightly lower than 
the expected value of 25 μM. This discrepancy is likely a result of differences in the 
relationship between peak area and concentration for the two compounds, especially since 
estimates from 1H-NMR analysis of the sample suggest the initial concentration of the 
deconjugated isomer is approximately 4 μM. However, irrespective of the relative 
responses of the two enone isomers, the exponential decay should still faithfully report the 
rate of reaction for the α,β-unsaturated ketones 36 and 37. 
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2.4.4. Narwedine: 
Initial attempts to monitor the reaction of narwedine (30) with N-acetyl-L-cysteine methyl 
ester (66) using LCMS failed because the reaction was too slow at concentrations typically 
used during LCMS analyses. Instead, the reaction was monitored using 1H-NMR which 
allows for much higher concentrations. Quantification of the starting material remaining in 
the reaction mixture is achieved by measuring the integration of a peak present only in the 
starting material relative to the integration of a peak present in the starting material and the 
product. In this manner, the percentage of starting material remaining can be determined 
and used to determine the concentration. For the method to be accurate the peaks used to 
determine the percentage of starting material remaining need to be well resolved from each 
other and any other peaks in the spectrum. While there was significant overlap of peaks in 
the alkyl region of the NMR spectrum below 4 ppm, above 4 ppm the peaks were well 
resolved, except between 4.5-6.0 ppm where a peak arising from N-acetyl-L-cysteine 
methyl ester (66) masked all peaks in this region.  
 
Figure 2.37: 1H-NMR spectra obtained over the course of the reaction  
between narwedine (30) and N-acetyl-L-cysteine methyl ester 
The 1H-NMR spectra obtained over the course of a reaction of racemic narwedine (30) 
with 20 equivalents of N-acetyl-L-cysteine methyl ester (66) are shown in Figure 2.37. 
Over the course of the reaction the peaks corresponding to the alkene protons (H7 and H8) 
disappear and the peaks corresponding to the aromatic protons (H1 and H2) and one of the 
C12 protons shift slightly downfield and split into two separate peaks corresponding to the 
two separate diastereomers, which form at similar rates.  
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Either of the two alkene protons could be used as the peak present only in the starting 
material. However, close examination of the NMR spectra acquired later in the experiment 
revealed a small, broad peak underneath the H8 peak introducing inaccuracy to the 
integrations obtained for this proton. Therefore the H7 proton was used as the peak present 
only in the starting material. Similarly, it was established that traces of impurities were 
present underneath the aromatic peaks and the peaks corresponding to the C12 proton were 
used as the peak present in starting material and product instead. By dividing the 
integration of the H7 peak by the combined integration of the H12α peaks, the percentage of 
starting material remaining was obtained. This was multiplied by the initial concentration 
(10 mM) to determine the concentration of starting material remaining at each time. A plot 
of these concentrations vs time is shown in Figure 2.38 below. 
 
Figure 2.38: Concentration of narwedine (30) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 10 mM  
Despite the fact that two different products are formed in the reaction of racemic 
narwedine (30 and 30a) with N-acetyl-L-cysteine methyl ester (66), the data fit well with a 
simple exponential decay equation. This suggests that the rate of reaction is similar for 
each enantiomer. The data were not fitted to an exponential decay with non-zero asymptote 
because narwedine (30) does not isomerize to an unreactive unconjugated ketone like 
codeinone (36) and morphinone (37). 
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Replicate experiments were performed and the resulting data were combined to generate 
the graph shown in Figure 2.39 below. The observed pseudo-first order rate constant (kobs) 
was (2.28 ± 0.04) × 10–4 s–1 which corresponds to a second-order rate constant (k) of  
(1.14 ± 0.02) × 10–3 M–1 s–1. This value is three orders of magnitude smaller than the 
values obtained for codeinone (36) and morphinone (37) reflecting the significantly slower 
reactivity of narwedine (30) with N-acetyl-L-cysteine methyl ester (66). Additionally, the 
initial concentration estimated from the equation is 9.8 ± 0.1 mM which is very close to the 
initial concentration submitted to reaction. Individual plots for the second and third 
experiments can be found in Appendix A. 
 
Figure 2.39: Concentration of narwedine (30) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 10 mM   
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2.5. Potential for application of the analogues as thiol reactive probes: 
For a ligand analogue to be suitable for use as a thiol reactive probe in the substituted 
cysteine accessibility method it must satisfy two key criteria. Firstly, the modifications to 
the ligand structure must not be so drastic as to alter the binding properties of the ligand; 
otherwise the analogue may not bind in the same location as the original ligand. As 
discussed in section 2.1.3, the targeted analogues were designed with this in mind. 
Secondly, the modifications must result in an analogue that reacts with the cysteine 
residues and this reactivity must be selective over other reactive residues in the protein. If 
the analogue does not react selectively with the cysteine residue it may covalently attach to 
other residues present in the protein potentially leading to a false positive result.  
In the absence of kinetic data of the binding of galanthamine (23), codeine (25) and 
morphine (35) at nAChRs, an evaluation of the rates of reaction with free cysteine is reliant 
on comparison with reagents that have been successfully used in the substituted cysteine 
accessibility method. The reactions of traditional SCAM reagents such as MTSEA (32) 
with protected cysteine derivatives have not been studied. However, second-order rate 
constants for their reaction with 2-mercaptoethanol (74) at 20 °C in aqueous phosphate 
buffer (pH 7) have been determined64. The rate constant for the reaction of MTSEA (32) 
with 2-mercaptoethanol (74) shown in Scheme 2.19 was (7.6 ± 0.4) × 104 M–1 s–1. The rate 
constants of other methanethiosulfonate reagents were of a similar magnitude64. This is 
four orders of magnitude larger than the rate constants obtained for the reaction of 
codeinone (36) and morphinone (37) with N-acetyl-L-cysteine methyl ester (66) and seven 
orders of magnitude larger than the rate constant obtained for the reaction of  
narwedine (30). Based on these comparisons, the α,β-unsaturated ketones are less reactive 
towards thiols than the methanethiosulfonate reagents. However, as previously discussed, 
the reactivity of the α,β-unsaturated ketones with cysteine residues in the binding site will 
be influenced by proximity effects and decreased absolute reactivity may not necessarily 
be an issue. 
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Scheme 2.19: Reaction of MTSEA (32) with 2-mercaptoethanol (74)  
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MLA maleimide 33 discussed in Section 2.1.2, illustrates this fact and provides another 
reasonable source of comparison. Maleimide 33 reacts with cysteine residues via an 
analogous mechanism to that of the α,β-unsaturated ketones. The reaction of a simple ester 
analogue 75 with N-acetyl-L-cysteine (67) at 20°C in DMSO was monitored to determine 
the second-order rate constant (Scheme 2.20)62. The location and stereochemical outcome 
of the reaction was not determined but based on studies of similar reactions84,85 it is 
proposed that reaction is at the more hindered carbon generating a mixture of 
diastereomers. The rate constant for the reaction was (2.0 ± 0.1) × 10–2 M–1 s–1 which is an 
order of magnitude larger than the value for narwedine (30) and two orders of magnitude 
smaller than the values for codeinone (36) and morphinone (37). 
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Scheme 2.20: Reaction of ester 75 with N-acetyl-L-cysteine (67) 
In another study, the reaction of N-ethyl-2-methylmaleimide (76) with glutathione (77) at 
25 °C in aqueous buffer (pH 7.2) was monitored to determine the second-order rate 
constant (Scheme 2.21)85. The rate constant for the reaction was 4.69 M–1 s–1 which is of 
comparable magnitude to the values for codeinone (36) and morphinone (37). Although the 
measured rate constants for the maleimides (75 and 76) were significantly smaller than the 
rate constants for traditional SCAM reagents, covalent trapping of MLA maleimide 33 
within the binding site was still successful29,62. 
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Scheme 2.21: Reaction of N-ethyl-2-methylmaleimide (76) with glutathione (77) 
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Furthermore, if it is assumed that the reaction between thiol reactive compounds and a 
cysteine mutant is second-order, the rates of reaction of MTSEA (32) and maleimide 33 
with cysteine mutants can be directly compared. In this manner, the effect of binding 
affinity on the reaction rates can also be evaluated. The second order rate constants for the 
reaction of MTSEA (32) with various receptor channel pore cysteine mutants were in the 
range of 0.2-480 M–1 s–1 in the active state and 2.2-16800 M–1 s–1 in the desensitised state86. 
These results suggest that the reaction of MTSEA (32) with cysteine mutants is slower than 
with 2-mercaptoethanol (74). In contrast, the rate constant for the reaction of MLA 
maleimide 33 with a cysteine mutant was 0.0058 s–1 at a concentration of 10 nM. This 
corresponds to a second-order rate constant of 5.8 × 105 M–1 s–1 which is 5 orders of 
magnitude larger than the rate constant for the reaction of N-ethyl-2-methylmaleimide (76) 
with glutathione (77). Therefore although the reactions of narwedine (30), codeinone (36) 
and morphinone (37) are significantly slower than the reaction of MTSEA (32) with free 
thiols in solution, the affinity of these compounds for the binding site is likely to 
significantly increase the rate of reaction with appropriately positioned cysteine residues in 
the binding site. Based on these comparisons it was determined that narwedine (30), 
codeinone (36) and morphinone (37) were of suitable reactivity for use in covalent 
trapping experiments. It should be noted that the rates obtained for the three  
α,β-unsaturated ketones are for reaction at the less hindered face of the cyclohexenone 
ring. Reaction at the more hindered face can still occur but in solution the rate is 
significantly slower. In covalent trapping experiments, the face at which the cysteine 
residue reacts will be governed by the position of the residue relative to the α,β-unsaturated 
ketone when bound in the mutant receptor. 
In terms of selectivity, the α,β-unsaturated ketones are reactive towards nucleophiles. The 
main nucleophilic amino acid residues are the thiol of cysteine, and the alcohols of serine 
and threonine. Stock solutions of codeinone (36) and morphinone (37) were prepared in 
aqueous buffer with 10% methanol as a co-solvent to increase the solubility of the ketones. 
Additionally, the reaction kinetics of narwedine (30) were studied in deuterated methanol. 
Despite this no traces of products resulting from the conjugate addition with water or 
methanol were observed suggesting that the α,β-unsaturated ketones react selectively with 
thiol residues over alcohol residues. It should also be noted that the structurally similar 
maleimides are known to show selectivity for thiols over other residues87 and the  
α,β-unsaturated ketones would be expected to show similar selectivity. 
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The chlorinated codeine analogues (38 and 39) were found to be too reactive and unstable 
to be of any use in SCAM studies reacting with water to generate the hydroxy products 
(Figure 2.40). Since SCAM studies are carried out in aqueous solution, it is important that 
the analogues are stable in water. Codeine mustard 38 reacted with water generating the 
hydroxyethyl amine 52 with a half-life of approximately 30 minutes at a concentration of 
20 μM. While the targeted benzyl chloride 39 could not be synthesised cleanly, the 
stability of protected benzyl chloride 58 was assessed and its reaction with water was too 
fast to accurately measure the half-life (t½ < 1 min). The reactivity of these analogues with 
water demonstrates that they do not have adequate selectivity to differentiate cysteine 
residues from other nucleophilic residues in the protein such as serine and threonine.  
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Figure 2.40: Products of the reaction of the chlorinated 
codeine analogues (38 and 39) with water. 
The high reactivity of chlorinated codeine analogues 38 and 39 is unsurprising given their 
structure. Codeine mustard 38 readily forms the aziridinium ion 50, a strong alkylating 
agent, under neutral or basic conditions. Benzyl chloride 39 contains a highly electron rich 
aromatic ring with a strongly electron donating alkoxy substituent ortho to the benzyl 
chloride moiety and two moderately electron donating alkyl substituents. The combined 
effect of these substituents stabilizes the benzyl carbocation formed by loss of the chloride 
ion.            
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2.6. Conclusions and Future Work: 
Thiol reactive analogues of codeine (25), morphine (35) and galanthamine (23) were 
prepared as probes to study the binding site of these compounds at nAChRs (Figure 2.41). 
The conjugated ketone derivatives; codeinone (36), morphinone (37) and narwedine (30) 
were prepared via oxidation of the corresponding allylic alcohol. Codeine (25) and 
galanthamine (23) were oxidised in one step with DMP in yields of 81% and 71% 
respectively. The phenol of morphine (35) precluded direct oxidation and morphinone (37) 
was instead prepared in a three step process involving selective protection of the phenol as 
the TBDMS ether followed by oxidation with DMP and subsequent deprotection to afford 
morphinone (37) in an overall yield of 18%. An enantioenriched sample of narwedine (30) 
was also prepared via oxidation of galanthamine (23) with MnO2 in 77% yield and 58% ee 
(determined by optical rotation). 
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Figure 2.41: Structures of the prepared thiol reactive analogues 
Codeine mustard 38 was prepared from codeine (25) in two steps involving  
N-demethylation with α-chloroethyl chloroformate followed by reductive amination with 
chloroacetaldehyde and NaBH(OAc)3 in an overall yield of 70%. While benzyl chloride 39 
could not be prepared in sufficient purity, the protected analogue 58 was prepared in five 
steps from morphine (35). Triflation of the phenol and protection of the allylic alcohol as 
the TBDMS ether afforded protected triflate 55 which was carried through carbonylative 
coupling, reduction and subsequent chlorination to afford protected benzyl chloride 58 in 
an overall yield of 38%. 
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The kinetics of the reaction between the conjugated ketones and N-acetyl-L-cysteine 
methyl ester were studied as a model for their reactivity with cysteine residues in mutant 
nAChRs. Codeinone (36) and morphinone (37) reacted exclusively at the least hindered 
face of the cyclohexenone ring with second order rate constants (k) of 4.0 ± 0.2 M–1 s–1 and  
3.6 ± 0.2 M–1 s–1 respectively. Narwedine (30) reacted at one face of the cyclohexenone 
ring with a second order rate constant (k) of (1.14 ± 0.04) × 10–3 M–1 s–1.  
The suitability of the prepared analogues for use as thiol reactive probes was assessed 
based on their reactivity and the difference between their structure and the structure of their 
parent compounds. The modifications to the structure of the three compounds were 
deemed to be small enough that the analogues should still exhibit similar binding 
properties to their parent compounds. However, only the conjugated ketones were deemed 
to have acceptable reactivity for use as probes. Codeine mustard 38 reacted rapidly with 
water in buffered solutions to afford the hydroxy derivative with a half-life of 30 minutes 
at a concentration of 20 μM. While the benzyl chloride 39 could not be prepared, the 
reactivity of its protected analogue 58 was assessed and its reaction with water was very 
rapid (t½ < 1 min) at concentrations as low as 10 μM.  
Based on these results it has been established that the conjugated ketone derivatives are 
suitable for use as thiol reactive probes and these have been sent to the University of 
Sydney, Faculty of Pharmacy for further testing. This testing will involve the use of mutant 
receptors with cysteine residues introduced in the proposed binding sites discussed in the 
beginning of this chapter. The results of these tests will potentially identify the binding site 
of galanthamine and codeine at nAChRs of different subtypes. Since galanthamine and 
codeine are reported to be allosteric modulators of nAChRs, knowledge of their binding 
site at nAChRs could provide an insight into the mechanism of allosteric modulation of 
nAChRs. Such knowledge would allow for the development of novel drugs to treat 
neurological diseases such as Alzheimer’s disease, epilepsy and schizophrenia.  
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Figure 2.42: Structures of the fluorinated analogues of codeine (25) 
Some promising results were achieved in initial attempts to prepare benzyl fluoride 65. 
Future work would expand upon these initial studies to prepare the product for evaluation 
as a potential thiol reactive probe. It is expected that the increased stability of the  
carbon-fluorine bond may reduce the reactivity such that the analogue is a viable 
alternative to codeinone (37). Similarly, N-fluoroethyl-norcodeine (78) could be prepared 
(Figure 2.42). If these were found to be suitable as probes the corresponding analogues of 
galanthamine (23) could also be studied.    
73 
 
Chapter 3  
 
Chapter 3: Analogues of Methyllycaconitine 
3.1. Introduction: 
3.1.1. Delphinium Alkaloids:  
The Delphinium class of plants, known colloquially as Larkspur, are a major cause of cattle 
losses on western rangelands in the US88. The toxicity of Larkspur plants results from the 
presence of norditerpenoid alkaloids. Over 40 different norditerpenoid alkaloids have been 
reported in Larkspur species of which MLA (13), nudicauline (NUD, 79) and  
14-deacetylnudicauline (14-DAN, 80) are the most toxic (Figure 3.1). 
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Figure 3.1: Structure and relative toxicities of the three most toxic alkaloids found in 
Larkspurs, a lower value for relative toxicity indicates a lower toxicity   
Since norditerpenoid alkaloids are rapidly eliminated from the blood, Larkspur poisoning 
in the field presumably results from continuous consumption of the plants. Toxicity is 
characterised by neuromuscular paralysis causing muscle weakness, tremors, collapse and 
eventually death from respiratory failure88,89. If treated quickly death can be prevented by 
administering AChE inhibitors such as neostigmine (81) and physostigmine (24) which 
increase ACh responses and thus reduce the toxic effects (Figure 3.2). 
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Figure 3.2: Structures of acetylcholinesterase inhibitors  
used to reduce the toxic effects of Larkspur   
Alkaloid Compound Number R Relative Toxicity 
MLA 13 OMe 1 
NUD 79 OAc 1.7 
14-DAN 80 OH 1.3 
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3.1.2. Methyllycaconitine and nAChRs: 
Methyllycaconitine (13) is the most important alkaloid contributing to the toxicity of 
Larkspurs due to its prevalence in most species along with its high toxicity. It was first 
extracted in 1938 from Delphinium brownii90 and its structure was determined based on 
chemical correlation with the parent alkaloid lycoctonine (82), which is 100 times less 
toxic than MLA (13). Because salts formed from lycoctonine (82) did not form stable 
crystals, the structure of lycoctonine (82) was inferred from x-ray crystallography studies 
on a des-(hydroxymethyl)-lycoctonine (83) salt91. Based on these studies the structures 
were assigned as those in Figure 3.3. 
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Figure 3.3: Structures of lycoctonine (left) and des-(hydroxymethyl)-lycoctonine (right) 
The structure of the ester moiety of MLA (13) was determined based on analysis of its 
hydrolysis products92 (Scheme 3.1). Hydrolysis of MLA (13) gives lycoctonine (82), 
anthranilic acid (84) and methylsuccinic acid (85). The stereochemistry of the methyl 
maleimide ring in the MLA (13) ester sidechain was confirmed by analysis of the 
methylsuccinic acid (85) obtained from MLA (13) hydrolysis and comparison with an 
enantiopure sample of (S)-methylsuccinic acid (85)93. 
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Scheme 3.1: Hydrolysis of MLA (13)   
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While the total synthesis of MLA (13) has yet to be achieved, its semi-synthesis from the 
parent alkaloid lycoctonine (82) has been reported94 and is shown in Scheme 3.2. 
Lycoctonine (82) was acylated with isatoic anhydride in the presence of 4-dimethylamino 
pyridine (DMAP) with the loss of carbon dioxide, forming inuline (86) in 21% yield. 
Inuline (86) was then treated with (S)-methylsuccinic anhydride to afford the two half-acid 
amides (87a and 87b) and the succinimide ring was then closed with carbonyl diimidazole 
(CDI) giving MLA (13) in 55% yield over two steps. 
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Scheme 3.2: Semi-synthesis of MLA (13) from lycoctonine (82) 
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As previously noted, MLA (13) is well known for its competitive antagonism of α7 
nAChRs, but it also acts as an antagonist at α4β2 receptors although it is much less potent. 
As a competitive antagonist, it exerts its action on α7 receptors by binding to the same 
binding site as ACh. Based on analysis of the time course of blockade and recovery from 
inhibition, it has been shown that there are five potential binding sites for MLA (13) on a 
single α7 nAChR95. Binding of a single molecule of MLA (13) is enough to elicit an 
antagonistic effect. As such, recovery from inhibition occurs only when all five binding 
sites on the receptor are free from MLA (13). Similar studies have shown that MLA (13) 
has two potential binding sites on α4β2 receptors, suggesting that it binds at the α4-β2 
interface. However, results from more recent studies suggest that MLA (13) also acts on 
α4β2 receptors by binding to the α4-α4 interface. 
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Figure 3.4: Correlation between the structures of ACh (left)  
and methyllycaconitine (right) at physiological pH 
Some structure-activity relationship data has been obtained by comparing toxicity data 
(LD50) of MLA (13) with other alkaloids extracted from Delphinium species. Such 
comparisons have revealed that the presence of the ester moiety is of primary importance 
as shown by the significantly greater activity in alkaloids with the ester than in those 
without88. It has been suggested that this observation can be explained by considering the 
structure of MLA (13) at physiological pH and comparing it with the structure of ACh 
(Figure 3.4). While this hypothesis only requires that the benzoic acid ester is present, loss 
of components of the ester group result in a drop in activity. For example, loss of the 
methyl substituent on the succinimide ring results in a 4.3-fold drop in toxicity, while 
removal of the succinimide ring entirely results in a 33-fold drop in toxicity. This 
hypothesis is supported by crystal structures of MLA (13) bound to the AChBP in which 
the ethyl piperidine ring is situated within the aromatic box much like the quaternary 
ammonium of ACh96. 
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In addition to the effects of changing the ester moiety in MLA (13), other structure-activity 
relationships have been ascertained for the lycoctonine backbone88. Loss of the ethyl group 
on the amine results in a 20-fold drop in activity. Replacement of the C1 methoxy group 
with a hydroxyl or acetoxy group results in a drop in toxicity. Similarly, replacement of the 
C16 methoxy group with an acetoxy group results in a drop in toxicity. Conversely, 
replacement of the C14 methoxy group with a hydroxyl or acetoxy group results in an 
increase in toxicity. Conversion of the C7 and C8 hydroxyls to a methylenedioxy group 
results in a 2-fold drop in activity. These structure-activity relationships are summarised in 
Figure 3.5.  
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Figure 3.5: Summary of structure-activity relationships for  
MLA (13) derived from studies of related alkaloids  
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Figure 3.6: Analogues of MLA formed by varying substitution on the succinimide ring 
There has also been an attempt to determine structure activity relationships for MLA (13) 
by studying synthetic analogues. Work by Carroll et al.97 involving the analogues 
presented in Figure 3.6 above demonstrated the effects of changing the substituents of the 
succinimide ring of MLA (13). It was found that simply changing the stereochemistry of 
the methyl group from (S) to (R) giving compound 88a halved the affinity for α7 nAChRs 
(Ki = 2.1 nM). Increasing substitution on the succinimide ring lead to similar decreases in 
affinity (Ki for compound 88b = 1.8 nM, Ki for compound 88c = 2.5 nM). The relative 
configuration of compound 88c was not defined in the study. Replacement of the methyl 
group with a phenyl group as in compound 88d also halved the affinity for the α7 nAChR 
(Ki = 1.8 nM), while substituting with a cyclohexyl group as in compound 88e lead to an 
almost 30-fold drop in affinity (Ki = 27 nM). In an effort to further elucidate the structure 
activity relationships of MLA (13) and to characterise its biological activity, smaller 
analogues have been studied for their activity at a variety of nAChRs and these are covered 
in the following section. 
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3.1.3. Simplified Analogues of MLA:  
The simplest analogue of MLA (13) that has been synthesised and studied is analogue 89 
consisting of the ester moiety and the piperidine ring (Figure 3.7). Synthesised by  
Doisy et al.98, this analogue has no potency at the α4β2 nAChR (IC50 > 1 mM) but modest 
potency at the α7 nAChR (IC50 = 50 μM). Replacement of the succinimide ring in  
analogue 89 with a chlorine atom led to a decrease in potency by a factor of two  
(IC50 = 100 μM), while removing substitution entirely to form the benzoate resulted in a 
16-fold decrease in potency (IC50 = 800 μM).  
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Figure 3.7: Monocyclic analogue of MLA 
In this same study restricted monocyclic analogue 90 was prepared (Figure 3.8) which was 
found to bind with 10 fold lower potency (IC50 = 500 μM) for the α7 nAChR than  
analogue 89. Replacement of the succinimide ring in analogue 90 with a chlorine atom led 
to an increase in potency by a factor of 10 (IC50 = 50 μM), while removing substitution 
from the ester entirely to give the benzoate resulted in a five-fold increase in potency  
(IC50 = 100 μM). 
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Figure 3.8: Restricted monocyclic analogue of MLA 
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Further, more extensive work on monocyclic analogues has been carried out by Bergmeier 
and co-workers looking at the effect of altering substitution on the piperidine nitrogen  
(Figure 3.9) generating analogues 91a-f and 92. Early studies tested the ability of these 
analogues to inhibit nicotine-stimulated catecholamine release by adrenal chromaffin cells 
which express multiple nAChR subtypes including the α7 subtype99. More recent studies 
identified the likely nAChR subtype at which these analogues were active to be the α3β4 
receptor as they exhibit no effect at α4β2 nAChRs and little to no antagonist activity at the 
α7 receptor100. Increasing or decreasing the length of the alkyl chain (R2), or introducing 
an oxygen atom, was found to have little to no effect on antagonist activity. As expected, 
based on previous structure-activity studies, removal of the methyl group (R1) from the 
succinimide ring led to a decrease in activity99. 
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91  
Figure 3.9: Monocyclic analogues of MLA varying the substitution on the piperidine ring 
More promising results were achieved when introducing a much bulkier 3-phenyl-propyl 
substituent on the amine (Figure 3.10). While substitution with a phenyl-ethyl group led to 
no significant change in antagonist activity, relative to the other analogues tested, a 
separation of three carbons as shown in Figure 3.12 resulted in a significant increase in 
activity (86% inhibition), almost as high as MLA (13) at α3β4 nAChRs (95% inhibition)99. 
The results of these and further studies by Bergmeier and co-workers101 have led to the 
development of a pharmacophore model for α3β4 nAChR binding. Studies investigating 
the importance of stereochemistry established that binding is non-stereoselective at α3β4 
receptors (all stereoisomers are equipotent)102.   
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Figure 3.10: Monocyclic analogue of MLA incorporating a bulky phenyl  
group. The two key stereocentres are marked with an asterisk 
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Figure 3.11: Bicyclic analogue of MLA  
While extensive work has been carried out synthesising bicyclic analogues (Figure 3.11) 
and tricyclic analogues (Figure 3.12) of MLA (13), very few of these analogues have been 
tested for their biological activity. The simplest bicyclic analogue, prepared by the McLeod 
group, is analogue 34 shown in Figure 3.1161. It is a competitive antagonist at the α7 
receptor (IC50 = 21 μM) and a non-competitive antagonist at the α4β2 receptor  
(IC50 = 4.7 μM). Interestingly, when a methoxy group is introduced in the analogous 
position to that in MLA (13), marked with an asterisk the antagonist activity at the α7 
receptor decreases (37% inhibition vs 95% inhibition at 300 μM concentrations)103.  
Tricyclic analogue 93 (Figure 3.12) has also been studied alongside the bicyclic analogues 
previously discussed61,103. It is a competitive antagonist at the α7 nAChR (IC50 = 11 μM) 
but a non-competitive antagonist at the α4β2 nAChR (IC50 = 7.2 μM). It is a more potent 
antagonist than analogue 34 at α7 receptors but a less potent antagonist at α4β2 receptors. 
As expected based on the previously discussed structure activity relationships, removal of 
the ester moiety giving the free alcohol leads to a decrease in antagonist activity for both 
bicyclic analogue 34 and tricyclic analogue 9361.  Interestingly, this removal also results in 
a shift from competitive to non-competitive antagonist activity at the α7 nAChR in both 
cases. 
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Figure 3.12: Tricyclic analogue of MLA  
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Figure 3.13: Structure of azabicyclic alcohol 94 
Because azabicyclic alcohol 94 (Figure 3.13) is a non-competitive inhibitor, it is not likely 
to act at the agonist binding site and its binding site is not immediately obvious. However, 
by applying the SCAM technique discussed in chapter 2, alcohol 94 was demonstrated to 
bind within the channel pore61. This fact is supported by the voltage dependent antagonism 
alcohol 94 exhibits at α4β2 nAChRs. The thiol reactive analogue of alcohol 94 employed 
in this study was azabicyclic mustard 95 which interacts with the introduced cysteine via a 
simple substitution reaction as shown in Figure 3.14.  
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Figure 3.14: Covalent trapping of a cysteine residue with azabicyclic mustard 95 
In a similar manner, binding sites for MLA (13) at the α7 and α4β2 nAChRs have been 
identified or confirmed through the application of covalent trapping. At α7 nAChRs, where 
it is a competitive antagonist, it was demonstrated that MLA (13) binds at the agonist 
binding site at the α7–α7 interface62. More recently, it was demonstrated that MLA (13) 
binds at the α4–α4 interface of α4β2 nAChRs29, which is found only in the (α4)3(β2)2 
stoichiometry. Inhibition of ACh evoked current at α4β2 nAChRs in the (α4)3(β2)2 
stoichiometry was found to be insurmountable. This suggests that, in addition to its 
competitive binding at the α4–β2 interface, MLA (13) binds non-competitively at the  
α4–α4 interface. Since MLA (13) binds at the α4–β2 and α4–α4 interfaces in addition to 
the α7–α7 interface, it provides a suitable model on which to base analogues that may bind 
selectively to one interface over another. Such analogues could then be used as tools for 
mapping the location of α7 and α4β2 nAChRs (both stoichiometries) in the brain and to 
study their roles in brain functions. 
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3.1.4. Project Aims: 
From the available literature it is clear that there is a need for a greater understanding of 
the structure and functionality of nAChRs in order to develop effective treatments for 
diseases associated with these receptors. Towards this goal, the work detailed in this 
chapter aims to develop novel compounds that can be used as probes to further elucidate 
the structure and functionality of α4β2 nAChRs in both stoichiometries. 
 
Figure 3.15: Key residues found in the MLA (13) binding sites at  
the α4–β2 (left), α7–α7 (centre) and α4–α4 (right) interfaces  
Computational ligand protein docking studies with MLA (13) at α4β2 nAChRs were 
carried out by Dr Thomas Balle at the Faculty of Pharmacy, University of Sydney. By 
replacing residues in the X-Ray crystal structure of a mutant AChBP104 with the 
corresponding residues in the rat α7 and α4β2 nAChRs, models of the α4–β2, α7–α7 and 
α4–α4 interfaces were prepared. These revealed three key residues in the α4–β2 and α4–α4 
binding sites that differ in the binding site of α7 nAChRs. Models of the α4–β2, α4–α4 and 
α7–α7 interfaces, with these key residues highlighted are shown in Figure 3.15. Of these 
residues two are located in close proximity to the ester side chain of MLA (13). A serine 
residue in the α7–α7 interface located above the MLA (13) sidechain is replaced by the 
acidic aspartate residue in the α4–β2 interface and the non-polar leucine residue in the  
α4–α4 interface. An isoleucine residue in the α7–α7 interface located below the MLA (13) 
sidechain is replaced by the polar threonine residue in the α4–β2 interface and the large 
hydrophobic aromatic tryptophan residue in the α4–α4 interface. Therefore, by designing 
ester derivatives of MLA (13) with functional groups targeting these changes it should be 
possible to generate analogues that bind selectively to one interface of α4β2 nAChRs. 
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Since MLA (13) can only be obtained by isolation from natural sources it is prohibitively 
expensive to develop extensive libraries of ester analogues with the MLA (13) backbone. 
However, as discussed earlier in this chapter bicyclic analogue 34 has similar functional 
properties to MLA (13) albeit with much lower efficacy. As such, ester analogues of 
compound 34 were targeted to develop a library of compounds that could be screened for 
activity at α7 and α4β2 nAChRs. 
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Figure 3.16: Interaction between the two key residues identified in α4β2  
nAChRs and one of the proposed compounds to be synthesised and tested 
The aspartic acid residue can potentially be targeted via interactions between the aspartic 
acid proton and an acetamidopyridine moiety (Figure 3.16). Since the aspartic acid residue 
and acetamidopyridine moiety have comparable pKa values (≈4–4.5), the 
acetamidopyridine moiety may be protonated by the aspartic acid residue generating a salt 
bridge. The tryptophan residue can be targeted via hydrogen bonding interactions with the 
carbonyl of an acetamide moiety (Figure 3.16). To this end, analogues 96a-f containing 
both functionalities in addition to analogues 97a-c containing the pyridine moiety and 
analogues 98a-b containing the amide moiety have been prepared. These were sent for 
biological testing and preliminary screening results are also presented in this chapter. 
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Figure 3.17: General structure of the analogues prepared for biological testing 
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3.2. Synthetic Strategies:  
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Scheme 3.3: Retrosynthetic strategies for the preparation of  
analogues 96-98, key disconnections are highlighted in red 
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Considering the structure of the target analogues, two logical disconnections are apparent. 
These are at the ester functional group and at the biaryl bond (Scheme 3.3). Since these 
disconnections are unrelated, the processes (Suzuki coupling and esterification) can be 
carried out in either order. By switching the order of the two key processes, two synthetic 
routes were devised as shown. 
Initial studies involved esterification as the final step (Scheme 3.3, Route 1). In this 
scheme, analogues 96–98 were generated via esterification of bicyclic alcohol 94 with the 
corresponding biaryl acids 99–101. These acids could in turn be prepared via a Suzuki 
coupling between an aryl boronic acid (or boronate ester) with an appropriate functional 
group in the 2-position, and the corresponding aryl bromides 102–104. This would be 
followed by functional group conversion to the carboxylic acids.  
As a result of difficulties that will be detailed later in this chapter, a route involving Suzuki 
coupling as the final step was devised (Scheme 3.3, Route 2). In this scheme, analogues 
96–98 were generated via Suzuki coupling of aryl boronate 105 with the corresponding 
aryl bromides 102–104. Aryl boronate 105 could be prepared by borylation of iodo  
ester 106. This in turn could be prepared via esterification of bicyclic alcohol 94 with  
2-iodobenzoic acid (107). This route was more suited to the rapid generation of a library of 
compounds as variations to the substitution in the biaryl ester side chain were only 
introduced in the final step.  
It should be noted that analogues with the acetamide in the 2-position were not targeted 
due to an expected intramolecular condensation reaction (Scheme 3.4). The acetamide 
nitrogen could react at the carbonyl of the ester (or acid) generating the stable cyclic  
imide 108 as shown, with bicyclic alcohol 94 or water as a by-product. As a result, of the 
three possible acetamidophenyl analogues only two were targeted (98a-b) and only six of 
the ten possible acetamidopyridyl analogues were targeted (96a-f).  
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Scheme 3.4: Intramolecular condensation reaction expected for 2-acetamido analogues 
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3.3. Synthesis of Bicyclic Alcohol: 
Bicyclic alcohol 94 is a key intermediate in both routes to prepare analogues 96–98 
outlined in the previous section. It was prepared from commercially available ethyl  
2-oxocyclohexane-1-carboxylate (109) in three steps (Scheme 3.5)105. In our hands, the 
first step, involving a double Mannich reaction with one equivalent of ethylamine and two 
equivalents of formaldehyde, produced ester 110 in 28% yield. Ester 110 was then carried 
through a Wittig olefination with methyl triphenylphosphonium bromide (MePPh3Br) and 
potassium tert-butoxide (t-BuOK), giving ester 111 in 71% yield. Finally, ester 111 was 
reduced to bicyclic alcohol 94 with LiAlH4 in 93% yield.      
EtO
O
O
N
HO
N
EtO
N
EtO
O
CH3CH2NH2
 
/ CH2O
Ethanol Reflux 3 d
Yield = 28%
THF RT 2 h
Yield = 93%
LiAlH4
MePPh3Br / t-BuOK
THF RT 16 h
Yield = 71%
O
O
109 110
94 111  
Scheme 3.5: Synthesis of Bicyclic Alcohol 94 from  
ethyl 2-oxocyclohexane-1-carboxylate (109) 
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Formation of the double Mannich product 110 was readily apparent with the distinctive 
1H-NMR pattern of the 3-azabicyclo[3.3.1]nonane system (Figure 3.18). Peaks in the  
1H-NMR and 13C-NMR spectra were fully assigned with the aid of COSY, HSQC and 
HMBC data, with reference to structural studies on the N-methyl derivative106. In general, 
the 1H-NMR and 13C-NMR data were in agreement with those reported in the literature105. 
 
 Figure 3.18: 1H-NMR spectrum of the double Mannich product 110 
The relative position of the axial and equatorial protons on each carbon was determined 
using the NOESY spectrum of iodo ester 106 as this compound had greater resolution of 
peaks. An nOe interaction between the C6 and C8 axial protons was used to differentiate 
these from the C6 and C8 equatorial protons. Similarly, an nOe interaction between the C2 
and C4 axial protons was used for their identification. The axial proton on C7 was identified 
by its significant downfield shift resulting from deshielding by the nitrogen. Additionally, 
the methylidene protons in the subsequent products were differentiated based on nOe 
interactions with the C5 proton and the C1a protons.  
N
Hax
Hax
Heq
Heq
Heq
Hax
Hax
Heq
Ha
H Hb
Et
Hax
Heq 1
2
3
4
5
OR
H H
1a
6
7
8
9
10
    
Figure 3.19: Key nOe interactions (red) observed between protons  
of the 3-azabicyclo[3.3.1]nonane system in iodo ester 106  
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Figure 3.20: Formation of the intermediate iminium ion and enol 
Given that the double Mannich reaction is a four component reaction, it is unsurprising that 
the first step in this synthesis was also the lowest yielding. For the reaction to proceed 
ethylamine and formaldehyde need to react to form the iminium ion and compound 109 
needs to be in its enol form (Figure 3.20). Addition of the iminium ion to the enol double 
bond followed by loss of a proton results in the formation of the monosubstituted 
intermediate 112 (Figure 3.21). This can react with a second molecule of formaldehyde 
forming the iminium ion, which undergoes cyclisation to form bicyclic ester 110.  
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Figure 3.21: Reaction of the intermediate iminium ion and enol,  
and subsequent intramolecular Mannich reaction 
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In ethyl 2-oxocyclohexane carboxylate (109) the enol form is stabilised by conjugation 
with the adjacent carboxyl group. However, the enol form of the monosubstituted 
intermediate 112 does not benefit from this same stabilising effect and is much less stable. 
As such, one possible reason for the low yield observed in this reaction is that the final 
cyclisation does not proceed efficiently. Additionally, analysis of the crude reaction 
mixture by gas chromatography – mass spectrometry (GCMS) suggested a number of side 
reactions were also occurring, further lowering the yield. These included conversion of the 
ester to an ethyl amide giving compounds 113 and 114, and amination at the ketone to 
form compounds 115 and 116. Proposed structures of the identifiable components in the 
crude reaction mixture are shown in Figure 3.22. In addition to the other products 
previously mentioned, an unidentified product of mass 206 was also detected. It should be 
noted that only compound 113 remained as an impurity following acid-base extraction.  
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Figure 3.22: Proposed structures of the components of the crude reaction mixture 
Formation of alkene 111 in the subsequent Wittig olefination was supported by analysis of 
the 1H-NMR and 13C-NMR spectra. Two singlets were detected in the 1H-NMR spectrum 
at 4.5 ppm and 4.7 ppm corresponding to the methylidene protons. In the 13C-NMR 
spectrum the peak at 213 ppm corresponding to the ketone carbonyl was replaced with a 
peak at 153 ppm. An additional carbon peak at 104 ppm was detected corresponding to the 
methylidene carbon. The NMR spectra were also in agreement with literature data105. 
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The Wittig reaction proceeded without major difficulty aside from the formation of a side 
product that could not be adequately separated from the desired compound. Analysis of the 
mass spectrum of the impure product revealed a peak at m/z = 265 consistent with the 
formation of tert-butyl ester 116. Additionally, a strong singlet at 1.5 ppm was detected in 
the 1H-NMR spectrum consistent with the t-butyl protons. It is believed that 
transesterification of compound 111 occurs, with the base used in the Wittig reaction  
(t-BuOK), resulting in the formation of tert-butyl ester 116 (Scheme 3.6).    
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Scheme 3.6: Proposed side-reaction in the Wittig olefination 
The presence of this side-product did not pose a significant problem in subsequent steps in 
the synthesis as it was reduced alongside the Wittig product 111 generating bicyclic 
alcohol 94. However, longer reaction times were needed to ensure complete reduction. 
Reduction of the ester was evident in the 1H-NMR spectrum with the loss of the triplet at 
1.3 ppm and the quartet at 4.2 ppm. These were replaced with a set of doublets centred 
around 3.6 ppm corresponding to the methylene protons adjacent to the alcohol. The OH 
proton was detected as a broad singlet underneath the multiplet corresponding to H7eq and 
H8ax. Additionally, upfield shifts (0.1–0.5 ppm) were noted for the C2 and C8 protons 
reflecting the change in the C1 substituent. In the 13C-NMR spectrum, the absence of peaks 
above 160 ppm corresponding to carbonyl carbons suggested that the ester had been 
reduced. In general, the NMR data were in agreement with the literature data105.   
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3.4. Ester Coupling Route: 
3.4.1. Synthesis of Biaryl Acids: 
Two different routes to the required acids, based on literature procedures107, were 
considered using the pyridyl derivatives as a model (Scheme 3.7). The ester route  
(Scheme 3.7, Route 1), involved Suzuki coupling of the bromopyridine 103a-c with 
boronate ester 117, followed by hydrolysis of the resulting pyridyl ester 118a-c. The tolyl 
route (Scheme 3.7, Route 2) involved Suzuki coupling with o-tolyl boronic acid (119), 
followed by permanganate oxidation of the resulting pyridyl toluene 120a-c. Since 
boronate ester 117 was not commercially available, it needed to be synthesised from ethyl 
benzoate (121) adding an extra step108. However, in our hands the overall yields for the 
subsequent steps (42-69%) were far greater than those for the tolyl route (24-42%). Based 
on these results it was decided that the ester route would be used to prepare the remaining 
acids. 
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Scheme 3.7: Synthesis of the pyridyl benzoic acids 100a-c via two different routes 
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Suzuki coupling of the aryl bromides 102–104 with boronate ester 117 was performed to 
synthesise the acetamidopyridyl (122a-f), pyridyl (118a-c) and acetamidophenyl (123a-b) 
esters. In each case, formation of the desired product was supported by thin-layer 
chromatography (TLC) and analysis of the 1H-NMR spectra, particularly in the aromatic 
region. Only one UV-active spot was detected during TLC analysis, with a different 
retention factor (rf) to the starting materials, suggesting a single product was present. This, 
combined with the fact that peaks corresponding to the aromatic protons in each aromatic 
ring were detected in a 1:1 ratio, suggested the desired coupling had taken place. 
Percentage yields for each of the biaryl esters are given in Table 3.1. 
Table 3.1: Percentage yields in the Suzuki coupling  
of aryl bromides 102–104 with boronate ester 117  
B
OO
OEt
O
+ OEt
O
Pd(PPh3)4
 
/ K2CO3
Toluene / Ethanol
BrAr
Ar
 
Ar Product Yield  Ar Product Yield 
N
H
N
O
 
122a 45% 
 
N
 
118a 77% 
N
N
H
O
 
122b 69% 
 
N  
118b 53% 
N
H
N
O
 
122c 60% 
 
N
 
118c 78% 
N
H
N
O
 
122d 74% 
 H
N
O
 
123a 63% 
N N
H
O
 
122e 67% 
 
N
H
O
 
123b 56% 
N
H
N
O
 
122f 64% 
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While modest yields (53-78%) were achieved in the majority of cases, yields for the 
preparation of ester 122a were consistently low and the maximum yield obtained was 45%. 
The low yields in this example can be explained by the fact that a significant amount of  
4-amino-2-bromopyridine (124) was formed as a by-product, identified by 1H-NMR 
comparison with an authentic sample. It is believed that this forms by hydrolysis of the 
acetamide group (Scheme 3.8) under the basic conditions employed in the Suzuki reaction. 
Hydrolysis of the acetamide was not observed for any of the other aryl bromides during the 
Suzuki reaction. Additionally, compound 125a, which would result from Suzuki coupling 
of 4-amino-2-bromopyridine (124) with boronate ester 117, was not detected. This is likely 
to result from the electron donating amine giving rise to a highly electron rich aromatic 
ring which is less susceptible to oxidative addition by the palladium catalyst.   
N
H
NBr O OH
102a 124
- AcO N
NH2Br OEt
O
N
NH2
125a
 
Scheme 3.8: Hydrolysis of 4-acetamido-2-bromopyridine 
When carrying out the Suzuki reaction with 4-bromopyridine (103c) the hydrochloride salt 
was required due to the instability of the free pyridine. In its free base form,  
4-bromopyridine (103c) undergoes self-condensation forming a polymer (Scheme 3.9). In 
reactions with the hydrochloride salt, the free base was generated in situ by adding an extra 
equivalent of K2CO3. 
N Br N
n
103c  
Scheme 3.9: Self-condensation of 4-bromopyridine (103c) 
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The mechanism of the Suzuki reaction (Figure 3.23) is similar to the mechanism for 
carbonylative coupling presented in Chapter 2. First the aryl bromide (103a) undergoes 
oxidative addition with the palladium complex Pd(0)(PPh3)2, generating the first 
intermediate 126, which reacts with hydroxide to form intermediate 127. This reacts with 
the base activated boronic acid 128 via transmetallation forming the final intermediate 129, 
which undergoes reductive elimination to regenerate the palladium complex along with the 
target biaryl compound (118a). It should be noted that under the basic conditions in this 
reaction boronate ester 117 is hydrolysed to boronic acid 117a. 
(PPh3)2Pd(0)
B
OH
OH
OEt
O
NBr
N
OEt
O
Pd(II)(PPh3)2
OEt
O
N
B
OH
OH
OEt
O
OH
Br Pd(II)(PPh3)2
N
HO Pd(II)(PPh3)2
N
Br
OH
B(OH)4
OH
103a
126
127
129
128 117a
118a
(PPh3)4Pd(0)
H2O 117
 
Figure 3.23: Mechanism of the Suzuki reaction    
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The ethyl esters (118, 122, and 123) were hydrolysed to their corresponding biaryl acids  
99–101 under basic conditions in ethanol. Extraction of the products proved problematic 
owing to the presence of acidic and basic functional groups. The products were very 
soluble in aqueous solutions and a narrow pH range was necessary for their extraction. 
After trialling a number of different organic solvents over a wide pH range, successful 
extraction was achieved with a 3:1 mixture of chloroform and isopropanol at pH 4–5. In 
addition to the increased aqueous solubility, hydrolysis of the esters was indicated in the 
1H-NMR spectrum by the absence of peaks around 4 ppm and 1 ppm corresponding to the 
ethyl CH2 and CH3 respectively. Percentage yields for each of the biaryl acids 99–101 are 
given in Table 3.2. 
Table 3.2: Percentage yields in the hydrolysis of the ethyl esters (118, 122 and 123)  
NaOH / Ethanol
OEt
OAr
OH
OAr
 
Ar Product Yield  Ar Product Yield 
N
H
N
O
 
99a 45% 
 
N
 
100a 89% 
N
N
H
O
 
99b 23% 
 
N  
100b 74% 
N
H
N
O
 
99c 41% 
 
N
 
100c 88% 
N
H
N
O
 
99d 70% 
 H
N
O
 
101a 99% 
N N
H
O
 
99e 47% 
 
N
H
O
 
101b 85% 
N
H
N
O
 
99f 50% 
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O
N
H
O
N
H  
Figure 3.24: Amide resonance reducing the electrophilicity of the carbonyl carbon 
While hydrolysis of the pyridyl esters 118 proceeded without too much difficulty, 
hydrolysis of the esters containing the amide functionality (122a-f and 123a-b) was 
complicated by hydrolysis of the amide. Amides are generally more resistant to hydrolysis 
because the carbonyl carbon is less electrophilic as a result of delocalisation of the nitrogen 
lone pair (Figure 3.24). However, when the amide nitrogen is bonded to an unsaturated 
group, such as the phenyl group, the nitrogen lone pair is less available for delocalisation 
into the amide carbonyl. This weakens the amide resonance effect leading to increased 
electrophilicity in the carbonyl carbon. This in turn increases the rate of hydrolysis.  
OEt
O
125
N
NH2
 
Figure 3.25: Proposed structure of the intermediate in the hydrolysis of acetamidopyridyl 
esters (122) with the amide in the 2 or 4 position relative to the pyridine nitrogen 
The increased rate of hydrolysis was more apparent with acetamidopyridyl esters 122a-f 
when the amide was in the 2 or 4 position relative to the ring nitrogen. In these cases 
hydrolysis of the amide occurred before the ester. This was supported by the isolation of 
intermediates with 1H-NMR spectra consistent with hydrolysis of the amide to generate 
esters 125 of the form shown in Figure 3.25. The more significant increase in the rate of 
hydrolysis can be explained by the extra electron withdrawing effect of the pyridine 
nitrogen. Based on the resonance structures shown in Figure 3.26, the added resonance 
effect is only apparent at the 2 and 4 positions, thus explaining why the amide was only 
hydrolysed first in these cases. 
N N N N
NH NH NH NH
O O O O
N
NH
O
 
Figure 3.26: Electron withdrawing effect of the pyridine nitrogen 
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To overcome the amide hydrolysis issue a work-around was implemented in which the 
fully hydrolysed products were reacetylated with acetic anhydride prior to work-up. For 
the acetamidophenyl acids 101a-b and one of the acetamidopyridyl acids with the amide 
meta to the pyridine nitrogen (99d), the rate of amide hydrolysis was sufficiently slow that 
acetic anhydride could be added directly to the basic reaction mixture to obtain the desired 
acids in high yields (70–99%). However, for the acetamidopyridyl acids with the amide 
ortho or para to the pyridine nitrogen (99a,c,e and f) the rate of amide hydrolysis was too 
rapid and when acetic anhydride was added to the reaction mixture any reacetylated 
product was rapidly hydrolysed. Instead, the reaction mixture was neutralised, the solvent 
was removed and the residue was stirred in neat acetic anhydride at 50 °C. This process 
was less efficient and lower yields (41–50%) were obtained. Acetamidopyridyl acid 99b 
could not be reacetylated, when acetic anhydride was added an unknown product, possibly 
an oligomer, was formed instead. To obtain a pure sample of acid 99b the reaction was 
stopped before any of the amide was hydrolysed. This significantly lowered the yield as 
complete hydrolysis of the ester could not be achieved without hydrolysing some of the 
amide. 
Reacetylation to obtain acetamidopyridyl acids 99a-c with the nitrogen in the 2-position 
was accompanied by an intense colour change in the solution and care had to be taken to 
ensure the residue was free of ethanol and sodium ethoxide. When these were present the 
starting ester 122a-c was obtained as the sole product. This is believed to result from 
formation of the reactive acyl pyridinium species 130 via mixed anhydride 131 as shown in 
Scheme 3.10. The acyl pyridinium species 130 would be hydrolysed by water to the 
desired acid 99a-c during work-up. 
OH
O
N
HN
O N
H
NO
O
O
O
N
HN
O O
131 13099  
Scheme 3.10: Proposed formation of the reactive acyl pyridinium  
compounds (130) when reacetylating pyridyl acids 99a-c 
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3.4.2. Esterification of Bicyclic Alcohol with Biaryl Acids: 
The esterification of bicyclic alcohol 94 with biaryl acids 99–101 was performed under 
Steglich conditions using 1,3-dicyclohexylcarbodiimide (DCC) to activate the carboxylic 
acids with DMAP as a catalyst. Acetamidopyridyl acids 99a-f could not be dissolved in 
DCM so DMF was used as the solvent instead. Formation of the desired esters was 
indicated in the 1H-NMR spectrum by a downfield shift in the set of doublets 
corresponding to the C1a protons. The remaining protons of the 3-azabicyclo[3.3.1]nonane 
system were shifted upfield with the most significant shifts associated with the C2 and C8 
protons. Percentage yields for each of the esters 96–98 are given in Table 3.3. 
Table 3.3: Percentage yields in the esterification of biaryl acids 99–101  
N
HO
OH
O
+
N
O
Ar
Ar
DCC / DMAP O
DCM or DMF
1a
1a2
2
8
8
 
Ar Product Yield  Ar Product Yield 
N
H
N
O
 
96a 24% 
 
N
 
97a 71% 
N
N
H
O
 
96b 28% 
 
N  
97b 51% 
N
H
N
O
 
96c 32% 
 
N
 
97c 57% 
N
H
N
O
 
96d - 
 H
N
O
 
98a 42% 
N N
H
O
 
96e - 
 
N
H
O
 
98b 50% 
N
H
N
O
 
96f - 
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Figure 3.27: Activation of the acids 99–101 by DCC 
Biaryl acids 99–101 were activated by reacting with DCC to form the O-acylisourea 
intermediate 132 as shown in Figure 3.27. Addition of DMAP or bicyclic alcohol 94 to the 
protonated form of this reactive intermediate releases 1,3-dicyclohexylurea (DCU, 133) as 
shown in Figure 3.28. The formation of this highly stable by-product is the driving force 
for the reaction109. If DMAP reacts with the protonated form of intermediate 132, the 
resulting acylated DMAP 134 reacts with bicyclic alcohol 94 forming the corresponding 
ester. Alternatively, the corresponding ester is formed directly if bicyclic alcohol 94 reacts 
with the protonated form of intermediate 132.  
O
O
R1 NH
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R1 NH
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O
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 = N
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Figure 3.28: Reaction of intermediate 132 with DMAP (top) or alcohol 94 (bottom) 
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O
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R1 NH
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Cy
O N
H
N
Cy
Cy
O
R1
132 135  
Figure 3.29: Intramolecular 1,3-rearrangement of  
the O-acylisourea 132 to the N-acylurea 135 
If reaction with the O-acylisourea 132 is slow it can undergo a 1,3-rearrangement 
generating the N-acylurea 135 as shown in Figure 3.29. Formation of this by-product 
proved problematic for purification of esters 96–98 as, unlike DCU, its solubility in 
organic solvents was similar to esters 96–98. Additionally, multiple applications of flash 
chromatography were required to completely remove the by-product leading to lower 
yields. A significant increase in the rate of reaction was observed, along with a subsequent 
decrease in the formation of the N-acylurea by-product 135, for those acids containing the 
pyridine nitrogen in the 2-position (99a-c and 100a). This is believed to result from 
formation of reactive acyl pyridinium compound 130 as shown in Figure 3.30 for 
acetamidopyridyl acids 99a-c. Compound 130 would react rapidly with bicyclic alcohol 94 
to generate the corresponding esters (96a-c and 97a).   
O
O
N
H
HN
Cy
CyN N
O
O N
H
HN
Cy
Cy
+
HN
O
H
NO
130132 133  
Figure 3.30: Proposed formation of reactive acyl pyridinium compounds 130  
when carrying out esterification with the 2-pyridyl acids 99a-c and 100a 
Of the acetamidopyridyl esters 96a-f only analogues 96a-c with the pyridine nitrogen in 
the 2-position could be prepared in pure form. For analogues 96d-f, esterification was too 
slow and significant amounts of the N-acylurea by-product 135 were formed. Additionally, 
the reactions did not proceed to completion and significant amounts of bicyclic alcohol 94 
remained. Neither of these impurities could be adequately separated from analogues 96d-f 
and yields for these esters could not be obtained. 
  
102 
 
                                                                                                                                 Chapter 3 
 
N
HO
OH
O
+
N
O
Ar
Ar
O
Cl
OAr
(COCl)2
 
/ DMF
DCM
OTs
OAr
N
HO
+
p-TsCl / Pyridine
136
137  
Scheme 3.11: Alternative conditions trialled for esterification 
Considering the issues with purifying the esters prepared via Steglich esterification, two 
alternative methods for activating the acids were trialled (Scheme 3.11) but neither was 
successful. Preparation of acid chloride 136 using oxalyl chloride ((COCl)2) and DMF in 
DCM led to a complex mixture of products and the desired ester could not be detected 
following reaction of this mixture with bicyclic alcohol 94. It is likely that the complex 
mixture of products results from side-reactions with the acetamide and pyridine moieties. 
While mixed anhydride 137 could be prepared, analysis of the 1H-NMR spectrum of the 
major product of its reaction with bicyclic alcohol 94 suggested that tosylate 138 was 
formed instead (Figure 3.31). Therefore, an alternative route involving esterification before 
Suzuki coupling was devised to more easily prepare the desired esters in pure form. This 
route is discussed in the next section.   
N
TsO
138   
Figure 3.31: Structure of tosylate 138  
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3.5. Azabicyclo Arylboronate Route: 
3.5.1. Synthesis of the Azabicyclo Arylboronate: 
N
HO
OH
O
+
N
O
I
I
O
Cl
OI
(COCl)2
 
/ DMF
DCM
OTs
OI
N
HO
+
p-TsCl / Pyridine
139
140 106
107
Et3N / DCM
94
94
Yield = 75% (2 steps)
Yield = 71% (2 steps)
1a
 
Scheme 3.12: Esterification of the bicyclic alcohol 94 with 2-iodobenzoic acid (107) 
Iodo ester 106 was prepared via the two alternative esterification routes that were trialled 
for the biaryl acids in the previous section (Scheme 3.12). Acid chloride 139, prepared by 
reacting 2-iodobenzoic acid (107) with oxalyl chloride and DMF, reacted with bicyclic 
alcohol 94 under basic conditions to afford iodo ester 106 in 75% yield over two steps. 
Reaction of bicyclic alcohol 94 with mixed anhydride 140, prepared with p-TsCl in 
pyridine, gave iodo ester 106 in 71% yield over 2 steps. Although the yields for 
esterification via mixed anhydride 140 were slightly lower, the reaction was less time 
consuming and the product was more easily purified. Formation of iodo ester 106 was 
supported in each case by 1H-NMR analysis with a downfield shift in the set of doublets 
corresponding to the C1a protons and an upfield shift in the remaining protons of the  
3-azabicyclo[3.3.1]nonane system.  
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Figure 3.32: Formation of iminium intermediate 141 
While the intermediate mixed anhydride 140 is generated via a simple nucleophilic 
substitution at the sulfonyl chloride of p-TsCl, the mechanism of acid chloride formation 
with oxalyl chloride and DMF is more complex. Oxalyl chloride reacts with DMF as 
shown in Figure 3.32 forming iminium intermediate 141 and releasing carbon dioxide and 
carbon monoxide as gaseous by-products. Intermediate 141 is highly electrophilic, reacting 
with the carbonyl of 2-iodobenzoic acid (107) to afford the α-amino ester which loses a 
chloride to form the α-imino ester (Figure 3.33). Nucleophilic substitution by the chloride 
at the carbonyl gives the acid chloride and DMF. Therefore, DMF is only required in 
catalytic amounts. 
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Figure 3.33: Reaction of iminium intermediate 141 with 2-iodobenzoic acid (107)  
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Scheme 3.13: Synthesis of arylboronate 105 via palladium catalysed borylation 
Arylboronate 105 was prepared from iodo ester 106 under literature conditions110 via the 
Miyaura borylation reaction (Scheme 3.13). The mechanism of this reaction is very similar 
to that for the Suzuki reaction discussed in section 3.4.1. The key difference is in the 
transmetallation step where the aryl boronate in the Suzuki reaction is replaced by 
bis(pinacolato)diboron. Since arylboronate 105 could not be adequately separated from 
bis(pinacolato)diboron, yields of the product could not be accurately measured. However, 
the yields were estimated at approximately 40% by considering the percentage of the major 
impurity, bis(pinacolato)diboron, determined by 1H-NMR. Since arylboronate 105 could 
not be purified, characterisation of the product was not performed and yields for the 
subsequent Suzuki reaction were reported over two steps starting from iodo ester 106.   
Although the product could not be purified, formation of arylboronate 105 was supported 
by analysis of the 1H-NMR spectrum. A strong singlet, integrating for 12 protons, appeared 
at around 1.4 ppm, corresponding to the methyl protons of the pinacolboron group. This 
was distinct from the singlet corresponding to the methyl protons of bis(pinacolato)diboron 
which appeared at around 1.25 ppm. Additionally, the pattern of peaks corresponding to 
the aromatic protons was very similar to the aromatic proton peaks of boronate ester 117.  
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3.5.2. Suzuki Coupling with the Azabicyclo Arylboronate:  
A number of conditions were trialled for the Suzuki reaction of aryl bromides with the 
arylboronate 105 using 2-bromopyridine (103a) as a model. In each case a mixture of 
products believed to be the desired ester 97a, bicyclic alcohol 94 and benzoate 142 was 
formed. Bicyclic alcohol 94 would be formed by hydrolysis of arylboronate 105, and 
benzoate 142 would be formed via protodeboronation. Ratios of these products for each set 
of conditions, determined by analysis of the crude 1H-NMR spectra, are presented in Table 
3.4 below.  
Table 3.4: Products formed during the Suzuki coupling  
of 2-bromopyridine (103a) with arylboronate 105 
N
O
OB
O O
105
N
O
O
97a
N
N
O
O
142
N
HO
94  
Conditions Products 
(97a:94:142) 2-BrPy (103a) Catalyst / Base 2 eq Pd(PPh3)4 (0.1 eq) / K2CO3 (2 eq) 3:2:1 Pd(PPh3)4 (0.1 eq) / KHCO3 (2 eq) No Reaction 
Pd2(dba)3 (0.1 eq) / P(o-tol)3 (0.2 eq) / K2CO3 (2 eq) 5:8:3 5 eq Pd(PPh3)4 (0.1 eq) / K2CO3 (2 eq) 6:3:2 10 eq Pd(PPh3)4 (0.1 eq) / K2CO3 (2 eq) 3:1:1 
Using standard literature conditions as employed to prepare the biaryl esters earlier in this 
chapter107, a 3:2:1 ratio of the desired ester 97a, bicyclic alcohol 94 and benzoate 142 was 
obtained. Using a weaker base (KHCO3) led to no reaction while switching to the more 
electron rich tri-o-tolyl phosphine ligand on palladium resulted in increased hydrolysis. 
Increasing the amount of 2-bromopyridine (103a) to five equivalents resulted in a slight 
increase in the percentage of the desired product. Better results were achieved when the 
amount of 2-bromopyridine (103a) was increased further to ten equivalents.  
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Since the best results were achieved when using ten equivalents of the aryl bromide, with 
Pd(PPh3)4 and K2CO3 in a mixture of toluene and ethanol, these conditions were selected 
to prepare the remaining esters. Additionally, biphenyl ester 143 was prepared by coupling 
with bromobenzene (144). Formation of the desired esters was supported in the 1H-NMR 
spectrum with an upfield shift in the C1a protons. The remaining protons of the  
3-azabicyclo[3.3.1]nonane system were also shifted upfield with the most significant shifts 
associated with the C2 and C8 protons. Yields for each of the desired esters, reported over 
two steps, are given in Table 3.5.   
Table 3.5: Percentage yields (2 steps) for the coupling of 
iodo ester 106 with the aryl bromides (102–104 and 144)  
N
O
OAr
N
O
OI
106
B
O
O
KOAc / Pd(dppf)Cl2
 
/ DMF
B
O
O
1.
2. Ar-Br /
 
Pd(PPh3)4
 
/ K2CO3
toluene / ethanol
1a
2
8
1a
2
8
 
Ar Product Yield  Ar Product Yield 
N
H
N
O
 
96a 8% 
 
N
 
97a 14% 
N
N
H
O
 
96b 10% 
 
N  
97b 22% 
N
H
N
O
 
96c 19% 
 
N
 
97c - 
N
H
N
O
 
96d 11% 
 
 
143 12% 
N N
H
O
 
96e 14% 
 HN
O
 
98a 18% 
N
H
N
O
 
96f 22% 
 
N
H
O
 
98b 16% 
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The yields were very low (8–22%) as a result of the general low yield in the borylation 
step and the side-reactions in the subsequent Suzuki reaction. Multiple applications of flash 
chromatography were required to separate the desired esters from the side-products and the 
large excess of aryl bromide. Only one of the aryl bromides (4-bromopyridine, 103c) failed 
to yield any of the corresponding ester 97c. As discussed in section 3.4.1, the 
hydrochloride salt of 4-bromopyridine (103c) had to be used for Suzuki coupling as the 
free base form is prone to self-condensation. It is believed that the Suzuki reaction with 
arylboronate 105 is much slower than the analogous reaction with the ethyl ester 
(arylboronate 117) due to the increased steric bulk of the 3-azabicyclo[3.3.1]nonane 
system. As a result, it is proposed that self-condensation of 4-bromopyridine (103c) 
occurred before it could react with arylboronate 105.  
An additional side-product was formed in significant quantities when attempting to 
synthesise biphenyl ester 143. It is proposed that this side-product results from the Heck 
coupling of excess bromobenzene (144) with biphenyl ester 143 to give styrene 145 
(Figure 3.34). Formation of this product was supported by the 1H-NMR spectrum in which 
the two singlet peaks around 4.3 ppm and 4.6 ppm corresponding to the alkene protons 
(H10a and H10b) were replaced by a single peak at around 6.0 ppm. This would correspond 
to the alkene proton (H10) shifted further downfield due to proximity to the aromatic ring. 
The E-isomer shown in Figure 3.32 is the expected product as this minimises steric 
interactions with the ester side chain.  
N
O
O
10
145  
Figure 3.34: Proposed structure of the major side-product formed  
during the Suzuki reaction with bromobenzene (144) 
Preliminary screening has been carried out on acetamidopyridyl analogues 96a-f along 
with pyridyl analogue 97a and biphenyl analogue 143. The results of these studies are 
discussed in the following section. These studies were carried out by Taima Qudah from 
the Faculty of Pharmacy at the University of Sydney.   
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3.6. Preliminary Screening Results: 
Receptors of the α4β2 sub-type in both stoichiometries ((α4)3(β2)2 and (α4)2(β2)3), along 
with the α7 sub-type were expressed in Xenopus oocytes. Each of the selected esters (10 
μM) was co-applied with ACh (1 mM for (α4)3(β2)2 and α7, 100 μM for (α4)2(β2)3) and 
the evoked current was measured. The average current measured for each compound at 
each receptor, normalised to the maximal current elicited by ACh (1 mM or 100 μM) alone 
is given in Figure 3.35. Compounds that display greater inhibition of a particular receptor 
give rise to lower normalised currents. 
 
Figure 3.35: Currents elicited by ACh co-applied with each compound  
to nAChRs, normalised to current elicited by ACh alone.   
Unlike MLA (13), none of the ester analogues that were tested appeared to have any 
significant inhibitory effect on the α7 nAChR. At α4β2 nAChRs of both stoichiometries, 
the ester analogues appeared to have similar inhibitory effects to MLA (13). The inhibitory 
effect was more significant at (α4)3(β2)2 nAChRs (20–40% inhibition) compared to 
(α4)2(β2)3 nAChRs (<20% inhibition), except for compound 97a where the inhibitory 
effect was comparable at both stoichiometries. In some cases the average measured current 
was slightly higher than the current elicited by ACh alone. This is most likely a result of 
small variations in the current elicited by ACh when measured alone and when measured 
in the presence of the analogue rather than an additive effect of the analogue itself.  
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In general, ligands can take some time to diffuse into the binding site of receptors. 
Therefore, by exposing the receptors to each compound for a short period of time prior to 
applying ACh (incubation), a better indication of the inhibitory effect of the compounds 
can be obtained. Average normalised currents elicited by ACh (1 mM or 100 μM)  
co-applied with each of the selected esters (10 μM) at each receptor after preincubation 
with the esters alone (10 μM) for 30 seconds are given in Figure 3.36. In each case the 
average normalised currents are lower compared to measurements taken without 
preincubation.  
 
Figure 3.36: Currents elicited by ACh applied after incubation with each  
compound to nAChRs, normalised to current elicited by ACh alone. 
At first glance it is clear that MLA (13) is a much stronger inhibitor than the bicyclic 
analogues at the nAChR sub-types tested, especially the α7 nAChR. Of the ester analogues 
tested, only biphenyl analogue 143 appeared to have any significant inhibitory effect on α7 
nAChRs after preincubation, although this was still significantly lower than MLA (13). 
Additionally, although the bicyclic esters have been designed to target residues unique to 
the α4β2 nAChRs, their inhibitory effects at the two stoichiometries of this sub-type are 
still lower than MLA (13). This is likely a result of the contribution of the MLA (13) 
backbone to its potency at α4β2 nAChRs. The bicyclic succinimide ester (34), which is 
closer in structure to the ester analogues than MLA (13), has a 20-fold lower potency at 
α4β2 nAChRs than MLA (IC50 = 4.66 μM vs. IC50 = 200 nM)29,61. Therefore ester 
analogues of MLA (13) that retain the hexacyclic backbone would be expected to exhibit 
much higher inhibitory effects. It should be noted that the potencies for MLA (13) and 
bicyclic analogue 34 were measured at (α4)3(β2)2 nAChRs based on the measured ACh 
EC50.   
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At α4β2 nAChRs of both stoichiometries, the ester analogues appeared to have more 
significant inhibitory effects. As was the case when testing without preincubation, the 
inhibitory effect of compound 97a on the different stoichiometries of α4β2 nAChRs was 
comparable. For the remaining ester analogues, the inhibitory effect was significantly 
greater at (α4)3(β2)2 nAChRs (65–85% inhibition) compared to (α4)2(β2)3 nAChRs  
(30–50% inhibition). The most significant inhibitory effects were observed for 
acetamidopyridyl esters 96b and 96c (Figure 3.37), both of which have the pyridine 
nitrogen in the 2-position. Based on these results, compounds 96a–c and 97a have been 
selected for further testing to generate dose-response curves and establish whether they act 
as competitive or non-competitive inhibitors. 
N
O
O
N
O
O
96c
NN
H
N
O
HN
O
96b  
Figure 3.37: Acetamidopyridyl esters with the most  
significant inhibitory effects at (α4)3(β2)2 nAChRs 
For all of the tested analogues the inhibitory effect with incubation was most significant at 
(α4)3(β2)2 nAChRs. Differences in inhibition for each compound between (α4)3(β2)2 
receptors and other nAChRs are given in Figure 3.38. These differences were calculated by 
subtracting the normalised current elicited by ACh at (α4)3(β2)2 nAChRs from the 
normalised current elicited by ACh at α7 or (α4)2(β2)3 nAChRs and give an indication of 
the selectivity of each compound for the (α4)3(β2)2 nAChRs. Additionally, the only 
difference between the two stoichiometries of α4β2 nAChRs is that the (α4)3(β2)2 
stoichiometry contains an α4–α4 binding site in addition to the two α4–β2 binding sites 
common to both stoichiometries. As a result, selectivity for (α4)3(β2)2 nAChRs suggests 
selective binding at the α4–α4 binding site. However, the fact that inhibition was still 
observed at (α4)2(β2)3 nAChRs suggests that these compounds also bind at the α4–β2 
binding sites.  
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Figure 3.38: Difference in normalised current at (α4)3(β2)2 nAChRs  
vs. other nAChRs (current at (α4)2(β2)3 / α7 – current at (α4)3(β2)2)     
For all of the ester analogues, selectivity for (α4)3(β2)2 nAChRs over α7 nAChRs was 
greater than the selectivity over (α4)2(β2)3 nAChRs. However, with the exception of 
compound 97a, all of the analogues exhibited some selectivity for the (α4)3(β2)2 receptor 
over the (α4)2(β2)3 receptor. Since the inhibitory effect on (α4)2(β2)3 nAChRs was similar 
for all compounds, the compounds that led to the greatest inhibition at (α4)3(β2)2 nAChRs 
(96b and 96c) also had the greatest selectivity for these receptors. 
It is important to note that there are limitations to the interpretation of these screening 
results. While the majority of compounds did not appear to have any significant inhibitory 
effect at α7 nAChRs, the measurements are taken at only one concentration. It is therefore 
possible that the ester analogues act as inhibitors at α7 nAChRs but at higher 
concentrations. Additionally the differences in inhibition at the different receptors may be 
more pronounced at higher concentrations. These screening results also give no indication 
as to whether inhibition is competitive or non-competitive. Each of these limitations can be 
addressed by generating inhibitory dose-response and ACh dose-response curves for each 
compound. 
Preliminary screening studies have not yet been performed on the remaining pyridyl 
analogues (97b-c) and the acetamidophenyl analogues (98a-b). Once these results have 
been obtained, structure activity relationships may emerge that can be used to develop 
further targets for synthesis and screening.  
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3.7. Conclusions and Future Work: 
Bicyclic ester analogues of MLA (13) were prepared with functional groups targeting key 
residues in the binding sites of α4β2 nAChRs of both stoichiometries (Figure 3.39). Two 
different routes to the ester analogues were investigated. The first route involved 
esterification as the final step while the second route involved Suzuki coupling as the final 
step. Both routes required bicyclic alcohol 94 which was prepared in a three step process 
from ethyl 2-oxocyclohexane-1-carboxylate (109) involving a double Mannich reaction 
followed by Wittig olefination and ester reduction in an overall yield of 18%. 
N
O
O
N
NH
O
96
N
O
O
N N
O
O
NH
O
97 98   
Figure 3.39: General structure of the analogues prepared for biological testing 
In the first route, the corresponding biaryl acids for each ester were prepared from boronate 
ester 117 via Suzuki coupling with the corresponding aryl bromides 102–104 followed by 
hydrolysis of the resulting esters in overall yields of 16–69%. These were then coupled 
with bicyclic alcohol 94 under Steglich esterification conditions to afford analogues 96–98 
in yields ranging from 24% to 71%. Of the acetamidopyridyl esters 96 only those with the 
pyridine nitrogen in the 2-position 96a–c could be prepared via this route. 
In the second route, iodo ester 106 was prepared by esterification of bicyclic alcohol 94 
with 2-iodobenzoic acid (107) via acid chloride 139 in 75% yield or via mixed  
anhydride 140 in 71% yield. Analogues 96–98 were then prepared from iodo ester 106 in 
two steps involving Miyaura borylation followed by Suzuki coupling of the resulting 
arylboronate 105 with the corresponding aryl bromides in overall yields of 8–22%. All of 
the ester analogues except the 4-pyridyl ester 97c could be prepared via this route. 
  
114 
 
                                                                                                                                 Chapter 3 
 
Preliminary screening for inhibition at α7 nAChRs and α4β2 nAChRs of both 
stoichiometries was carried out on acetamidopyridyl analogues 96a-f along with pyridyl 
analogue 97a and biphenyl analogue 143. All of the analogues tested appeared to have 
greater selectivity for α4β2 nAChRs over α7 nAChRs giving rise to greater inhibition of 
current at α4β2 nAChRs. Additionally, treatment with all except pyridyl analogue 97a 
resulted in significantly greater inhibition at (α4)3(β2)2 nAChRs suggesting selectivity for 
the α4–α4 binding site over the α4–β2 binding sites. The greatest inhibition at (α4)3(β2)2 
nAChRs was observed for acetamidopyridyl esters 96b and 96c, both of which have the 
pyridine nitrogen in the 2-position. Of the simplified MLA analogues discussed earlier in 
this chapter, esters 96b and 96c are closest in structure to bicyclic succinimide ester 34, an 
antagonist at α7 nAChRs (IC50 = 20.7 μM) and α4β2 nAChRs (IC50 = 4.33 μM) that is less 
potent than MLA (13) at both sub-types.  Based on these results, compounds 96a–c and 
97a (Figure 3.40) have been selected for further testing to generate dose-response curves 
and determine whether they act as competitive or non-competitive inhibitors at α7 and 
α4β2 nAChRs. 
N
O
O
HN
O
96a-c
N
O
O
97a
NN
  
Figure 3.40: Structure of the analogues selected for further testing 
These analogues were designed to target unique residues in the binding sites of the two 
stoichiometries of α4β2 nAChRs. As such, they may act as selective inhibitors of either 
stoichiometry. Those that are identified as selective inhibitors have the potential for use in 
mapping the location of α4β2 nAChRs of either stoichiometry in the brain providing 
information on the functions of α4β2 nAChRs and their role in various neurological 
diseases. Knowledge of the role of the two α4β2 nAChR stoichiometries in neurological 
diseases and their functions in the brain may enable the development of novel drugs to 
better treat neurological diseases associated with these receptors.  
115 
 
Chapter 3  
 
N
OH
H
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OMe
OH
MeO
H
MeO
O
OAr
146  
Figure 3.41: General structure of MLA ester analogues 146 
Future work could involve preparing MLA ester analogues 146 with the general structure 
shown in Figure 3.41 above. Since replacement of the hexacyclic backbone with the 
bicyclic backbone results in a 20-fold drop in potency at (α4)3(β2)2 nAChRs  
(IC50 = 200 nM for MLA), it is expected that MLA ester analogues 146 will be more  
potent inhibitors than the corresponding bicyclic analogues. In particular, analogues with 
the pyridine nitrogen in the 2 position will be targeted as these were the easiest to prepare 
and, in the case of acetamidopyridyl derivatives 96a–c, gave rise to the greatest inhibition 
and selectivity at the (α4)3(β2)2 nAChRs. Once prepared, these will be sent to the 
University of Sydney, Faculty of Pharmacy for further testing.  
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Chapter 4: Experimental 
4.1. General Experimental: 
All reactions were performed under an atmosphere of nitrogen unless otherwise stated. 
Reaction temperatures were controlled using oil baths for temperatures greater than room 
temperature, standard ice baths for 0 °C, brine / ice baths for -10 °C or dry ice / acetone 
baths for -78 °C. Removal of solvent in vacuo refers to the concentration of samples by 
rotary evaporation under reduced pressure. ‘Ether’ refers to diethyl ether, ‘hexane’ refers to 
petroleum ether (b.p. 40 – 60 °C) and ‘brine’ refers to saturated aqueous NaCl. 
Melting points were determined using an Optimelt automated melting point system. 
Optical rotations were determined using a Perkin-Elmer Model 343 Polarimeter set at  
the 589 nm sodium D line, in a 1.00 dm cell at 20 °C. The specific rotation is reported 
along with the concentration in g/100 mL and solvent. Infrared (IR) absorption spectra 
were obtained using a Perkin-Elmer Spectrum One FTIR spectrometer. Biaryl acids were 
analysed as solids pressed into KBr disks while all other compounds were analysed as a 
thin-film on NaCl plates. Key absorbance bands are reported in wavenumbers (cm-1) and 
assigned to their respective functional group.  
Nuclear Magnetic Resonance (NMR) spectra were obtained on a Bruker 400 (400 MHz) or 
a Bruker 800 (800 MHz) NMR spectrometer. Samples were analysed at room temperature 
and dissolved in either deuterated chloroform (CDCl3) or dimethyl sulfoxide (DMSO, 
(CD3)2SO). The machine was operated at 400 MHz or 800 MHz for 1H-NMR or 100 MHz 
for 13C-NMR. Chemical shifts (δ) are reported in ppm relative to TMS (δ = 0) and the 
splitting of 1H-NMR peaks are reported with the following codes; s = singlet,  
d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of 
triplets, dm = doublet of multiplets, td = triplet of doublets, br = broad. Where two protons 
are attached to the same carbon they are assigned as axial or equatorial where appropriate 
as shown in Figures 4.1 and 4.2. Where axial or equatorial assignment is not appropriate 
the protons are assigned as α (top face) or β (bottom face).  
Low-resolution mass spectrometry (LRMS) and high-resolution mass spectrometry 
(HRMS) were performed using positive electron ionisation (EI) on a Micromass VG 
Autospec mass spectrometer, or using positive electrospray ionisation (ESI) on a 
Micromass ZMD ESI-Quad (LRMS) or a Waters LCT Premier XE mass spectrometer 
(HRMS).   
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The axial (Hax) and equatorial (Heq) protons of the piperidine ring of codeine and morphine 
derivatives are assigned as shown in Figure 4.1.  
N
O
Me
R
OH
Hax
Heq
H
H
Hax
Hβ
Hα
Heq H H H
H
R
O
HO
N
H Hα
Hβ
Hax
Heq  
Figure 4.1: Assignment of axial (Hax) and equatorial (Heq) protons  
of the piperidine ring of codeine and morphine derivatives 
The methylene protons and axial (Hax) and equatorial (Heq) protons of the azabicyclic 
systems are assigned as shown in Figure 4.2.  
N
R
Hax
Hax
Heq
Heq
Heq
Hax
Hax
Heq
Ha
H Hb
R
NEt
Hb
Ha
Heq
Hax
Et
Hax
Heq
 
Figure 4.2: Assignment of axial (Hax) and equatorial (Heq)  
protons and methylene protons in azabicyclic ring systems 
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4.2. Experimental for Chapter 2: 
4.2.1: Synthesis of Ketones: 
codeinone 67,111: 
O
O
HO
N
Dess-Martin periodinane
DCM RT 1 h
O
O
O
N
H H
25 36  
Dess-Martin periodinane (100 mg, 234 µmol) was added to a stirred solution of codeine  
(25, 50 mg, 166 µmol) in dichloromethane (2 mL). The resulting solution was stirred at room 
temperature for 1 hour, turning orange over time. After 1 hour 2 M aq NaOH (2 mL) was added 
and the resulting two phase mixture stirred vigorously for a further hour. After this time the two 
phases were separated and the organic phase was dried over anhydrous MgSO4. The solvent was 
removed in vacuo to yield the title compound (36) as a pale yellow solid (40 mg, 81%).  
O
O
O
N
1
2
33a
4
5
6
7
8
9
10
11
12
13
14
15
16
17
17a
H
 
mp: 163 °C (decomposes, literature 111 182-183 °C) [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 –207° (c 1.0, CHCl3)  
literature 67 –218° (c 1.0, CHCl3) IR (NaCl) 1675 (C=O), 1637, 1609 (C=C),  
1279 (C–O) 1H-NMR (δ, 400 MHz, CDCl3): 6.58-6.69 (3H, m, H1, H2, H8),  
6.07 (1H, dd, J = 10.4 Hz, 2.8 Hz, H7), 4.69 (1H, s, H5), 3.83 (3H, s, H3a), 3.44 (1H, m, H9),  
3.24 (1H, s, br, H14), 3.10 (1H, d, J = 18.4 Hz, H10α), 2.63 (1H, dd, J = 12.4 Hz, 4.4 Hz, H16eq),  
2.46 (3H, s, H17a), 2.26-2.36 (2H, m, H10β, H16ax), 2.08 (1H, td, J = 12.4 Hz, 4.8 Hz, H15ax),  
1.84 (1H, dd, J = 12.4 Hz, 2.0 Hz, H15eq), 13C-NMR (δ, 100MHz, CDCl3): 194.6 (C6),  
149.0 (C8), 145.0 (C4), 142.7 (C3), 132.7 (C7), 129.1 (C12), 126.0 (C11), 120.1 (C1), 115.0 (C2),  
88.2 (C5), 59.2 (C9), 57.0 (C3a), 47.0 (C16), 43.2 (C13), 43.0 (C17a), 41.5 (C14), 34.0 (C15), 20.6 (C10) 
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morphinone: 
3-(tert-butyldimethylsilyl)morphine 71,72: 
HO
O
HO
N
TBDMSO
O
HO
N
TBDMS-OTf / NEt3
DCM RT 2 h
H H
35 42  
tert-Butyldimethylsilyl triflate (160 µL, 699 µmol) was added to a solution of morphine  
(35, 100 mg, 352 µmol) and triethylamine (140 µL, 1.00 mmol) in dichloromethane (4 mL) and the 
resulting solution was stirred at room temperature for 2 hours. After 2 hours the reaction mixture 
was diluted with dichloromethane to a total volume of 10 mL and washed with saturated  
aq NaHCO3 (10 mL). The remaining solution was dried over anhydrous MgSO4 and the solvent 
was removed in vacuo to yield a yellow oil, purified by flash chromatography  
(17:3 chloroform : methanol) to give the title compound (42) as a yellow solid (42 mg, 30%).  
O
Si
O
HO
N
1
2
3
3a 4
5
6
7
8
9
10
11
12
13
15
16
17
17a
3a
3b
3c
3c
3c
6a
14
H
 
mp: 118-121 °C (literature 71 122-123 °C) [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 –77° (c 1.0, CHCl3) IR (NaCl) 3369 (O–H),  
1631, 1603 (C=C), 1273, 1254 (C–O) 1H-NMR (δ, 400 MHz, CDCl3): 6.57 (1H, d, J = 8.0 Hz, H2), 
6.48 (1H, d, J = 8.0 Hz, H1), 5.67 (1H, dm, J = 10.0 Hz, H7), 5.28 (1H, dt, J = 10.0 Hz, 2.8 Hz, H8),  
4.85 (1H, dd, J = 6.4 Hz, 1.2 Hz, H5), 4.16 (1H, m, H6), 3.34 (1H, dd, J = 6.0 Hz, 3.2 Hz, H9),  
3.02 (1H, d, J = 18.8 Hz, H10α), 2.78 (1H, s, br, H6a), 2.65 (1H, m, H14),  
2.58 (1H, dd, J = 12.4 Hz, 4.8 Hz, H16eq), 2.44 (3H, s, H17a) 2.41 (1H, td, J = 12.4 Hz, 3.6 Hz, H16ax) 
2.29 (1H, dd, 18.8 Hz, 6.0 Hz, H10β), 2.05 (1H, td, J = 12.4 Hz, 5.2 Hz, H15ax),  
1.85 (1H, dm, J = 12.4 Hz, H15eq), 0.99 (9H, s, H3c), 0.19 (3H, s, H3a), 0.16 (3H, s, H3a),  
13C-NMR (δ, 100MHz, CDCl3): 148.4 (C4), 137.4 (C3), 133.4 (C7), 131.4 (C12), 128.6 (C8),  
127.8 (C11), 121.1 (C2), 119.8 (C1), 91.1 (C5), 66.5 (C6), 59.0 (C9), 46.6 (C16), 43.3 (C17a),  
43.1 (C13), 40.9 (C14), 36.0 (C15), 25.8 (C3c), 20.7 (C10), 18.4 (C3b), -4.22 (C3a), -4.48 (C3a) 
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3-(tert-butyldimethylsilyl)morphinone 71,72: 
TBDMSO
O
HO
N
TBDMSO
O
O
N
Dess-Martin periodinane
DCM RT 1 h
H H
42 43  
Dess-Martin periodinane (60 mg, 140 µmol) was added to a stirred solution of compound 42  
(40 mg, 100 µmol) in dichloromethane (4 mL). The resulting solution was stirred at room 
temperature for 1 hour, turning yellow over time. After 1 hour 2 M aq NaOH (4 mL) was added 
and the resulting two phase mixture stirred vigorously for a further hour. After this time the two 
phases were separated and the organic phase was dried over anhydrous MgSO4. The solvent was 
removed in vacuo to yield the title compound (43) as a yellow solid (35 mg, 88%). 
O
Si
O
O
N
1
2
3
3a 4
5
6
7
8
9
10
11
12
13
15
16
17
17a
3a
3b
3c
3c
3c
H
14
 
mp: 99 °C (decomposes) [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 –176° (c 1.0, CHCl3) IR (NaCl) 1677 (C=O),  
1634, 1606 (C=C), 1269 (C–O) 1H-NMR (δ, 400 MHz, CDCl3):  6.59-6.65 (2H, m, H8, H2),  
6.54 (1H, d, J = 8.0 Hz, H1), 6.07 (1H, dd, J = 10.0 Hz, 2.8 Hz, H7), 4.66 (1H, s, H5),  
3.40 (1H, m, H9), 3.17 (1H, m, H14), 3.09 (1H, d, J = 18.4 Hz, H10α),  
2.60 (1H, dd, J = 12.0 Hz, 4.8 Hz, H16eq), 2.45 (3H, s, H17a), 2.26-2.35 (2H, m, H10β, H16ax),  
2.04 (1H, td, J = 12.4 Hz, 4.8 Hz, H15ax), 1.82 (1H, dm, J = 12.4 Hz, H15eq), 0.97 (9H, s, H3c),  
0.18 (3H, s, H3a), 0.12 (3H, s, H3a) 13C-NMR (δ, 100MHz, CDCl3): 194.4 (C6), 149.3 (C8),  
147.0 (C4), 137.8 (C3), 132.7 (C7), 129.2 (C12), 126.7 (C11), 122.3 (C2), 120.0 (C1), 88.1 (C5),  
59.2 (C9), 46.9 (C16), 43.3 (C13), 43.1 (C17a), 41.7 (C14), 34.3 (C15), 25.8 (C3c), 20.7 (C10), 18.4 (C3b), 
-4.46, -4.61 (C3a)  
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morphinone 71: 
TBDMSO
O
O
N
HO
O
O
N
methanol / aq HCl
RT 1 h
H H
43 37  
Compound 43 (10 mg, 25 µmol) was dissolved in methanol (1 mL) and 1 M aq HCl (1 mL) was 
added. The resulting solution was stirred at room temperature for 1 hour. After this time the solvent 
was removed in vacuo and the residue was redissolved in water (5 mL). The solution was basified 
to pH 9 using 2 M aq NaOH and the product was extracted with a 3:1 mixture of chloroform and 
isopropanol (3 × 5 mL). The combined extracts were dried over anhydrous MgSO4 and the solvent 
was removed in vacuo to yield the title compound (37) as a pale yellow oil (5 mg, 70%). 
HO
O
O
N
1
2
3
4
5
6
7
8
9
10
11
12
13
15
16
17
17a
3a
H
14
 [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 –173° (c 0.5, CHCl3) IR (NaCl) 3600-2400 (O–H) 1672 (C=O), 1638, 1612 (C=C),  
1246 (C–O) 1H-NMR (δ, 400 MHz, CDCl3): 6.65-6.71 (2H, m, H8, H2),  
6.54 (1H, d, J = 8.0 Hz, H1), 6.08 (1H, dd, J = 10.4 Hz, 2.8 Hz, H7), 4.72 (1H, s, H5),  
3.49 (1H, m, H9), 3.27 (1H, s, br, H14), 3.11 (1H, d, J = 18.4 Hz, H10α),  
2.67 (1H, dd, J = 12.4 Hz, 4.8 Hz, H16eq), 2.47 (3H, s, H17a), 2.29-2.37 (2H, m, H10β, H16ax),  
2.12 (1H, td, J = 12.4 Hz, 4.8 Hz, H15ax), 1.85 (1H, dm, J = 12.4 Hz, H15eq), H3a not observed  
13C-NMR (δ, 100MHz, CDCl3): 195.2 (C6), 149.8 (C8), 143.5 (C4), 138.6 (C3), 132.5 (C7),  
128.6 (C12), 125.4 (C11), 120.6 (C2), 117.7 (C1), 88.6 (C5), 59.1 (C9), 47.0 (C16), 43.5 (C13),  
43.0 (C17a), 41.6 (C14), 33.9 (C15), 20.7 (C10) 
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narwedine 45,73: 
Method A: 
Dess-Martin periodinane
DCM RT 2 h
O
O
N
HO
O
O
N
O23 30  
Galanthamine hydrobromide (100 mg, 272 µmol) was dissolved in dichloromethane (40 mL) and 
the resulting solution was washed with 2 M aq, NaOH (40 mL), dried over anhydrous MgSO4 and 
the solvent was removed in vacuo. The residue was redissolved in dichloromethane (4 mL) and 
Dess-Martin periodinane (160 mg, 376 µmol) was added. The resulting solution was stirred for 1 
hour before an additional 160 mg of Dess-Martin periodinane was added and the solution left to stir 
for a further hour. After this time 2 M aq NaOH (4 mL) was added and the resulting two phase 
mixture was stirred vigorously for 1 hour. The phases were then separated and the organic phase 
was dried over anhydrous MgSO4. The solvent was removed in vacuo to yield the title compound 
(30) as a pale yellow oil (55 mg, 71%). 
O
O
N
O
1
2
3
4
4a
5
6 7
8
8a 9
10
11 11a
12
13
14
3a
 [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 –7° (c 1.0, CHCl3) literature 45 –408° (c 1.0, CHCl3) IR (NaCl) 1684 (C=O),  
1623 (C=C), 1284 (C–O) 1H-NMR (δ, 400 MHz, CDCl3): 6.95 (1H, d, J = 10.4 Hz, H8),  
6.69 (1H, d, J = 8.0 Hz, H2), 6.64 (1H, d, J = 8.0 Hz, H1), 6.03 (1H, d, J = 10.4 Hz, H7),  
4.72 (1H, m, H4a), 4.08 (1H, d, J = 15.6 Hz, H12β), 3.83 (3H, s, H3a), 3.73 (1H, d, J = 15.6 Hz, H12α),  
3.09-3.28 (3H, m, H5β, H10α, H10β), 2.74 (1H, dd, J = 17.6 Hz, 3.6 Hz, H5α), 2.43 (3H, s, H11a),  
2.26 (1H, td, J = 13.6 Hz, 3.6 Hz, H9β), 1.84 (1H, dm, J = 13.6 Hz, H9α)  
13C-NMR (δ, 100MHz, CDCl3): 194.6 (C6), 147.1 (C4) 144.5 (C8), 144.1 (C3), 130.7 (C14),  
129.5 (C13), 127.3 (C7), 122.2 (C1), 112.0 (C2), 88.1 (C4a), 60.8 (C12), 56.1 (C3a), 54.2 (C10),  
49.1 (C8a), 42.6 (C11a), 37.4 (C5), 33.4 (C9) 
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Method B: 
DCM RT 8 h
O
O
N
HO
O
O
N
O
MnO2
23 30  
Galanthamine hydrobromide (50 mg, 136 µmol) was dissolved in dichloromethane (20 mL) and the 
resulting solution was washed with 2 M aq, NaOH (20 mL), dried over anhydrous MgSO4 and the 
solvent was removed in vacuo. The residue was redissolved in dichloromethane (5 mL) and MnO2 
(250 mg, 2.88 mmol) was added. The resulting solution was stirred vigorously for 8 hours before 
the suspension was filtered to remove MnO2. The solvent was removed in vacuo to yield the title 
compound (30) as a white solid (30 mg, 77%).  
mp: 188 °C (decomposes, literature 43 184-190 °C) [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 –237° (c 1.0, CHCl3)  
literature 45 –408° (c 1.0, CHCl3). Spectral data were identical to those obtained for the product 
from method A.  
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(±)-galanthamine 45: 
L-Selectride
THF -78oC 2 h
O
O
N
O
O
O
N
HO30 23  
A solution of L-Selectride in THF (200 μL, 1 M, 200 μmol) was added to a solution of narwedine 
(30, 30 mg, 105 μmol) in THF (5 mL) and the resulting mixture was stirred at –78 °C for 2 hours. 
After this time the reaction was quenched with methanol (5 mL) and the volatile components of the 
mixture were removed in vacuo. The remaining residue was dissolved in ethyl acetate (5 mL) and 
washed with a 10% aq solution of sodium potassium tartrate (5 mL). The solution was dried over 
anhydrous MgSO4 and the solvent was removed in vacuo to yield a pale yellow oil, purified by 
flash chromatography (9:1 chloroform : methanol) to give the title compound (23) as a colourless 
oil (19 mg, 63%).   
O
O
N
HO
1
2
3
4
4a
5
6 7
8
8a 9
10
11 11a
12
13
14
3a
6a  [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 –10° (c 1.0, CHCl3) reference 45 –93° (c 1.0, CHCl3) IR (NaCl) 3357 (O–H), 1623 (C=C), 
1283, 1266 (C–O) 1H-NMR (δ, 400 MHz, CDCl3): 6.66 (1H, d, J = 8.0 Hz, H2),  
6.62 (1H, d, J = 8.0 Hz, H1), 6.07 (1H, dd, J = 10.4, 0.8 Hz, H8),  
6.00 (1H, ddd, J = 10.4 Hz, 4.8 Hz, 0.8 Hz, H7), 4.61 (1H, s, br, H4a),  
4.13 (1H, t, br, J = 4.8 Hz, H6), 4.08 (1H, d, J = 15.2 Hz, H12β), 3.83 (3H, s, H3a),  
3.68 (1H, d, J = 15.2 Hz, H12α), 3.26 (1H, td, J = 13.6 Hz, 1.6 Hz, H10β),  
3.05 (1H, dt, J = 14.4 Hz, 3.2 Hz, H10α), 2.68 (1H, dm, J = 15.6 Hz, H5α),  
2.40 (3H, s, H11a), 2.35 (1H, s, br, H6a), 2.08 (1H, td, J = 13.2 Hz, 2.8 Hz, H9β),  
2.01 (1H, ddd, J = 15.6 Hz, 5.2 Hz, 2.8 Hz, H5β), 1.57 (1H, dm, J = 13.6 Hz, H9α)  
13C-NMR (δ, 100MHz, CDCl3): 146.0 (C4), 144.2 (C3), 133.2 (C14), 129.5 (C13), 127.7 (C7), 
127.0 (C8), 122.2 (C1), 111.3 (C2), 88.9 (C4a), 62.2 (C12), 60.8 (C6), 56.1 (C3a), 54.0 (C10),  
48.4 (C8a), 42.3 (C11a), 34.0 (C9), 30.1 (C5) 
  
125 
 
Chapter 4  
 
4.2.2: Synthesis of Codeine Mustard: 
norcodeine 74: 
O
O
HO
N
1. ACE-Cl / NaHCO3
DCE reflux 16 h
O
O
HO
NH
2. Methanol reflux 16 h
H H
25 47  
α-Chloroethyl chloroformate (250 µL, 1.32 mmol) was added to a stirred solution of codeine  
(25, 50 mg, 166 µmol) and NaHCO3 (100 mg, 595 µmol) in dichloromethane (5 mL) and the 
resulting mixture was stirred at reflux overnight, turning yellow over time. The following morning 
the mixture was cooled and washed with water (2 × 5 mL). The solution was dried over anhydrous 
MgSO4 and the solvent was removed in vacuo. The residue was redissolved in methanol (5 mL) 
and stirred at reflux overnight. The following morning the solvent was removed in vacuo to yield a 
brown solid, purified by flash chromatography (90:10:1 chloroform : methanol : ammonia) to give 
the title compound (47) as a pale yellow solid (39 mg, 82%). 
O
O
HO
NH
1
2
33a
4
5
6
7
8
9
10
11
12
13
15
16
17
6a
H
14
 
mp: 181-183 °C (literature 74 182-183 °C) [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 –110° (c 1.0, CHCl3)  
literature 74 –91° (c 0.22, CHCl3) IR (NaCl) 3311 (O–H, N–H), 1634, 1603 (C=C),  
1282, 1261 (C–O) 1H-NMR (δ, 400 MHz, CDCl3): 6.67 (1H, d, J = 8.0 Hz, H2),  
6.58 (1H, d, J = 8.0 Hz, H1), 5.72 (1H, d, br, J = 10.0 Hz, H7),  
5.25 (1H, dt, J = 10.0 Hz, 2.4 Hz, H8), 4.87 (1H, d, J = 6.4 Hz, H5), 4.18 (1H, m, H6),  
3.84 (3H, s, H3a), 3.66 (1H, s, br, H9), 2.78-3.01 (4H, m, H10α, H10β, H16ax, H16eq),  
2.61 (1H, m, H14), 2.54 (2H, s, br, H6a, H17), 1.86-1.99 (2H, m, H15ax, H15eq)  
13C-NMR (δ, 100MHz, CDCl3): 146.5 (C4), 142.4 (C3), 133.9 (C7), 131.2 (C12), 128.1 (C8),  
127.4 (C11), 119.7 (C1), 113.1 (C2), 92.0 (C5), 66.4 (C6), 56.5 (C3a), 52.1 (C9), 43.9 (C13),  
41.2 (C14), 38.6 (C16), 36.6 (C15), 31.3 (C10) 
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N-(2-chloroethyl) norcodeine:  
O
O
HO
NH
chloroacetaldehyde / NaBH(OAc)3
DCE RT 10 min
O
O
HO
N
Cl
H H
47 38  
NaBH(OAc)3 (120 mg, 566 µmol) was added to a solution of norcodeine (47, 30 mg, 106 µmol) 
and chloroacetaldehyde (20 µL, 286 µmol) in dichloromethane (2 mL) and the resulting mixture 
was stirred at room temperature for 10 minutes. After this time, the mixture was diluted with 
dichloromethane (5 mL) and washed with water (2 × 5 mL).  The solution was dried over 
anhydrous MgSO4 and the solvent was removed in vacuo to yield the title compound (38) as a 
yellow oil (31 mg, 85%). 
O
O
HO
N
1
2
33a
4
5
6
7
8
9
10
11
12
13
15
16
17
6a
Cl
17a
17b
H
14
 [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 –103° (c 1.0, CHCl3) IR (NaCl) 3386 (O–H), 1635, 1604 (C=C), 1283, 1258 (C–O)  
1H-NMR (δ, 400 MHz, CDCl3): 6.66 (1H, d, J = 8.0 Hz, H2), 6.56 (1H, d, J = 8.0 Hz, H1),  
5.71 (1H, dm, J = 10.0 Hz, H7), 5.27 (1H, dt, J = 10.0 Hz, 2.8 Hz, H8),  
4.89 (1H, dd, J = 6.4 Hz, 1.2 Hz, H5), 4.17 (1H, s, br, H6), 3.84 (3H, s, H3a),  
3.58 (2H, t, J = 6.8 Hz, H17b), 3.43 (1H, m, H9), 2.77-2.97 (4H, m, H10α, H17a, H6a),  
2.64-2.71 (2H, m, H14, H16eq), 2.53 (1H, td, J = 12.0 Hz, 3.6 Hz, H16ax),  
2.42 (1H, dd, J = 18.4 Hz, 6.4 Hz, H10β), 2.05 (1H, td, J = 12.4 Hz, 5.2 Hz, H15ax),  
1.86 (1H, dm, J = 12.4 Hz, H15eq) 13C-NMR (δ, 100MHz, CDCl3): 146.4 (C4), 142.4 (C3),  
133.6 (C7), 131.2 (C12), 128.3 (C8), 127.0 (C11), 119.7 (C1), 113.0 (C2), 91.5 (C5),  
66.6 (C6), 58.1 (C9), 57.3 (C17a), 56.5 (C3a), 45.1 (C16), 43.4 (C13), 42.3 (C17b), 40.7 (C14),  
35.9 (C15), 22.9 (C10) LRMS (EI): m/z = 349 (M+·, 20), 347 (M+·, 50), 299 (20),  
298 ([M–CH2Cl]+·, 50) HRMS (EI): 349.1257 (M+·, C19H22NO337Cl gives 349.1259),  
347.1289 (M+·, C19H22NO335Cl gives 347.1288)  
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4.2.3: Synthesis of 3-chloromethyl-3-deoxymorphine:  
3-(trifluoromethanesulfonyl)morphine 78: 
HO
O
HO
N
TfO
O
HO
N
PhNTf2
 
/ NEt3
DCM reflux 16 h
H H
35 54  
Triethylamine (700 µL, 5.02 mmol) was added to a solution of morphine (35, 500 mg, 1.76 mmol) 
and N-phenyltriflimide (700 mg, 1.96 mmol) in dichloromethane (20 mL) and the resulting solution 
was stirred at reflux overnight. The following morning the mixture was cooled and the  
solvent was removed in vacuo to yield a yellow oil, purified by flash chromatography  
(9:1 chloroform : methanol) to give the title compound (54) as a pale yellow solid (598 mg, 82%). 
O
O
HO
N
1
2
3
4
5
6
7
8
9
10
11
12
13
15
16
17
17a
6a
S
O
F3C O3a
H
14
 
mp: 113-115 °C (literature 78 123-124 °C) [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 –145° (c 1.0, CHCl3), –70° (c 1.0, CH3OH), 
literature 78 –78° (c 1.0, CH3OH)  IR (NaCl) 3551 (O–H), 1623 (C=C), 1218 (C–O)  
1H-NMR (δ, 400 MHz, CDCl3): 6.89 (1H, d, J = 8.4 Hz, H2), 6.64 (1H, d, J = 8.4 Hz, H1),  
5.70 (1H, dm, J = 10.0 Hz, H7), 5.27 (1H, dt, J = 10.0 Hz, 2.8 Hz, H8), 5.01 (1H, d, J = 6.4 Hz, H5), 
4.21 (1H, m, H6), 3.40 (1H, m, H9), 3.08 (1H, d, J = 19.2 Hz, H10α), 3.02 (1H, s, br, H6a),  
2.74 (1H, s, br, H14), 2.64 (1H, dd, J = 12.4 Hz, 4.4 Hz, H16eq), 2.45 (3H, s, H17a),  
2.30-2.40 (2H, m, H10β, H16ax), 2.13 (1H, td, J = 12.4 Hz, 4.8 Hz, H15ax),  
1.89 (1H, dm, J = 12.8 Hz, H15eq) 13C-NMR (δ, 100MHz, CDCl3): 149.7 (C4), 135.7 (C11),  
133.9 (C7), 133.8 (C12), 130.8 (C3), 128.2 (C8), 121.3 (C2), 120.4 (C1), 118.8 (q, J = 319 Hz, C3a), 
93.7 (C5), 66.6 (C6), 58.7 (C9), 46.2 (C16), 43.4 (C13), 43.1 (C17a), 40.5 (C14), 35.3 (C15), 
21.2 (C10)  
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3-(trifluoromethanesulfonyl)-6-(tert-butyldimethylsilyl)morphine 79: 
TfO
O
HO
N
TfO
O
TBDMSO
N
2,6-lutidine / TBDMS-OTf
DCM RT 30 min
H H
54 55  
tert-Butyldimethylsilyl triflate (550 µL, 2.40 mmol) was added to a solution of compound 54  
(500 mg, 1.20 mmol) and 2,6-lutidine (400 µL, 3.73 mmol) in dichloromethane (10 mL) and the 
resulting solution was stirred at room temperature for 30 minutes. After this time, the mixture was 
diluted with dichloromethane (40 mL) and washed with saturated aq NaHCO3 (50 mL). The 
solution was dried over anhydrous MgSO4 and the solvent was removed in vacuo to yield a pale 
yellow oil, purified by flash chromatography (9:1 chloroform : methanol) to give the title 
compound (55) as a white solid (570 mg, 90%). 
O
O
O
N
1
2
3
4
5
6
7
8
9
10
11
12
13
15
16
17
17a
6a
S
O
F3C O3a
Si
6a
6b
6c
6c6c
14
H
 
mp: 76-77 °C (literature 79 75 °C) [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 –111° (c 1.0, CHCl3), literature 79 –128°  
(c 1.0, CHCl3) IR (NaCl) 1623 (C=C), 1207, 1249 (C–O) 1H-NMR (δ, 400 MHz, CDCl3):  
6.90 (1H, d, J = 8.4 Hz, H2), 6.56 (1H, d, J = 8.4 Hz, H1), 5.62 (1H, d, br, J = 9.6 Hz, H7),  
5.24 (1H, dt, J = 9.6 Hz, 2.8 Hz, H8), 4.81 (1H, d, J = 5.6 Hz, H5), 4.27 (1H, m, H6),  
3.39 (1H, m, H9), 3.07 (1H, d, J = 19.2 Hz, H10α), 2.71 (1H, s, br, H14),  
2.63 (1H, dd, J = 12.0 Hz, 4.4 Hz, H16eq), 2.45 (3H, s, H17a), 2.30-2.43 (2H, m, H10β, H16ax),  
2.08 (1H, td, J = 12.4 Hz, 4.8 Hz, H15ax), 1.86 (1H, dm, J = 12.8 Hz, H15eq), 0.93 (9H, s, H6c),  
0.14 (3H, s, H6a), 0.11 (3H, s, H6a) 13C-NMR (δ, 100MHz, CDCl3): 150.7 (C4), 135.1 (C11),  
134.4 (C7), 133.5 (C12), 130.8 (C3), 127.7 (C8), 121.8 (C2), 119.3 (C1), 118.9 (q, J = 319 Hz, C3a) 
94.2 (C5), 68.5 (C6), 58.8 (C9), 46.3 (C16), 43.9 (C13), 43.1 (C17a), 40.8 (C14), 35.6 (C15), 25.8 (C6c), 
21.2 (C10), 18.3 (C6b), -4.60 (C6a), -4.72 (C6a) 
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3-(methoxycarbonyl)-3-deoxy-6-(tert-butyldimethylsilyl)morphine: 
TfO
O
TBDMSO
N
O
TBDMSO
N
CO / Pd(dppf)Cl2
 
/ NEt3
DMF / MeOH 80 oC 16 h
MeO
O
H H
55 56  
Carbon monoxide was bubbled through a solution of compound 55 (100 mg, 188 µmol),  
Pd(dppf)Cl2·CH2Cl2 (50 mg, 61 µmol) and triethylamine (60 µL, 430 µmol) in a mixture of 
deoxygenated DMF (3 mL) and deoxygenated methanol (2 mL) for 10 minutes. The mixture was 
then sealed under an atmosphere of carbon monoxide and heated to 80 oC overnight, darkening 
over time. The following morning the mixture was vented for 30 minutes, then diluted with 
dichloromethane (50 mL). The resulting solution was washed with water (50 mL), then washed 
with brine (50 mL) and dried over anhydrous MgSO4. The solvent was removed in vacuo to yield a 
brown oil, purified by flash chromatography (19:1 chloroform : methanol) to give the title 
compound (56) as a brown oil (60 mg, 72%). 
O
O
N
1
2
3
4
5
6
7
8
9
10
11
12
13
15
16
17
17a
6a
3a
Si
6a
6b
6c
6c6c
O
O
3b
14
H
 [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 –70° (c 1.0, CHCl3) IR (NaCl) 1709 (C=O), 1630 (C=C), 1256, 1287 (C–O)  
1H-NMR (δ, 400 MHz, CDCl3): 7.63 (1H, d, J = 8.0 Hz, H2), 6.61 (1H, d, J = 8.0 Hz, H1),  
5.63 (1H, dm, J = 10.0 Hz, H7), 5.27 (1H, dt, J = 10.0 Hz, 2.8 Hz, H8), 4.84 (1H, d, J = 6.0 Hz, H5), 
4.30 (1H, m, H6), 3.87 (3H, s, H3b), 3.35 (1H, m, H9), 3.08 (1H, d, 19.2 Hz, H10α),  
2.68 (1H, m, H14), 2.58 (1H, dd, J = 12.0 Hz, 4.0 Hz, H16eq), 2.44 (3H, s, H17a),  
2.29-2.39 (2H, m, H10β, H16ax), 2.03 (1H, td, J = 12.4 Hz, 5.2 Hz, H15ax),  
1.85 (1H, dm, 12.4 Hz, H15eq), 0.95 (9H, s, H6c), 0.16 (3H, s, H6a), 0.13 (3H, s, H6a)  
13C-NMR (δ, 100MHz, CDCl3): 166.6 (C3a), 160.6 (C4), 140.6 (C11) 134.5 (C7), 131.5 (C12),  
130.3 (C2), 128.0 (C8), 118.6 (C1), 110.4 (C3), 92.9 (C5), 68.6 (C6), 58.6 (C9), 51.9 (C3b), 46.3 (C16), 
43.2 (C17a), 42.5 (C13), 41.0 (C14), 35.9 (C15), 25.9 (C6c), 21.8 (C10), 18.4 (C6b), -4.52 (C6a),  
-4.57 (C6a) LRMS (EI): m/z = 441 (M+·, < 10), 385 (40), 384 ([M–C4H9]+·, 100), 342 (35),  
341 (85), 73 (30) HRMS (ESI): 442.2416 ([M+H]+, C25H36NO4Si gives 442.2414)  
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3-(hydroxymethyl)-3-deoxy-6-(tert-butyldimethylsilyl)morphine: 
O
TBDMSO
N
O
TBDMSO
N
THF RT 3 h
HO
LiAlH4
MeO
O
H H
56 57  
Lithium aluminium hydride (15 mg, 395 µmol) was added to a solution of compound 56  
(60 mg, 136 µmol) in dry THF (5 mL) and the resulting mixture was stirred at room temperature 
for 3 hours. After this time the reaction is quenched by adding a 10% aq solution of sodium 
potassium tartrate (5 mL) and the mixture is stirred for a further hour. Then, the product was 
extracted with ethyl acetate (2 × 5 mL) and the combined extracts were dried over anhydrous 
MgSO4. The solvent was removed in vacuo to yield a brown oil, purified by flash chromatography 
(19:1 chloroform : methanol) to give the title compound (57) as a pale brown solid (47 mg, 84%).  
O
O
N
1
2
3
4
5
6
7
8
9
10
11
12
13
15
16
17
17a
6a
3a
Si
6a
6b
6c
6c6c
HO
3b
H
14
 
mp: 136-139 °C [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 –159° (c 1.0, CHCl3) IR (NaCl) 3363 (O–H), 1604 (C=C), 1251 (C–O)  
1H-NMR (δ, 400 MHz, CDCl3): 6.94 (1H, d, J = 7.6 Hz, H2), 6.55 (1H, d, J = 7.6 Hz, H1),  
5.56 (1H, dm, 10.0 Hz, H7), 5.22 (1H, dt, J = 10.0 Hz, 2.4 Hz, H8), 4.70-4.75 (2H, m, H3a, H5),  
4.49 (1H, d, J = 12.4 Hz, H3a), 4.25 (1H, m, H6), 3.34 (1H, m, H9),  
3.05 (1H, d, J = 18.8 Hz, H10α), 2.66 (1H, m, H14), 2.58 (1H, dd, J = 12.0 Hz, 3.6 Hz, H16eq),  
2.35-2.44 (4H, m, H16ax, H17a), 2.37 (1H, s, br, H3b), 2.30 (1H, dd, J = 18.8 Hz, 6.4 Hz, H10β),  
2.04 (1H, td, J = 12.4 Hz, 5.2 Hz, H15ax), 1.86 (1H, dm, J = 12.4 Hz, H15eq),  
0.93 (9H, s, H6c), 0.15 (3H, s, H6a), 0.11 (3H, s, H6a) 13C-NMR (δ, 100MHz, CDCl3):  
157.9 (C4), 134.8 (C11), 133.9 (C7), 129.8 (C12), 128.1 (C8), 127.7 (C2), 120.2 (C3), 118.8 (C1),  
92.3 (C5), 68.3 (C6), 61.2 (C3a), 59.0 (C9), 46.6 (C16), 43.2 (C17a), 42.8 (C13), 41.0 (C14), 35.7 (C15), 
25.9 (C6c), 21.2 (C10), 18.4 (C6b), -4.51 (C6a), -4.71 (C6a) LRMS (EI): m/z = 413 (M+·, < 10),  
357 (40), 356 ([M–C4H9]+·, 100), 299 (35), 238 (20), 75 (20), 73 (30) HRMS (EI): 413.2386  
(M+·, C24H35NO3Si gives 413.2386) 
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3-(chloromethyl)-3-deoxy-6-(tert-butyldimethylsilyl)morphine: 
O
TBDMSO
N
O
TBDMSO
N
DCM 0 oC 10 min
Cl
SOCl2
HO
H H
57 58  
Thionyl chloride (4 µL, 55 µmol) was added to a solution of compound 57 (10 mg, 24 µmol), and 
triethylamine (7 µL, 50 µmol) in dichloromethane (500 µL) at 0 oC and the resulting solution was 
stirred at 0 oC for 10 minutes. After this time the mixture was diluted with dichloromethane (5 mL) 
and washed with saturated aq NaHCO3 (5 mL). The solution was dried over anhydrous MgSO4 and 
the solvent was removed in vacuo to yield the title compound (58) as a brown oil (9 mg, 86%). 
O
O
N
1
2
3
4
5
6
7
8
9
10
11
12
13
15
16
17
17a
6a
3a
Si
6a
6b
6c
6c6c
Cl
14
H
 
IR (NaCl) 1604, 1639 (C=C), 1251 (C–O) 1H-NMR (δ, 400 MHz, CDCl3):  
7.01 (1H, d, J = 8.0 Hz, H2), 6.55 (1H, d, J = 8.0 Hz, H1), 5.60 (1H, dm, J = 10.0 Hz, H7), 
5.24 (1H, dt, J = 10.0 Hz, 2.4 Hz, H8), 4.74 (1H, dd, J = 6.0 Hz, 1.2 Hz, H5),  
4.66 (1H, d, J = 11.2 Hz, H3a), 4.49 (1H, d, J = 11.2 Hz, H3a), 4.25 (1H, m, H6), 3.34 (1H, m, H9),  
3.06 (1H, d, J = 19.2 Hz, H10α), 2.65 (1H, m, H14), 2.58 (1H, dd, J = 12.4 Hz, 4.4 Hz, H16eq),  
2.43 (3H, s, H17a), 2.38 (1H, td, J = 12.4 Hz, 3.6 Hz, H16ax), 2.29 (1H, dd, J = 19.2 Hz, 6.0 Hz H10β), 
2.02 (1H, td, J = 12.4 Hz, 5.2 Hz, H15ax), 1.86 (1H, dm, J = 12.4 Hz, H15eq), 0.94 (9H, s, H6c), 
0.16 (3H, s, H6a), 0.11 (3H, s, H6a),  13C-NMR (δ, 100MHz, CDCl3): 158.2 (C4), 135.9 (C11),  
134.3 (C7), 130.2 (C12), 129.0 (C8), 128.0 (C2), 118.8 (C1), 116.1 (C3), 92.4 (C5), 68.4 (C6),  
58.9 (C9), 46.5 (C16), 43.3 (C17a), 43.1 (C13), 41.2 (C3a), 41.0 (C14), 35.9 (C15), 25.9 (C6c), 21.3 (C10),  
18.4 (C6b), -4.35 (C6a), -4.63 (C6a) LRMS (EI): m/z = 431 (M+·, < 10), 396 ([M–Cl]+, 20),  
376 ([M–C4H9]+, 40), 374 ([M–C4H9]+, 100), 332 (30), 331 (45), 330 (30), 238 (25),  
75 (20), 73 (45) HRMS (EI): 433.2018 (M+·, C24H34NO2Si37Cl gives 433.2018), 431.2049  
(M+·, C24H34NO2Si35Cl gives 431.2047) 
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4.2.4: Synthesis of N-acetylcysteine methyl ester adducts:  
N-acetyl-L-cysteine methyl ester 112,113: 
H
N
OH
O
SH
O MeOH 0
oC - RT 2 h
SOCl2
H
N
OMe
O
SH
O
67 66  
Thionyl Chloride (300 μL, 4.13 mmol) was added to a solution of N-acetyl-L-cysteine  
(67, 500 mg, 3.07 mmol) in methanol (5 mL) at 0 °C. The resulting solution was stirred at 
room temperature for 2 hours. After this time the reaction was quenched with water (5 mL) 
and the volatile components of the mixture were removed in vacuo. The remaining solution 
was diluted with water (5 mL) and the product was extracted with a 3:1 mixture of 
chloroform and isopropanol (2 × 5 mL). The combined extracts were dried over anhydrous 
MgSO4 and the solvent was removed in vacuo to yield a white solid, purified by flash 
chromatography (19:1 chloroform : methanol) to give the title compound (66) as a white solid  
(202 mg, 37%). 
H
N
O
O
SH
O
1
2
3
3a
3b 1a
2a
2b  
mp: 79-80 °C (literature 112 78-80 °C) [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 +73° (c 1.0, CHCl3) reference 113 +71°  
(c 1.0, CHCl3) IR (NaCl): 3310 (N–H), 2565, 2543 (S–H), 1739 (C=O, ester), 1649 (C=O, amide), 
1254, 1229 (C–O) 1H-NMR (δ, 800 MHz, CDCl3): 6.40 (1H, s, br, H3), 4.89 (1H, m, H2),  
3.79 (3H, s, H1a), 3.01 (2H, m, H2a), 2.06 (3H, s, H3b), 1.34 (1H, t, J = 8.8 Hz, H2b)  
13C-NMR (δ, 100MHz, CDCl3): 170.8 (C1), 170.0 (C3a), 53.7 (C2), 53.0 (C1a), 27.0 (C2a),  
23.3 (C3b) 
General Procedure for Michael addition reaction: 
O
MeOH RT 16 h
O S
H
N
O
O
OMe
SH
H
N
MeO O
O
 
A solution of the unsaturated ketone (1 eq) and N-acetylcysteine methyl ester (2 eq) were dissolved 
in methanol (100 µL / mg of ketone) and the resulting solution was stirred at room temperature 
overnight. The following morning the solvent was removed in vacuo to give the crude compound, 
which was purified by flash chromatography.  
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Codeinone Adduct 80: 
O
O
O
N
1
2
33a
4
5
6
7
8
9
10
11
12
13
15 16
17
17a
S
H
N
O
O O
2a'
2'
1'
3'
3a'
3b'
1a'
H
14
 
The general procedure was applied to codeinone (36, 20 mg, 67 µmol), purifying by flash 
chromatography (9:1 chloroform : methanol), to yield the adduct (71) as a white solid  
(30 mg, 94%). mp: 86-88 °C [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 +22° (c 1.0, CHCl3) IR (NaCl): 3287 (N–H),  
1731, 1667 (C=O), 1277, 1259 (C–O) 1H-NMR (δ, 800 MHz, CDCl3): 6.70 (1H, d, J = 8.0 Hz, H2), 
6.68 (1H, d, J = 8.0 Hz, H1), 6.32 (1H, d, br, J = 6.8 Hz, H3’), 4.81 (1H, m, H2’), 
4.69 (1H, s, H5), 3.89 (3H, s, H3a), 3.63 (1H, s, br, H9), 3.46 (3H, s, H1a’),  
3.04 (1H, dd, J = 14.0 Hz, 4.4 Hz, H2a’), 3.01 (1H, d, J = 18.8 Hz, H10α),  
2.98 (1H, dd, J = 14.0 Hz, 4.0 Hz, H2a’), 2.70 (1H, dd, J = 13.2 Hz, 2.4 Hz, H7β),  
2.57 (1H, d, br, J = 11.6 Hz, H16eq), 2.53 (1H, t, J = 13.2 Hz, H7α), 2.44-2.49 (4H, m, H14, H17a), 
2.34 (1H, dd, J = 18.4 Hz, 5.2 Hz, H10β), 2.30 (1H, td, J = 12.8 Hz, 2.4 Hz, H8),  
2.20 (1H, td, J = 12.0 Hz, 2.8 Hz, H16ax), 2.06 (1H, td, J = 12.0 Hz, 4.0 Hz, H15ax), 1.97 (3H, s, H3b’), 
1.82 (1H, d, br, J = 12.0 Hz, H15eq), 13C-NMR (δ, 100MHz, CDCl3): 204.8 (C6), 170.9 (C1’),  
169.9 (C3a’), 145.2 (C4), 143.1 (C3), 126.8 (C12), 126.5 (C11), 120.4 (C1), 115.0 (C2), 91.5 (C5),  
57.0 (C3a), 56.9 (C9), 52.6 (C1a’), 52.3 (C2’), 47.5 (C7), 47.4 (C14), 47.3 (C16), 47.2 (C13), 43.0 (C17a), 
41.6 (C8), 35.7 (C15), 31.5 (C2a’), 23.2 (C3b’), 19.3 (C10) LRMS (EI): m/z = 474 (M+·, 15),  
299 (35), 298 ([M–C6H10NO3S]+, 100),  297 ([M–C6H11NO3S]+·, 30) HRMS (EI): 474.1827  
(M+·, C24H30N2O6S gives 474.1825) 
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Narwedine Adducts:      
The general procedure was applied to narwedine (30, 50 mg, 175 µmol), purifying by flash 
chromatography (9:1 chloroform : methanol), to yield adducts 73a (or 73b) (31 mg, 38%) and 73b 
(or 73a) (35 mg, 43%) as colourless oils. 
Characterisation Data for adduct 73a (or 73b): 
O
O
N
O
1
2
3
4
4a
5
6 7
8
8a 9
10
11 11a
12
13
14
3a
S
H
N
O
O O
2'
2a'
1'
1a'
3'
3a'
3b'
 [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 +3° (c 0.4, CHCl3) IR (NaCl): 3289 (N–H), 1744, 1721, 1675 (C=O), 1286, 1204 (C–O)  
1H-NMR (δ, 800 MHz, CDCl3): 6.68 (1H, d, J = 8.0 Hz, H2), 6.64 (1H, d, J = 8.0 Hz, H1), 
6.29 (1H, d, br, J = 7.6 Hz, H3’), 4.86 (1H, ddd, J = 7.6 Hz, 5.6 Hz, 4.0 Hz, H2’), 
4.68 (1H, t, J = 2.8 Hz, H4a), 4.11 (1H, d, J = 14.8 Hz, H12β), 3.83 (3H, s, H3a), 3.78 (3H, s, H1a’), 
3.63 (1H, d, J = 14.8 Hz, H12α), 3.58 (1H, s, br, H8), 3.41 (1H, t, br, J = 13.6 Hz, H10β), 
3.14 (1H, dd, J = 13.6 Hz, 4.0 Hz, H2a’), 3.10 (1H, d, br, J = 14.4 Hz, H10α),  
2.99 (1H, dd, J = 18.4 Hz, 2.8 Hz, H5β), 2.95 (1H, dd, J = 18.4 Hz, 2.8 Hz, H5α), 
2.88 (1H, dd, J = 13.6 Hz, 5.6 Hz, H2a’), 2.58 (1H, dd, J = 16.8 Hz, 3.6 Hz, H7β),  
2.50 (1H, dd, J = 16.8 Hz, 2.8 Hz, H7α), 2.32 (3H, s, H11a), 2.09 (1H, t, br, J = 14.0 Hz, H9α),  
2.07 (3H, s, H3b’), 1.96 (1H, dd, J = 14.0 Hz, 3.2 Hz, H9β) 13C-NMR (δ, 100MHz, CDCl3):  
206.3 (C6), 171.1 (C1’), 170.0 (C3a’), 146.8 (C4), 144.0 (C3), 131.7 (C14), 129.5 (C13),  
123.0 (C1), 111.7 (C2), 87.9 (C4a), 60.0 (C12), 56.1 (C3a), 55.3 (C10), 53.0 (C1a’), 51.7 (C2’),  
51.4 (C8a), 44.3 (C8), 41.8 (C11a), 41.1 (C7), 40.2 (C5), 33.9 (C2a’), 32.8 (C9), 23.2 (C3b’)  
LRMS (EI): m/z = 462 (M+·, < 10), 286 (35), 285 ([M–C6H11NO3S]+·, 100),  242 (40),  
216 (25), 199 (25), 174 (45), 118 (20), 88 (45), 76 (50)  HRMS (ESI): 463.1904  
([M+H]+, C23H31N2O6S gives 463.1903) 
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Characterisation Data for adduct 73b (or 73a): 
O
O
N
O
1
2
3
4
4a
5
6 7
8
8a 9
10
11 11a
12
13
14
3a
S
H
N
O
O O
2'
2a'
1'
1a'
3'
3a'
3b'
 [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 +50° (c 0.4, CHCl3) IR (NaCl): 3271 (N–H), 1720, 1659 (C=O), 1286, 1204 (C–O)  
1H-NMR (δ, 800 MHz, CDCl3): 6.69 (1H, d, J = 8.0 Hz, H2), 6.64 (1H, d, J = 8.0 Hz, H1),  
6.19 (1H, d, J = 7.6 Hz, H3’), 4.78 (1H, td, J = 7.6 Hz, 4.0 Hz, H2’), 4.69 (1H, t, J = 2.8 Hz, H4a), 
4.19 (1H, d, J = 14.8 Hz, H12β), 3.84 (3H, s, H3a), 3.77 (3H, s, H1a’), 3.67 (1H, s, br, H8),  
3.63 (1H, d, J = 14.8 Hz, H12α), 3.39 (1H, t, br, J = 13.2 Hz, H10β),  
3.15 (1H, dd, J = 13.6 Hz, 4.0 Hz, H2a’), 3.09 (1H, d, br, J = 14.4 Hz, H10α),  
3.03 (1H, dd, J = 18.4 Hz, 2.8 Hz, H5α), 2.95 (1H, dd, J = 18.4 Hz, 2.8 Hz, H5β),  
2.78 (1H, dd, J = 13.6 Hz, 7.6 Hz, H2a’), 2.61 (1H, dd, J = 17.2 Hz, 3.6 Hz, H7β),  
2.52 (1H, dd, J = 17.2 Hz, 2.8 Hz, H7α), 2.34 (3H, s, H11a), 2.08-2.12 (4H, m, H9α, H3b’),  
1.98 (1H, dd, J = 14.0 Hz, 3.2 Hz, H9β) 13C-NMR (δ, 100MHz, CDCl3): 206.0 (C6), 171.2 (C1’), 
170.2 (C3a’), 146.8 (C4), 144.0 (C3), 131.7 (C14), 129.3 (C13), 123.1 (C1), 111.7 (C2), 88.0 (C4a),  
59.9 (C12), 56.1 (C3a), 55.3 (C10), 53.2 (C1a’), 51.3 (C8a), 51.2 (C2’), 43.3 (C8), 42.1 (C11a), 40.8 (C7), 
40.1 (C5), 33.3 (C2a’), 33.0 (C9), 23.4 (C3b’) LRMS (EI): m/z = 462 (M+·, < 10), 286 (35),  
285 ([M–C6H11NO3S]+·, 100), 242 (40), 216 (25), 199 (25), 174 (45), 118 (20), 88 (45), 76 (50) 
HRMS (ESI): 463.1900 ([M+H]+, C23H31N2O6S gives 463.1903)  
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4.2.5: Reaction Kinetics: 
Investigation of reaction kinetics by LC-MS: 
LCMS Parameters: 
The ketones and their adducts with N-acetyl-L-cysteine methyl ester were separated using an 
Agilent 1260 UHPLC system with an Agilent C18 column (50 mm with a 5 mm guard column, 2.1 
mm diameter, 1.8 µm particle size). The mobile phase consisted of 86% aqueous ammonium 
acetate (10 mM) adjusted to pH 5.5 and 14% acetonitrile with a flow rate of 0.5 mL min–1. 
Analytes were ionized by atmospheric pressure electrospray ionisation (AP-ESI) with an Agilent 
6120 quadrupole mass spectrometer and ions were monitored in positive mode for the protonated 
species ([M+H]+). The capillary voltage was 1500 V and the fragmentor voltage was 150 V. 
Reactions: 
Reactions were carried out in 10 mM HEPES buffer adjusted to pH 7.5 at 25 °C. A solution of the 
ketone (1 eq) was mixed with a solution of N-acetyl-L-cysteine methyl ester (20 eq) and the 
composition of the mixture was analysed by LCMS at regular intervals. The concentration of the 
ketone at each interval was determined with reference to a calibration curve and the pseudo first 
order rate constant for the reaction was estimated by least squares curve fitting from the plot of 
ln[ketone] against time using KaleidaGraph.   
Investigation of reaction kinetics by 1H-NMR: 
Reactions were carried out in deuterated methanol at 25 °C. A solution of the ketone (1 eq) was 
mixed with a solution of N-acetyl-L-cysteine methyl ester (20 eq) and the composition of the 
mixture was determined by 1H-NMR analysis at regular intervals. The concentration of the ketone 
at each interval was determined by comparing the relative integration of the H-7 olefinic proton in 
the starting material with the H12β benzylic proton in both the starting material and product. The 
pseudo first order rate constant for the reaction was estimated by least squares curve fitting from 
the plot of ln[ketone] against time using KaleidaGraph.  
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4.3. Experimental for Chapter 3: 
4.3.1: Synthesis of Bicyclic Alcohol: 
ethyl 3-ethyl-9-oxo-3-azabicyclo[3.3.1]nonane-1-carboxylate105 
EtO
O
N
EtO
O
O O
CH3CH2NH2
 
/ CH2O
Ethanol Reflux 3 d
109 110  
A mixture of ethyl 2-oxocyclohexane-1-carboxylate (109, 5.60 g, 32.9 mmol), 70% w/w aq 
ethylamine (2.60 mL, 32.7 mmol) and 36% w/w aq formaldehyde (5.00 mL, 65.3 mmol) were 
dissolved in ethanol (500 mL) and stirred at reflux for 3 days, turning yellow over time. After 3 
days the solvent was removed in vacuo and the orange oil that remained was redissolved in ether 
(100 mL). The product was extracted from the resulting solution with 2 M aq HCl (3 × 50 mL) and 
the combined extracts were basified to pH 12 with solid NaOH. The product was then extracted 
from the resulting solution with ether (3 × 50 mL) and the combined extracts were dried over 
anhydrous MgSO4. The solvent was removed in vacuo to yield a yellow oil, purified by flash 
chromatography (9:1 hexane : ethyl acetate) to give the title compound (110) as a bright yellow oil 
(2.19 g, 28%).  
N
O
O
O
1
2
3
4
5
6
7
8 9
3a
3b
1a1b
1c
 
IR (NaCl): 1736 (C=O, ketone), 1717 (C=O, ester), 1H-NMR (δ, 400MHz, CDCl3):  
4.20 (2H, q, J = 7.2 Hz, H1b) 3.20 (1H, dd, J = 11.6 Hz, 2.4 Hz, H2eq)  
3.13 (1H, dt, J = 10.8 Hz, 2.4 Hz, H4eq) 2.92 (1H, dd, J = 11.2 Hz, 1.6 Hz, H2ax)  
2.84 (1H, m, H7ax) 2.34-2.58 (5H, m, H4ax, H5, H8eq, H3a) 2.00-2.26 (3H, m, H8ax, H6ax, H6eq)  
1.51 (1H, m, H7eq), 1.27 (3H, t, J = 7.2 Hz, H1c), 1.09 (3H, t, J = 7.2 Hz, H3b),  
13C-NMR (δ, 100MHz, CDCl3): 212.9 (C9), 171.3 (C1a), 61.8 (C2), 61.2 (C4), 60.1 (C1b),  
59.0 (C1), 51.2 (C3a), 47.3 (C5), 36.9 (C8), 34.3 (C6), 20.7 (C7), 14.3 (C1c), 12.8 (C3b) 
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ethyl-3-ethyl-9-methylidene-3-azabicyclo[3.3.1]nonane-1-carboxylate105 
N
EtO O
t-BuOK / MePPh3Br
THF RT 16 h
N
EtO
O
O
111110  
A solution of potassium tert-butoxide (5.34 g, 47.6 mmol) in dry THF (80.0 mL) was slowly added 
via syringe to a solution of ester 110 (2.00 g, 8.36 mmol) and methyl triphenylphosphonium 
bromide (8.94 g, 25.0 mmol) in dry THF (50.0 mL) at 0 °C. The resulting cloudy mixture was left 
to stir at 0 °C for one hour before being allowed to warm to room temperature overnight. The 
following morning the reaction was quenched with water (60 mL) and the volatile solvents were 
removed in vacuo. The product was extracted from the remaining yellow solution with ethyl 
acetate (3 × 50 mL), then extracted from the combined organic extracts with 2 M aq HCl  
(3 × 50 mL). The combined HCl extracts were basified to pH 14 with solid NaOH then the product 
was again extracted with ethyl acetate (3 × 50 mL). The combined extracts were dried over 
anhydrous MgSO4 and the solvent was removed in vacuo to yield a yellow oily solid, purified by 
flash chromatography (9:1 hexane : ethyl acetate) to give the title compound (111) as a pale yellow 
oil (1.41 g, 71%).  
N
O O
1
2
3
4
5
6
7
8 9
3a
3b
1a1b
1c
10
 
IR (NaCl): 1727 (C=O, ester) 1H-NMR (δ, 400MHz, CDCl3): 4.74 (1H, s, H10a),  
4.46 (1H, s, H10b), 4.18 (2H, q, J = 7.2 Hz, H1b), 3.04 (1H, d, J = 10.8 Hz, H2eq), 
2.97 (1H, d, J = 10.4 Hz, H4eq), 2.76 (1H, m, H7ax), 2.54 (1H, d, J = 10.8 Hz,  H2ax),  
2.42 (1H, s, br, H5), 2.14-2.34 (4H, m, H3a, H4ax, H8eq), 1.71-1.97 (3H, m, H6ax, H6eq, H8ax),  
1.48 (1H, m, H7eq), 1.27 (3H, t, J = 7.2 Hz, H1c), 1.04 (3H, t, J = 7.2 Hz, H3b),  
13C-NMR (δ, 100MHz, CDCl3): 174.6 (C1a), 152.5 (C9), 103.5 (C10) 62.2 (C2), 60.7 (C4),  
60.5 (C1b), 52.1 (C3a), 50.7 (C1), 41.1 (C5), 36.0 (C8), 33.7 (C6), 21.5 (C7), 14.4 (C1c),  
12.7 (C3b) 
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[3-ethyl-9-methylidene-3-azabicyclo[3.3.1]non-1-yl] methanol105 
N
HO
THF RT 2 h
N
EtO O
LiAlH4
111 94  
Lithium aluminium hydride (400 mg, 10.6 mmol) was added to a solution of ester 111  
(1.00 g, 4.20 mmol) in dry THF (200 mL). The resulting suspension was left to stir at room 
temperature for two hours. After two hours the reaction was quenched with water  
(150 mL) and the volatile solvents were removed in vacuo. The product was extracted from the 
remaining pale yellow solution with ethyl acetate (3 × 50 mL), then extracted from the combined 
organic extracts with 2 M aq HCl (3 × 50 mL). The combined HCl extracts were basified to pH 14 
with solid NaOH then the product was again extracted with ethyl acetate (3 × 50 mL). The 
combined extracts were dried over anhydrous MgSO4 and the solvent was removed in vacuo to 
yield a pale yellow oil, purified by flash chromatography (1:1 hexane : ethyl acetate) to give the 
title compound (94) as an off white oily solid (760 mg, 93%).  
N
HO
1
2
3
4
5
6
7
8 9
3a
3b
1a
1b
10
 
mp 37-39 °C IR (NaCl): 3368 (O–H), 1649 (C=C) 1H-NMR (δ, 400MHz, CDCl3):  
4.74 (1H, s, H10a), 4.49 (1H, s, H10b), 3.60 (1H, d, J = 10.8 Hz, H1a), 3.53 (1H, d, J = 10.8 Hz, H1a),   
2.93-3.01 (2H, m, H2eq, H4eq), 2.76 (1H, m, H7ax), 2.39 (1H, s, br, H5),  
2.26 (2H, q, J = 7.2 Hz,  H3a), 2.17 (1H, d, br, J = 10.0 Hz, H4ax), 2.02 (1H, d, J = 10.4 Hz, H2ax), 
1.82-1.91 (2H, m, H6eq, H8eq), 1.70 (1H, m, H6ax), 1.40-1.51 (3H, m, H1b, H7eq, H8ax),  
1.05 (3H, t, J = 7.2 Hz, H3b) 13C-NMR (δ, 100MHz, CDCl3): 155.6 (C9), 101.1 (C10), 69.3 (C1a) 
62.6 (C2), 60.9 (C4), 52.4 (C3a), 42.4 (C1), 42.1 (C5), 36.4 (C8), 34.4 (C6), 21.7 (C7), 12.8 (C3b) 
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4.3.2: Synthesis of Biaryl Acids: 
Preparation of Aryl Boronate 108 
O
OEt
O
OEt
B
O
O
1. B(OiPr)3
 
/ LiTMP
2. neopentyl glycol
121 117
 
A solution of n-butyllithium (23.4 mL, 1.6 M, 37.4 mmol) in hexanes is added to a solution of 
TMP (6.54 mL, 38.8 mmol) in THF (40 mL) at –10 °C and stirred for 30 min. The mixture was 
then cooled to –78 °C and triisopropyl borate (11.5 mL, 50.0 mmol) was added, then ethyl 
benzoate (121, 3.75 g, 25.0 mmol) was added and the mixture was left to stir for a further 2 hours 
at –78 °C, then allowed to warm to room temperature over 3 hours. Then, the reaction was 
quenched with saturated aq NH4Cl (100 mL) and the product was extracted from the resulting 
mixture with ethyl acetate (3 × 100 mL). The combined extracts were dried over anhydrous MgSO4 
and the solvent was removed in vacuo. The resulting residue was combined with neopentyl glycol  
(3.13 g, 30 mmol) and stirred in toluene (100 mL) at room temperature overnight. The following 
morning the mixture was washed with water (3 × 50 mL), dried over anhydrous MgSO4 and the 
solvent was removed in vacuo to yield the title compound (117) as an orange oil (4.95 g, 76%). 
O
O
B
O
O
1
2
3
4
5
6
2a
2b
2c
2c2a
1a 1b 1c
 
IR (NaCl): 1709 (C=O, ester), 1315 (B–O), 1278 (C–O, ester), 1134 (C–O, boronate)  
1H-NMR (δ, 400MHz, CDCl3): 7.94 (1H, dt, J = 7.6 Hz, 0.8 Hz, H6), 7.47-7.52 (2H, m, H3, H4),  
7.38 (1H, ddd, J = 7.6 Hz, 6.0 Hz, 2.8 Hz, H5), 4.38 (2H, q, J = 7.2 Hz, H1b), 3.80 (4H, s, H2a),  
1.40 (3H, t, J = 7.2 Hz, H1c), 1.11 (6H, s, H2c) 13C-NMR (δ, 100MHz, CDCl3): 168.7 (C1a),  
133.3 (C1), 132.0 (C4), 131.4 (C3), 128.8 (C6), 128.4 (C5), 72.7 (C2a), 61.3 (C1b), 32.0 (C2b),  
22.3 (C2c), 14.5 (C1c), C2 absent in 13C spectrum, appears at 138.7 in HMBC. 
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Suzuki Coupling of Aryl Bromides with Aryl Boronates 
General Procedure for Biaryl Esters: 
O
OEt
Ar
Pd(PPh3)4
 
/ K2CO3
O
OEt
B
O
O
+ Ar Br toluene / ethanol
117
 
A solution of tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4, see Table 4.1) in toluene  
(10 mL) was transferred to a mixture of the aryl bromide (see Table 4.1), boronate 117  
(see Table 4.1) and K2CO3 (see Table 4.1) in 95% v/v aq ethanol (5 mL). The resulting mixture was 
stirred at reflux overnight, darkening over time. The following morning the reaction was allowed to 
cool and quenched with water (10 mL). The resulting mixture was filtered to remove Pd(0) and the 
volatile components were removed in vacuo. The product was extracted from the remaining 
solution with ethyl acetate (3 × 50 mL) and the combined extracts were dried over anhydrous 
MgSO4. The solvent was removed in vacuo giving the crude compound, which was purified by 
flash chromatography. 
Table 4.1: Amounts of each component used in the preparation of biaryl esters 
Aryl Bromide Boronate K2CO3 Pd(PPh3)4 
N
Br  
Free Base 
120 mg  
(760 μmol) 
180 mg 
(687 μmol) 
230 mg  
(1.67 mmol) 
35 mg  
(30.0 μmol) 
HCl Salt  
145 mg 
(751 μmol) 
180 mg 
(687 μmol) 
310 mg  
(2.24 mmol) 
35 mg  
(30.0 μmol) 
X
Br
H
N
O
X = CH or N  
X = CH 
100 mg  
(467 μmol) 
140 mg  
(534 μmol) 
150 mg  
(1.10 mmol) 
40 mg  
(34.3 μmol) 
X = N 
100 mg  
(465 μmol) 
140 mg  
(534 μmol) 
150 mg  
(1.10 mmol) 
40 mg  
(34.3 μmol) 
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ethyl 2-(2-pyridyl)benzoate 107: 
O
O
N
1
2
3
4
5
6
1a 1b 1c
1'
2'
3'
4'
5'
6'
 
The general procedure was applied to 2-bromopyridine (103a), purifying by flash chromatography 
(19:1 DCM : Ether), to yield the ester (118a) as a pale yellow solid (120 mg, 77%).  
mp: 67-69 °C IR (NaCl): 1721 (C=O), 1286 (C–O) 1H-NMR (δ, 400 MHz, CDCl3):  
8.64 (1H, d, J = 4.8 Hz H6’), 7.84 (1H, d, J = 7.6 Hz, H6), 7.74 (1H, td, J = 7.6 Hz, 1.6 Hz, H4’),  
7.53-7.57 (2H, m, H3, H4), 7.44-7.49 (2H, m, H3’, H5), 7.26 (1H, m, H5’),  
4.14 (2H, q, J = 7.2 Hz, H1b), 1.05 (3H, t, J = 7.2 Hz, H1c) 13C-NMR (δ, 100 MHz, CDCl3):  
168.9 (C1a), 159.0 (C2’), 149.1 (C6’), 141.1 (C2), 136.3 (C4’), 131.9 (C1), 131.2 (C4), 129.90 (C3), 
129.89 (C6), 128.4 (C5), 123.0 (C3’), 122.1 (C5’), 61.0 (C1b), 13.9 (C1c) 
ethyl 2-(3-pyridyl)benzoate 107: 
O
O
N
1
2
3
4
5
6
1a 1b 1c
1'
2'
3'
4'
5'
6'
 
The general procedure above was applied to 3-bromopyridine (103b), purifying by flash 
chromatography (19:1 DCM : Ether), to yield the desired ester (118b) as a yellow oil  
(83 mg, 53%) IR (NaCl): 1719 (C=O), 1287, 1252 (C–O) 1H-NMR (δ, 400 MHz, CDCl3):  
8.60 (1H, dd, br, J = 4.8 Hz, 1.2 Hz, H6’), 8.57 (1H, d, br, J = 1.6 Hz, H2’),  
7.97 (1H, dd, J = 7.6 Hz, 1.2 Hz, H6), 7.67 (1H, dt, J = 8.0 Hz, 2.0 Hz, H4’),  
7.59 (1H, td, J = 7.6 Hz, 1.2 Hz, H4), 7.49 (1H, td, J = 7.6 Hz, 1.2 Hz, H5),  
7.31-7.35 (2H, m, H3, H5’), 4.13 (2H, q, J = 7.2 Hz, H1b), 1.06 (3H, t, J = 7.2 Hz, H1c),  
13C-NMR (δ, 100 MHz, CDCl3): 167.9 (C1a), 149.2 (C2’), 148.4 (C6’), 139.2 (C2), 137.5 (C3’),  
135.9 (C4’), 131.8 (C4), 131.0 (C3, C1), 130.6 (C6), 128.2 (C5), 122.9 (C5’), 61.2 (C1b), 13.9 (C1c) 
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ethyl 2-(4-pyridyl)benzoate 107 
O
O
N
1
2
3
4
5
6
1a 1b 1c
1'
2'
3'
4'
3'
2'  
The general procedure above was applied to 4-bromopyridine-HCl (103c), purifying by  
flash chromatography (19:1 DCM : Ether), to yield the ester (118c) as a pale yellow  
solid (122 mg, 78%) mp: 62-64 °C (literature 107 67 °C) IR (NaCl): 1702 (C=O),  
1306 (C–O) 1H-NMR (δ, 400 MHz, CDCl3): 8.63 (1H, d, br, J = 5.6 Hz, H2’),  
7.92 (1H, dd, J = 7.6 Hz, 1.2 Hz, H6), 7.57 (1H, td, J = 7.6 Hz, 1.6 Hz, H4),  
7.49 (1H, dt, J = 7.6 Hz, 1.2 Hz, H5), 7.32 (1H, dd, J = 7.6 Hz, 1.2 Hz, H5),  
7.24 (2H, m, H3’), 4.11 (2H, q, J = 7.2 Hz, H1b), 1.03 (3H, t, J = 7.2 Hz, H1c)  
13C-NMR (δ, 100 MHz, CDCl3): 167.8 (C1a), 149.8 (C4’), 149.5 (C2’), 140.1 (C2),  
131.7 (C4), 130.7 (C1), 130.5 (C6), 130.3 (C3), 128.5 (C5), 123.6 (C3’), 61.3 (C1b),  
13.8 (C1c) 
ethyl 2-(3-acetamidophenyl)benzoate: 
O
O
1
2
3
4
5
6
1a 1b 1c
1'
2'
3'
4'
5'
6'
H
N
O
1a'
1b'
1c'
 
The general procedure was applied to 3-bromoacetanilide (104a), purifying by flash 
chromatography (9:1 DCM : Ether), to yield the ester (123a) as a pale yellow solid (83 mg, 63%)  
mp: 128-129 °C IR (NaCl): 3309 (N–H), 1714 (C=O, ester), 1668 (C=O, amide),  
1288 (C–O, C–N) 1H-NMR (δ, 400 MHz, CDCl3): 7.82 (1H, d, J = 7.6 Hz, H6)  
7.56 (1H, d, J = 8.0 Hz, H6’) 7.50 (1H, t, J = 7.6 Hz, H4) 7.28-7.43 (5H, m, H3, H5, H1a’, H2’, H5’)  
7.05 (1H, d, J = 7.6 Hz, H4’) 4.12 (2H, q, J = 7.2 Hz, H1b) 2.14 (3H, s, H1c’) 
1.04 (3H, t, J = 7.2 Hz, H1c) 13C-NMR (δ, 100 MHz, CDCl3): 168.8 (C1a), 168.4 (C1b’),   
142.4 (C3’), 142.1 (C2), 137.9 (C1’), 131.3 (C4, C1), 130.8 (C3), 129.9 (C6), 128.7 (C5’)  
127.5 (C5), 124.6 (C4’), 119.9 (C2’), 118.8 (C6’), 61.1 (C1b), 24.8 (C1c’), 13.9 (C1c)  
LRMS (EI): m/z = 283 (M+·, 99), 241 ([M–COCH2]+·, 100), 213 (15), 196 (50), 169 (90), 139 (25) 
HRMS (EI): 283.1208 (M+·, C17H17NO3 gives 283.1208) 
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ethyl 2-(4-acetamidophenyl)benzoate: 
O
O
1
2
3
4
5
6
1a 1b 1c
1'
2'
3'
4'
2'
3'
1a'
1b'
1c'
N
H
O
 
The general procedure was applied to 4-bromoacetanilide (104b), purifying by flash 
chromatography (9:1 DCM : Ether), to yield the ester (123b) as a pale yellow solid (74 mg, 56%).  
mp: 135-137 °C IR (NaCl): 3310 (N–H), 1712 (C=O, ester), 1668 (C=O, amide),  
1285 (C–O, C–N) 1H-NMR (δ, 400 MHz, CDCl3): 7.80 (1H, d, J = 7.6 Hz, H6)  
7.49-7.54 (3H, m, H4, H2’) 7.33-7.42 (3H, m, H3, H5, H1a’) 7.26 (2H, d, J = 8.0 Hz, H3’)  
4.13 (2H, q, J = 7.2 Hz, H1b) 2.15 (3H, s, H1c’) 1.08 (3H, t, J = 7.2 Hz, H1c)  
13C-NMR (δ, 100 MHz, CDCl3): 169.0 (C1a), 168.4 (C1b’),  141.9 (C2), 137.4 (C1’,C4’), 131.4 (C1)  
131.3 (C4), 130.8 (C3), 129.8 (C6), 129.1 (C3’) 127.2 (C5),  119.5 (C2’), 61.2 (C1b), 24.7 (C1c’),  
14.0 (C1c) LRMS (EI): m/z = 283 (M+·, 93), 241 ([M–COCH2]+·, 100), 213 (30), 196 (40),  
167 (30), 139 (20) HRMS (EI): 283.1208 (M+·, C17H17NO3 gives 283.1208) 
ethyl 2-(4-acetamido-2-pyridyl)benzoate: 
O
O
N
1
2
3
4
5
6
1a 1b 1c
1'
2'
3'
6'
5'
4'
H
N
O
4a'
4b'
4c'
 
The general procedure was applied to 4-acetamido-2-bromopyridine (102a), purifying by flash 
chromatography (3:2 DCM : Ether), to yield the ester (122a) as a yellow oil (60 mg, 45%).  
IR (NaCl): 3324 (N–H), 1710 (C=O), 1261 (C–O, C–N) 1H-NMR (δ, 400 MHz, CDCl3):  
8.39 (1H, d, J = 5.6 Hz, H6’), 8.12 (1H, s br, H4a’), 7.81 (1H, d, J = 7.6 Hz, H6),  
7.63 (1H, d, J = 1.2 Hz, H3’), 7.42-7.56 (3H, m, H3, H4, H5), 7.38 (1H, dd, J = 5.6 Hz, 1.6 Hz, H5’),  
4.20 (2H, q, J = 7.2 Hz, H1b), 2.10 (3H, s, H4c’), 1.16 (3H, t, J = 7.2 Hz, H1c),  
13C-NMR (δ, 100 MHz, CDCl3): 169.3 (C1a), 169.1 (C4b’), 159.7 (C2’), 149.5 (C6’),  
145.9 (C4’), 140.8 (C2), 131.9 (C1), 131.3 (C4), 129.9 (C3), 129.8 (C6), 128.6 (C5),  
112.7 (C3’), 112.2 (C5’), 61.3 (C1b), 24.7 (C4c’), 14.1 (C1c) LRMS (ESI): m/z = 285 ([M+H]+, 100) 
HRMS (ESI): 285.1238 ([M+H]+, C16H17N2O3 gives 285.1239) 
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ethyl 2-(5-acetamido-2-pyridyl)benzoate: 
O
O
N
1
2
3
4
5
6
1a 1b 1c
1'
6'
3'
4'
2'
5'
5a'
5b'
5c'
N
H
O
 
The general procedure was applied to 3-acetamido-6-bromopyridine (102b), purifying by flash 
chromatography (3:2 DCM : Ether), to yield the ester (122b) as a yellow oil (91 mg, 69%).  
IR (NaCl): 3309 (N–H), 1719 (C=O, ester), 1696 (C=O, amide), 1286 (C–O, C–N)  
1H-NMR (δ, 400 MHz, CDCl3): 8.50 (1H, d, J = 2.4 Hz, H6’) 8.30 (1H, dd, J = 8.4 Hz, 2.4 Hz, H4’), 
8.01 (1H, s br, H5a’), 7.77 (1H, d, J = 7.6 Hz, H6), 7.52-7.57 (2H, m, H3, H4), 
7.42-7.49 (2H, m, H5, H3’), 4.20 (2H, q, J = 7.2 Hz, H1b), 2.11 (3H, s, H5c’),  
1.15 (3H, t, J = 7.2 Hz, H1c) 13C-NMR (δ, 100 MHz, CDCl3): 169.9 (C1a), 169.1 (C5b’),  
153.6 (C2’), 140.3 (C6’), 140.2 (C2), 134.1 (C5’), 132.0 (C1), 131.2 (C4), 129.7 (C3),  
129.6 (C6), 128.3 (C5), 127.4 (C4’), 122.7 (C3’), 61.4 (C1b), 24.4 (C5c’), 14.1 (C1c)  
LRMS (EI): m/z = 284 (M+·, 45), 239 (100), 213 (20), 197 (95), 170 (60), 139 (20)  
HRMS (EI): 284.1161 (M+·, C16H16N2O3 gives 284.1161) 
ethyl 2-(6-acetamido-2-pyridyl)benzoate: 
O
O
N
1
2
3
4
5
6
1a 1b 1c
1'
2'
3'
4'
5'
6'
H
N
O
6a'
6b'
6c'
 
The general procedure was applied to 2-acetamido-6-bromopyridine (102c), purifying by flash 
chromatography (3:2 DCM : Ether), to yield the ester (122c) as a yellow solid (79 mg, 60%).  
mp: 116-117 °C IR (NaCl): 3312 (N–H), 1720 (C=O, ester), 1698 (C=O, amide),  
1290 (C–O, C–N) 1H-NMR (δ, 400 MHz, CDCl3): 8.17 (1H, d, J = 8.0 Hz, H5’),  
8.00 (1H, s br, H6a’), 7.83 (1H, dd, J = 7.6 Hz, 0.8 Hz, H6), 7.76 (1H, t, J = 8.0 Hz, H4’),  
7.44-7.58 (3H, m, H3, H4, H5), 7.19 (1H, d, J = 7.6 Hz, H3’), 4.10 (2H, q, J = 7.2 Hz, H1b),  
2.16 (3H, s, H6c’), 1.03 (3H, t, J = 7.2 Hz, H1c) 13C-NMR (δ, 100 MHz, CDCl3): 168.85 (C1a),  
168.8 (C6b’), 157.5 (C2’), 150.7 (C6’), 140.4 (C2), 138.8 (C4’), 131.8 (C1), 131.3 (C4),  
130.0 (C6), 129.8 (C3), 128.6 (C5), 118.9 (C3’), 112.2 (C5’), 61.1 (C1b), 24.8 (C6c’), 14.0 (C1c)  
LRMS (EI): m/z = 284 (M+·, 35), 242 ([M–COCH2]+·, 100), 197 (100), 170 (55)  
HRMS (EI): 284.1161 (M+·, C16H16N2O3 gives 284.1161) 
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ethyl 2-(5-acetamido-3-pyridyl)benzoate: 
O
O
N
1
2
3
4
5
6
1a 1b 1c
1'
2'
3'
4'
5'
6'
H
N
O
5a'
5b'
5c'
 
The general procedure was applied to 3-acetamido-5-bromopyridine (102d), purifying by flash 
chromatography (3:2 DCM : Ether), yielding the ester (122d) as a white solid (98 mg, 74%).  
mp: 96-104 °C IR (NaCl): 3262 (N–H), 1718 (C=O, ester), 1676 (C=O, amide),  
1288 (C–O, C–N) 1H-NMR (δ, 400 MHz, CDCl3): 8.53 (1H, s, H6’), 8.27 (1H, s, H2’),  
8.15 (1H, s, H4’), 7.95 (1H, dd, J = 8.0 Hz, 1.2 Hz, H6), 7.79 (1H, s, br, H5a’),  
7.57 (1H, td, J = 7.6 Hz, 1.2 Hz, H4), 7.48 (1H, td, J = 7.6 Hz, 1.2 Hz, H5),  
7.35 (1H, dd, J = 7.6 Hz, 1.2 Hz, H3), 4.17 (2H, q, J = 7.2 Hz, H1b), 2.18 (3H, s, H5c’),  
1.12 (3H, t, J = 7.2 Hz, H1c) 13C-NMR (δ, 100 MHz, CDCl3): 169.1 (C5b’), 167.9 (C1a),  
144.4 (C2’), 139.5 (C6’), 138.8 (C2), 137.7 (C3’), 134.6 (C5’), 131.9 (C4), 131.2 (C3),  
130.8 (C1), 130.5 (C6), 128.3 (C5), 127.0 (C4’), 61.4 (C1b), 24.5 (C5c’), 14.0 (C1c)  
LRMS (EI): m/z = 284 (M+·, 80), 242 ([M–COCH2]+·, 75), 197 (100), 170 (40)  
HRMS (EI): 284.1159 (M+·, C16H16N2O3 gives 284.1161) 
ethyl 2-(6-acetamido-3-pyridyl)benzoate: 
O
O
N
1
2
3
4
5
6
1a 1b 1c
1'
5'
2'
4'
3'
6'
6a'
6b'
6c'
N
H
O
 
The general procedure was applied to 2-acetamido-5-bromopyridine (102e), purifying by flash 
chromatography (3:2 DCM : Ether), yielding the ester (122e) as a white solid (89 mg, 67%).  
mp: 95-97 °C IR (NaCl): 3247 (N–H), 1716 (C=O, ester), 1699 (C=O, amide)  
1303 (C–O, C–N) 1H-NMR (δ, 400 MHz, CDCl3): 8.38 (1H, s, br, H6a’), 
8.25 (1H, d, J = 8.4 Hz, H4’), 8.20 (1H, d, J = 2.4 Hz, H2’), 7.93 (1H, dd, J = 7.6 Hz, 1.2 Hz, H6), 
7.67 (1H, dd, J = 8.4 Hz, 2.4 Hz, H4’), 7.56 (1H, td, J = 7.6 Hz, 1.2 Hz, H4),  
7.46 (1H, td, J = 7.6 Hz, 1.2 Hz, H5), 7.33 (1H, dd, J = 7.6 Hz, 1.2 Hz, H3),  
4.15 (2H, q, J = 7.2 Hz, H1b), 2.23 (3H, s, H6c’), 1.11 (3H, t, J = 7.2 Hz, H1c)  
13C-NMR (δ, 100 MHz, CDCl3): 168.8 (C6b’), 168.0 (C1a), 150.5 (C6’), 147.0 (C2’), 138.8 (C2), 
138.5 (C4’), 133.5 (C3’), 131.7 (C4), 131.0 (C1, C3), 130.6 (C6), 128.0 (C5), 113.1 (C5’), 61.2 (C1b),  
24.9 (C6c’), 14.1 (C1c) LRMS (EI): m/z = 284 (M+·, 50), 242 ([M–COCH2]+·, 100), 197 (70)  
HRMS (EI): 284.1161 (M+·, C16H16N2O3 gives 284.1161) 
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ethyl 2-(2-acetamido-4-pyridyl)benzoate: 
O
O
N
1
2
3
4
5
6
1a 1b 1c
1'5'
4'
3'
2'
6'
H
N
O
2a'
2b'
2c'
 
The general procedure above was applied to 2-acetamido-4-bromopyridine (102f) to yield the 
desired ester (122f) as a pale yellow solid (84 mg, 64%). mp: 119-121 °C IR (NaCl): 3207 (N–H),  
1719 (C=O, ester), 1699 (C=O, amide) 1265 (C–O, C–N) 1H-NMR (δ, 400 MHz, CDCl3):  
8.44 (1H, s, br, H2a’), 8.25 (1H, d, J = 4.8 Hz, H6’), 8.21 (1H, s, H3’), 7.93 (1H, d, J = 7.6 Hz, H6),  
7.56 (1H, t, J = 7.2 Hz, H4), 7.47 (1H, t, J = 7.2 Hz, H5), 7.36 (1H, d, J = 7.6 Hz, H3)  
6.99 (1H, d, J = 4.8 Hz, H5’), 4.16 (2H, q, J = 7.2 Hz, H1b), 2.21 (3H, s, H2c’),  
1.10 (3H, t, J = 7.2 Hz, H1c) 13C-NMR (δ, 100 MHz, CDCl3): 168.7 (C2b’),  
167.6 (C1a),  152.5 (C4’), 151.4 (C2’), 147.0 (C6’), 140.3 (C2), 131.7 (C4), 130.6 (C1),  
130.5 (C3), 130.4 (C6), 128.5 (C5), 120.1 (C5’), 113.8 (C3’), 61.3 (C1b), 24.9 (C2c’), 13.9 (C1c)  
LRMS (EI): m/z = 284 (M+·, 50), 242 ([M–COCH2]+·, 75) 197 (40) 170 (100)  
HRMS (EI): 284.1161 (M+·, C16H16N2O3 gives 284.1161) 
 
General Procedure for Pyridyl Toluenes: 
Ar
Pd(PPh3)4
 
/ K2CO3
B
+ Ar Br toluene / ethanol
119
OH
OH
 
A solution of Pd(PPh3)4 (35 mg, 30.0 μmol) in toluene (10 mL) was transferred via cannula to a 
mixture of the bromopyridine or bromopyridine hydrochloride (760 μmol), 2-tolylboronic acid 119 
(110 mg, 809 μmol) and K2CO3 (210 mg, 1.52 mmol) in 95% v/v aq ethanol (5 mL). The resulting 
mixture was stirred at reflux overnight, turning brown over time. The following morning the 
reaction was allowed to cool and quenched with water (10 mL). The resulting mixture was filtered 
to remove Pd black and the volatile components were removed in vacuo. The remaining solution 
was washed with ethyl acetate (3 × 50 mL) and the combined washes were dried over anhydrous 
MgSO4. The solvent was removed in vacuo giving the crude compound, which was purified by 
flash chromatography. (Note: an extra equivalent of K2CO3 was added when the hydrochloride salt 
of the aryl bromide was used) 
  
148 
 
                                                                                                                                 Chapter 4 
 
2-(2-pyridyl)toluene 107: 
N
1
2
3
4
5
6
1a
1'
2'
3'
4'
5'
6'
 
The general procedure was applied to 2-bromopyridine (103a) to yield the desired  
product (120a) as a pale brown oil (110 mg, 86%). IR (NaCl): 1425, 1469 (C–H aliphatic), 
752 (C–H aromatic) 1H-NMR (δ, 400 MHz, CDCl3): 8.70 (1H, dm, J = 4.8 Hz, H6’),  
7.75 (1H, td, J = 7.6 Hz, 2.0 Hz, H4’), 7.39-7.42 (2H, m, H4, H5) 7.23-7.31 (4H, m, H3, H6, H3’, H5’), 
2.39 (3H, s, H1a) 13C-NMR (δ, 100 MHz, CDCl3): 160.2 (C2’), 149.4 (C6’), 140.6 (C1), 136.2 (C4’), 
135.9 (C2), 130.9 (C3), 129.8 (C5), 128.4 (C6), 126.0 (C4), 124.2 (C5’), 121.8 (C3’), 20.4 (C1a) 
2-(3-pyridyl)toluene 107: 
N
1
2
3
4
5
6
1a
1'
2'
3'
4'
5'
6'
 
The general procedure was applied to 3-bromopyridine (103b) to yield the desired product (120b) 
as a pale brown oil (74 mg, 58%). IR (NaCl): 1407, 1471 (C–H aliphatic) 717, 757 (C–H aromatic)  
1H-NMR (δ, 400 MHz, CDCl3): 8.59-8.61 (2H, m, H2’, H6’), 7.66 (1H, dt, J = 7.6 Hz, 2.0 Hz, H4’), 
7.20-7.37 (5H, m, H3, H4, H5, H6, H5’), 2.28 (3H, s, H1a) 13C-NMR (δ, 100 MHz, CDCl3):  
150.1 (C2’), 148.3 (C6’), 138.2 (C1), 137.6 (C3’), 136.6 (C4’), 135.7 (C2), 130.7 (C3), 130.0 (C5), 
128.3 (C6), 126.2 (C4), 123.1 (C5’), 20.5 (C1a) 
2-(4-pyridyl)toluene 107: 
N
1
2
3
4
5
6
1a
1'
2'
3'
4'
3'
2'  
The general procedure was applied to 4-bromopyridine-HCl (103c) to yield the desired  
product (120c) as a pale brown oil (101 mg, 79%). IR (NaCl): 1408, 1480 (C–H aliphatic)  
761, 829 (C–H aromatic) 1H-NMR (δ, 400 MHz, CDCl3): 8.64 (2H, m, H2’),  
7.18-7.34 (6H, m, H3, H4, H5, H6, H3’), 2.28 (3H, s, H1a) 13C-NMR (δ, 100 MHz, CDCl3):  
149.9 (C4’), 149.7 (C2’), 139.2 (C1), 135.1 (C2), 130.8 (C3,), 129.4 (C5), 128.5 (C6), 126.2 (C4), 
124.4 (C3’), 20.4 (C1a) 
 
149 
 
Chapter 4  
Preparation of Biaryl Acids:  
General Procedure – Ester Hydrolysis: 
O
OH
Ar
NaOH / ethanol
O
OEt
Ar  
A solution of the biaryl ester (1 eq) and NaOH (2.1 eq) in ethanol (2 mL) was stirred at reflux 
overnight, darkening over time. The following morning the reaction was allowed to cool and 
carried through one of three work-up methods: 
Method A: 
The mixture was quenched with water (5 mL) and the volatile components of the mixture were 
removed in vacuo. The remaining solution was washed with chloroform (5 mL), acidified to  
pH 4 – 5 using 2M aq HCl and washed with a 3:1 mixture of chloroform and isopropanol  
(3 × 5 mL). The combined washes were dried over anhydrous MgSO4 and the solvent was removed 
in vacuo to yield the desired acid. 
Method B: 
Acetic anhydride (1 mL) was added and the mixture was stirred for a further hour. Then, the 
mixture was quenched with water (5 mL), made basic with 2M aq NaOH and carried through the 
same extraction procedures as in Method A. 
Method C: 
The mixture was quenched with water (5 mL), neutralised to pH 7 using 2M aq HCl and the water 
and ethanol were removed in vacuo. The remaining residue was combined with acetic anhydride  
(3 mL) and stirred for a further hour at 50°C. Then, the mixture was quenched with a 1:1 mixture 
of acetone and water (5 mL), made basic with 2M aq NaOH and carried through the same 
extraction procedures as in Method A. 
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General Procedure – Permanganate Oxidation: 
O
OH
Ar
aq KMnO4
Ar  
A solution of 10% w/v aq KMnO4 (2 mL, 1.27 mmol) was added to the pyridyl toluene  
(85mg, 503 μmol) and the resulting mixture was stirred at reflux for 2 hours. A further  
2 mL of 10% w/v aq KMnO4 was added after the first hour. After this time the suspension was 
filtered to remove MnO2 and the filtrate was acidified to pH 4 – 5. The resulting solution was 
washed with a 3:1 mixture of chloroform and isopropanol (3 × 5 mL) and the combined washes 
were dried over anhydrous MgSO4. The solvent was removed in vacuo to yield the desired acid. 
2-(2-pyridyl)benzoic acid 107: 
O
OH
N
1
2
3
4
5
6
1a
1b
1'
2'
3'
4'
5'
6'
 
The general procedure for ester hydrolysis was applied to ethyl 2-(2-pyridyl)benzoate  
(118a, 100 mg, 441 μmol), applying work-up method A to yield the acid (100a) as a  
white solid (78 mg, 89%). mp 179 °C (decomposes, literature 107 202 °C)  
IR (NaCl): 1720 (C=O), 1286 (C–O) 1H-NMR (δ, 400 MHz, (CD3)2SO): 12.6 (1H, s, br, H1b),  
8.58 (1H, dm, J = 4.8 Hz, H6’), 7.85 (1H, td, J = 7.6 Hz, 1.6 Hz, H4’), 7.70 (1H, d, J = 7.6 Hz, H6), 
7.56-7.60 (3H, m, H3, H4, H3’), 7.50 (1H, ddd, J = 3.2 Hz, 5.6 Hz, 7.6 Hz, H5),  
7.33 (1H, ddd, J = 7.6 Hz, 4.8 Hz, 0.8 Hz, H5’) 13C-NMR (δ, 100 MHz, (CD3)2SO): 169.7 (C1a), 
158.0 (C2’), 148.7 (C6’), 139.9 (C2), 136.5 (C4’), 133.2 (C1), 130.5 (C4), 129.7 (C3), 128.9 (C6), 
128.2 (C5), 122.7 (C3’), 122.2 (C5’) 
The general procedure for permanganate oxidation was applied to biaryl compound 120a to yield 
the desired acid (100a) as a white solid (49 mg, 49%) with physical and spectroscopic properties 
identical to those reported above. 
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2-(3-pyridyl)benzoic acid 107: 
O
OH
N
1
2
3
4
5
6
1a
1b
1'
2'
3'
4'
5'
6'
 
The general procedure for ester hydrolysis was applied to ethyl 2-(3-pyridyl)benzoate  
(118b, 100mg, 441 μmol), applying work-up method A to yield the acid (100b) as a white solid  
(65 mg, 74%). mp 187 °C (decomposes, literature 107 150 °C) IR (NaCl): 1687 (C=O),  
1289 (C–O) 1H-NMR (δ, 400 MHz, (CD3)2SO): 12.9 (1H, s, br, H1b), 8.55 (1H, d, J = 3.6 Hz, H6’),  
8.51 (1H, s, br, H2’), 7.86 (1H, dd, J = 7.6 Hz, 1.2 Hz, H6), 7.75 (1H, dt, J = 8.0 Hz, 2.0 Hz, H4’), 
7.64 (1H, td, J = 7.6 Hz, 1.2 Hz, H4), 7.53 (1H, td, J = 7.6 Hz, 1.2 Hz, H5),  
7.41-7.46 (2H, m, H3 H5’) 13C-NMR (δ, 100 MHz, (CD3)2SO): 168.8 (C1a), 148.6 (C2’), 148.1 (C6’), 
138.2 (C2), 136.8 (C3’), 135.8 (C4’), 131.7 (C1), 131.5 (C4), 130.9 (C3), 129.8 (C6), 128.1 (C5),  
123.1 (C5’) 
The general procedure for permanganate oxidation was applied to biaryl compound 120b to yield 
the desired acid (100b) as a white solid (41 mg, 41%) with physical and spectroscopic properties 
identical to those reported above. 
2-(4-pyridyl)benzoic acid 107: 
 
The general procedure for ester hydrolysis was applied to ethyl 2-(4-pyridyl)benzoate  
(118c, 100mg, 441 μmol), applying work-up method A to yield the acid (100c) as a white solid  
(77 mg, 88%). mp 241 °C (decomposes, literature 107 180 °C) IR (NaCl): 1697 (C=O),  
1272 (C–O) 1H-NMR (δ, 400 MHz, (CD3)2SO): 12.9 (1H, s, br, H1b), 8.59 (2H, m, H2’),  
7.83 (1H, dd, J = 7.6 Hz, 0.8 Hz, H6), 7.63 (1H, td, J = 7.6 Hz, 1.2 Hz, H4), 
7.54 (1H, td, J = 7.6 Hz, 0.8 Hz, H5), 7.41 (1H, dd, J = 7.6 Hz, 0.8 Hz, H3)  
7.35 (2H, m, H3’) 13C-NMR (δ, 100 MHz, (CD3)2SO): 168.9 (C1a), 149.2 (C2’), 148.8 (C4’),  
138.8 (C2), 131.9 (C1), 131.3 (C4), 130.2 (C3), 129.6 (C6), 128.4 (C5), 123.4 (C3’) 
The general procedure for permanganate oxidation was applied to biaryl compound 120c to yield 
the desired acid (100c) as a white solid (48 mg, 48%) with physical and spectroscopic properties 
identical to those reported above. 
O
OH
N
1
2
3
4
5
6
1a 1b
1'
2'
3'
4'
3'
2'
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2-(3-acetamidophenyl)benzoic acid: 
O
OH
1
2
3
4
5
6
1a 1b
1'
2'
3'
4'
5'
6'
H
N
O
1a'
1b'
1c'
 
The general procedure for ester hydrolysis was applied to ethyl 2-(3-acetamidophenyl)benzoate  
(123a, 100 mg, 354 μmol), applying work-up method B to yield the acid (101a) as a brown solid  
(89 mg, 99%). mp 187 °C (decomposes) IR (KBr disc): 3306 (N–H) 1695 (C=O),  
1290, 1273 (C–O, C–N) 1H-NMR (δ, 400 MHz, (CD3)2SO): 12.7 (1H, s, br, H1b),  
9.99 (1H, s, H1a’), 7.71 (1H, d, J = 7.6 Hz, H6), 7.54-7.60 (3H, m, H4, H2’, H6’),  
7.45 (1H, t, J = 7.6 Hz, H5), 7.28-7.36 (2H, m, H3, H5’), 6.98 (1H, d, J = 7.6 Hz, H4’),  
2.05 (3H, s, H1c’) 13C-NMR (δ, 100 MHz, (CD3)2SO): 169.5 (C1a), 168.3 (C1b’), 141.4 (C3’),  
140.9 (C2), 139.1 (C1’), 132.3 (C1), 130.8 (C4), 130.3 (C3), 129.0 (C6), 128.4 (C5’), 127.3 (C5),  
123.0 (C4’), 118.8 (C2’), 117.6 (C6’), 24.0 (C1c’) LRMS (ESI): m/z = 278 ([M+Na]+, 100), 196 (20)  
HRMS (ESI): 278.0796 ([M+Na]+, C15H13NO3Na gives 278.0793) 
2-(4-acetamidophenyl)benzoic acid: 
O
OH
1
2
3
4
5
6
1a
1b
1'
2'
3'
4'
2'
3'
1a'
1b'
1c'
N
H
O
 
The general procedure for ester hydrolysis was applied to ethyl 2-(4-acetamidophenyl)benzoate  
(123b, 100 mg, 354 μmol), applying work-up method B to yield the acid (101b) as a brown solid  
(77 mg, 85%). mp 206 °C (decomposes) IR (KBr disc): 3315 (N–H) 1696 (C=O),  
1266 (C–O, C–N) 1H-NMR (δ, 400 MHz, (CD3)2SO): 12.7 (1H, s, br, H1b), 10.0 (1H, s, H1a’),  
7.68 (1H, dd, J = 7.6 Hz, 1.2 Hz, H6), 7.60 (2H, m, H2’), 7.54 (1H, td, J = 7.6 Hz, 1.2 Hz, H4),  
7.41 (1H, td, J = 7.6 Hz, 1.2 Hz, H5), 7.36 (1H, dd, J = 7.6 Hz, 0.8 Hz, H3), 7.25 (2H, m, H3’),  
2.06 (3H, s, H1c’) 13C-NMR (δ, 100 MHz, (CD3)2SO): 169.8 (C1a), 168.3 (C1b’), 140.5 (C2),  
138.5 (C1’), 135.3 (C4’), 132.3 (C1), 130.7 (C4), 130.3 (C3), 129.0 (C6), 128.6 (C3’), 126.9 (C5),  
118.6 (C2’), 24.0 (C1c’) LRMS (ESI): m/z = 278 ([M+Na]+, 100) HRMS (ESI): 278.0796 
([M+Na]+, C15H13NO3Na gives 278.0793) 
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2-(4-acetamido-2-pyridyl)benzoic acid: 
O
OH
N
1
2
3
4
5
6
1a
1b
1'
2'
3'
6'
5'
4'
H
N
O
4a'
4b'
4c'
 
The general procedure was applied to ethyl 2-(4-acetamido-2-pyridyl)benzoate  
(122a, 100 mg, 352 μmol), applying work-up method C to yield the acid (99a) as a green solid  
(41 mg, 45%). mp 224 °C (decomposes) IR (KBr disc): 3401 (N–H) 1699 (C=O),  
1265 (C–O, C–N) 1H-NMR (δ, 400 MHz, (CD3)2SO): 10.4 (1H, s, H4a’),  
8.37 (1H, d, J = 5.6 Hz, H6’), 7.66 (1H, s, H3’), 7.59 (1H, d, J = 7.2 Hz, H6),  
7.38-7.56 (4H, m, H3, H4, H5, H5’), 1.89 (3H, s, H4c’) 13C-NMR (δ, 100 MHz, (CD3)2SO):  
172.3 (C1a, C4b’), 159.2 (C2’), 149.4 (C6’), 145.8 (C4’), 139.0 (C2), 137.0 (C1), 129.3 (C3),  
128.9 (C4), 128.3 (C6), 127.8 (C5), 112.4 (C3’), 111.4 (C5’), 21.3 (C4c’),  
LRMS (ESI): m/z = 279 ([M+Na]+, 25), 257 ([M+H]+, 100), 239 ([M–OH]+, 90)  
HRMS (ESI): 257.0924 ([M+H]+, C14H13N2O3 gives 257.0926) 
2-(5-acetamido-2-pyridyl)benzoic acid: 
O
OH
N
1
2
3
4
5
6
1a 1b
1'
6'
3'
4'
2'
5'
5a'
5b'
5c'
N
H
O
 
The general procedure was applied to ethyl 2-(5-acetamido-2-pyridyl)benzoate  
(122b, 100 mg, 352 μmol), applying work-up method A to yield the acid (99b) as a  
brown solid (21 mg, 23%). mp 212 °C (decomposes) IR (KBr disc): 3304 (N–H),  
1682 (C=O), 1255 (C–O, C–N) 1H-NMR (δ, 400 MHz, (CD3)2SO): 12.6 (1H, s, br, H1b),  
10.2 (1H, s, H5a’), 8.71 (1H, d, J = 2.0 Hz, H6’), 8.08 (1H, dd, J = 8.4 Hz, 2.4 Hz, H4’),  
7.66 (1H, d, J = 7.6 Hz, H6), 7.52-7.58 (3H, m, H3, H4, H3’), 7.46 (1H, m, H5), 2.08 (3H, s, H5c’)  
13C-NMR (δ, 100 MHz, (CD3)2SO): 170.0 (C1a), 168.9 (C5b’), 152.2 (C2’), 139.6 (C6’), 139.3 (C2),  
134.6 (C5’), 133.2 (C1), 130.3 (C4), 129.4 (C3), 128.8 (C6), 127.8 (C5), 126.2 (C4’), 122.5 (C3’),  
23.9 (C5c’) LRMS (ESI): m/z = 279 ([M+Na]+, 95), 257 ([M+H]+, 100), 239 ([M–OH]+, 75)  
HRMS (ESI): 257.0927 ([M+H]+, C14H13N2O3 gives 257.0926) 
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2-(6-acetamido-2-pyridyl)benzoic acid: 
O
OH
N
1
2
3
4
5
6
1a 1b
1'
2'
3'
4'
5'
6'
H
N
O
6a'
6b'
6c'
 
The general procedure was applied to ethyl 2-(6-acetamido-2-pyridyl)benzoate  
(122c, 100 mg, 352 μmol), applying work-up method C to yield the acid (99c) as a  
brown solid (37 mg, 41%). mp 173 °C (decomposes) IR (KBr disc): 3269 (N–H),  
1693 (C=O), 1297 (C–O, C–N) 1H-NMR (δ, 400 MHz, (CD3)2SO): 12.5 (1H, s, br, H1b),  
10.4 (1H, s, H6a’), 8.03 (1H, d, J = 8.0 Hz, H5’), 7.74-7.82 (2H, m, H6, H4’),  
7.59 (1H, m, H4), 7.47-7.52 (2H, m, H3, H5), 7.15 (1H, d, J = 7.6 Hz, H3’), 2.07 (3H, s, H6c’)  
13C-NMR (δ, 100 MHz, (CD3)2SO): 169.3 (C6b’,C1a), 157.2 (C2’), 151.3 (C6’), 140.1 (C2),  
138.3 (C4’), 130.6 (C4), 129.9 (C3), 129.1 (C6), 128.2 (C5), 118.3 (C3’), 111.6 (C5’), 23.9 (C6c’),  
C1 absent in 13C spectrum, appears at 132.6 in HMBC LRMS (ESI): m/z = 279  
([M+Na]+, 100), 257 ([M+H]+, 25), 239 ([M–OH]+, 50) HRMS (ESI): 257.0926  
([M+H]+, C14H13N2O3 gives 257.0926) 
2-(5-acetamido-3-pyridyl)benzoic acid: 
O
OH
N
1
2
3
4
5
6
1a 1b
1'
2'
3'
4'
5'
6'
H
N
O
5a'
5b'
5c'
 
The general procedure was applied to ethyl 2-(5-acetamido-3-pyridyl)benzoate  
(122d, 100 mg, 352 μmol), applying work-up method B to yield the acid (99d) as a  
brown solid (63 mg, 70%). mp 216 °C (decomposes) IR (KBr disc): 3274 (N–H),  
1705 (C=O), 1244, 1264 (C–O, C–N) 1H-NMR (δ, 400 MHz, (CD3)2SO): 12.8 (1H, s, br, H1b),  
10.2 (1H, s, H5a’), 8.70 (1H, d, J = 2.0 Hz, H6’), 8.18 (1H, d, J = 1.6 Hz, H2’), 
8.01 (1H, s, br, H4’), 7.83 (1H, d, J = 8.0 Hz, H6), 7.63 (1H, td, J = 7.6 Hz, 1.2 Hz, H4),  
7.53 (1H, td, J = 7.6 Hz, 0.8 Hz, H5), 7.40 (1H, d, J = 7.6 Hz, H3), 2.09 (3H, s, H5c’)  
13C-NMR (δ, 100 MHz, (CD3)2SO): 169.0 (C1a), 168.8 (C5b’), 142.9 (C2’), 139.0 (C6’), 137.8 (C2), 
136.6 (C3’), 135.3 (C5’), 131.9 (C1), 131.4 (C4), 130.7 (C3), 129.7 (C6), 128.1 (C5), 125.3 (C4’),  
23.9 (C5c’) LRMS (ESI): m/z = 279 ([M+Na]+, 100), 257 ([M+H]+, 50) HRMS (ESI): 257.0926  
([M+H]+, C14H13N2O3 gives 257.0926) 
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2-(6-acetamido-3-pyridyl)benzoic acid: 
O
OH
N
1
2
3
4
5
6
1a 1b
1'
5'
2'
4'
3'
6'
6a'
6b'
6c'
N
H
O
 
The general procedure was applied to ethyl 2-(6-acetamido-3-pyridyl)benzoate  
(122e, 100 mg, 352 μmol), applying work-up method B to yield the acid (99e) as a  
white solid (42 mg, 47%). mp 257 °C (decomposes) IR (KBr disc): 3257 (N–H),  
1703 (C=O), 1254 (C–O, C–N) 1H-NMR (δ, 400 MHz, (CD3)2SO): 10.5 (1H, s, H6a’),  
8.24 (1H, d, J = 2.0 Hz, H2’), 8.08 (1H, d, J = 8.4 Hz, H5’), 7.80 (1H, dd, J = 7.6 Hz, 1.2 Hz, H6),  
7.73 (1H, dd, J = 8.4 Hz, 2.4 Hz, H4’), 7.57 (1H, td, J = 7.2 Hz, 0.8 Hz, H4),  
7.47 (1H, td, J = 7.6 Hz, 1.2 Hz, H5), 7.39 (1H, dd, J = 7.6 Hz, 0.8 Hz, H3), 2.11 (3H, s, H6c’)  
13C-NMR (δ, 100 MHz, (CD3)2SO): 169.2 (C1a, C6b’), 150.9 (C6’), 146.7 (C2’), 137.9 (C4’),  
137.5 (C2, C3’), 132.1 (C4), 130.9 (C1), 130.5 (C3), 129.6 (C6), 127.6 (C5), 112.4 (C5’), 23.9 (C6c’),  
LRMS (ESI): m/z = 279 ([M+Na]+, 100), 257 ([M+H]+, 25) HRMS (ESI): 257.0926  
([M+H]+, C14H13N2O3 gives 257.0926) 
2-(2-acetamido-4-pyridyl)benzoic acid: 
O
OH
N
1
2
3
4
5
6
1a 1b
1'5'
4'
3'
2'
6'
H
N
O
2a'
2b'
2c'
 
The general procedure was applied to ethyl 2-(2-acetamido-4-pyridyl)benzoate  
(122f, 100 mg, 352 μmol), applying work-up method B to yield the acid (99f) as a  
white solid (45 mg, 50%). mp 220 °C (decomposes) IR (KBr disc): 3228 (N–H),  
1679 (C=O), 1270 (C–O, C–N) 1H-NMR (δ, 400 MHz, (CD3)2SO): 10.5 (1H, s, H2a’), 
8.29 (1H, d, J = 5.2 Hz, H6’), 8.07 (1H, s, H3’), 7.81 (1H, dd, J = 7.6 Hz, 1.2 Hz, H6),  
7.62 (1H, td, J = 7.6 Hz, 1.2 Hz, H4), 7.53 (1H, td, J = 7.6 Hz, 1.2 Hz, H5),  
7.37 (1H, d, J = 7.6 Hz, 1.2 Hz, H3), 7.03 (1H, dd, J = 5.2 Hz, 1.6 Hz, H5’),  
2.09 (3H, s, H2c’) 13C-NMR (δ, 100 MHz, (CD3)2SO): 169.3 (C2b’), 168.8 (C1a), 152.0 (C2’),  
150.9 (C4’), 147.3 (C6’), 139.2 (C2), 132.2 (C1), 131.1 (C4), 129.9 (C3), 129.5 (C6), 128.4 (C5), 119.1 
(C5’), 112.7 (C3’), 23.9 (C2c’) LRMS (ESI): m/z = 279 ([M+Na]+, 100), 257 ([M+H]+, 25)  
HRMS (ESI): 257.0926 ([M+H]+, C14H13N2O3 gives 257.0926) 
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4.3.3: Synthesis of Azabicyclo Aryl Iodide: 
Method A: 
N
O
pyridine RT 16 h
N
HO
p-TsCl OIOH
OI
+
94107 106  
2-iodobenzoic acid (107, 650 mg, 2.62 mmol) and p-toluenesulfonyl chloride (600 mg, 3.14 mmol) 
were dissolved in pyridine (10 mL) and stirred at room temperature for 2 hours. Then, a solution of 
bicyclic alcohol 94 (500 mg, 2.56 mmol) in pyridine (10 mL) was added and the resulting mixture 
was left to stir at room temperature overnight. The following morning the solution was diluted with 
dichloromethane (50 mL) and washed with water (2 × 50 mL). The remaining solution was dried 
over anhydrous MgSO4 and the solvent was removed in vacuo, toluene (50 mL) was added to aid in 
the removal of excess pyridine. The crude product was purified by flash chromatography  
(4:1 hexane : ethyl acetate) to give the title compound (106) as a pale yellow oil (783 mg, 71%).  
N
O
1
2
3
4
5
6
7
8 9
3a
3b
1a
10OI
1'2'3'
4'
5'
6'
1a'
 
IR (NaCl): 1730 (C=O ester), 1288, 1249 (C–O, C–N) 1H-NMR (δ, 400 MHz, CDCl3):  
7.99 (1H, dd, J = 8.0 Hz, 0.8 Hz, H3’), 7.80 (1H, dd, J = 7.6 Hz, 1.6 Hz, H6’),  
7.41 (1H, td, J = 7.6 Hz, 0.8 Hz, H5’), 7.15 (1H, td, J = 7.6 Hz, 1.6 Hz, H4’), 4.78 (1H, s, H10a),  
4.55 (1H, s, H10b), 4.28 (1H, d, J = 10.8 Hz, H1a), 4.32 (1H, d, J = 10.8 Hz, H1a),  
3.15 (1H, d, J = 10.8 Hz, H2eq), 3.05 (1H, d, J = 10.4 Hz, H4eq), 2.77 (1H, m, H7ax),  
2.45 (1H, m, H5), 2.22-2.38 (3H, m, H3a, H4ax), 2.04-2.13 (2H, m, H2ax, H8eq), 1.91 (1H, m, H6eq),  
1.74 (1H, m, H6ax), 1.57 (1H, m, H8ax), 1.49 (1H, m, H7eq), 1.07 (3H, t, J = 7.2 Hz, H3b)  
13C-NMR (δ, 100 MHz, CDCl3): 166.7 (C1a’), 154.3 (C9), 141.5 (C3’), 135.3 (C1’), 132.7 (C4’), 
131.0 (C6’), 128.1 (C5’), 101.8 (C10), 94.3 (C2’), 71.6 (C1a), 63.0 (C2), 60.7 (C4), 52.3 (C3a),  
42.0 (C5), 41.1 (C1), 36.6 (C8), 34.1 (C6), 21.6 (C7), 12.8 (C3b) LRMS (EI): m/z = 425 (M+·, 15), 
410 ([M–CH3]+·, 25), 231 (20), 194 (20), 179 (25), 178 (100), 58 (20) HRMS (EI): 425.0858  
(M+·, C19H24NO2I gives 425.0852) 
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Method B: 
N
O
2. 94 / Et3N / DCM
1. (COCl)2
 
/ DMF / DCM OIOH
OI
107 106  
Oxalyl chloride (5 mL) was added to a solution of 2-iodobenzoic acid (107, 3.00 g, 12.1 mmol) and 
DMF (10 drops) in dichloromethane (100 mL) and the resulting solution was left to stir at 30 °C 
overnight. The following morning the mixture was cooled and the solvent and excess oxalyl 
chloride were removed in vacuo, toluene (50 mL) was added to aid in the removal of excess oxalyl 
chloride. The residue was placed under high vacuum for 5 hours to ensure complete removal of 
oxalyl chloride. Then, a solution of bicyclic alcohol 94 (1.00 g, 5.12 mmol) and triethylamine  
(5 mL) in dichloromethane (50 mL) was added and the resulting solution was left to stir at 30 °C 
overnight. The following morning the mixture was allowed to cool, washed with 2M aq NaOH  
(50 mL) and dried over anhydrous MgSO4. The solvent was removed in vacuo to give the crude 
product, purified by flash chromatography (4:1 hexane : ethyl acetate) to give the title  
compound (106) as a pale yellow oil (1.63 g, 75%) with spectroscopic properties identical to  
those reported for method A.  
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4.3.4: Synthesis of Azabicyclo Esters: 
General Procedure – Steglich Esterification 
N
O
DCM or DMF RT 3 d
N
HO
DCC / DMAP OArOH
OAr
+
94
 
The biaryl acid (1.5 eq) was combined with bicyclic alcohol 94 (1 eq) and DMAP (0.2 eq) and 
dissolved in dichloromethane or DMF (2 mL). DIPEA (1.5 eq) was added to help solubilise the 
acid, then a 1M solution of DCC in dichloromethane (1.5 eq) was added and the resulting mixture 
stirred at reflux for 4 days, forming a solid precipitate over time. After this time, the suspension 
was filtered and the filtrate washed first with 2 mL of saturated aq NaHCO3, followed by 5 mL of 
brine. The solution was then dried over anhydrous MgSO4 and the solvent was removed in vacuo 
giving the crude compound which was purified by flash chromatography.   
General Procedure – Suzuki Coupling 
N
O
OAr1. B2(pin)2
 
/ KOAc / Pd(dppf)Cl2
 
/ DMF
N
O
OI
2. Pd(PPh3)4
 
/ K2CO3
 
/ toluene / ethanol
BrAr
106  
A solution of iodo ester 106 (100 mg, 235 μmol) in DMF (2 mL) was added to a mixture of 
B2(pin)2 (120 mg, 473 μmol), Pd(dppf)Cl2·CH2Cl2 (20 mg, 23 μmol) and KOAc (70 mg, 714 μmol) 
and the resulting solution was stirred at 100 °C for 3 hours. Then, the mixture was cooled and 
diluted with dichloromethane (10 mL). The resulting solution was washed with water (10 mL) and 
dried over anhydrous MgSO4. The solvent was removed in vacuo and the residue was redissolved 
in ethyl acetate (1 mL). The solution was passed through a plug of silica eluting with ethyl acetate 
and the solvent was removed in vacuo. The crude material was combined with the aryl bromide  
(4 eq) and K2CO3 (25 mg, 181 μmol) and dissolved in 99% v/v aq ethanol (1 mL). A solution of 
Pd(PPh3)4 (10 mg, 8.7 μmol) in toluene (2 mL) was added and the resulting mixture was stirred at 
reflux overnight. The following morning the mixture was cooled and diluted with dichloromethane  
(10 mL). The resulting solution was washed with water (10 mL) and dried over anhydrous MgSO4. 
The solvent was removed in vacuo giving the crude compound which was purified by flash 
chromatography.  
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The general procedure for Steglich esterification was applied to 2-(2-pyridyl)benzoic acid  
(100a, 80 mg, 402 μmol) in dichloromethane to yield the ester (97a) as a pink oil (68 mg, 71%).  
IR (NaCl): 1725 (C=O ester), 1283, 1249 (C–O, C–N) 1H-NMR (δ, 400 MHz, CDCl3):  
8.65 (1H, dm, J = 4.8 Hz, H6”), 7.83 (1H, d, J = 7.6 Hz, H6’), 7.74 (1H, td, J = 7.6 Hz, 1.6 Hz, H4”), 
7.55-7.57 (2H, m, H3’, H4’), 7.45-7.50 (2H, m, H5’, H3”), 7.24 (1H, m, H5”), 4.64 (1H, s, H10a),  
4.34 (1H, s, H10b), 4.08 (1H, d, J = 10.8 Hz, H1a),  4.01 (1H, d, J = 10.8 Hz, H1a),  
2.93 (1H, d, J = 10.4 Hz, H4eq), 2.57-2.70 (2H, m, H2eq, H7ax), 2.33 (1H, m, H5),  
2.04-2.22 (3H, m, H3a, H4ax), 1.82 (1H, m, H6eq), 1.58-1.70 (3H, m, H2ax, H6ax, H8eq),  
1.33 (1H, m, H7eq), 1.22 (1H, m, H8ax), 0.97 (3H, t, J = 7.2 Hz, H3b)  
13C-NMR (δ, 100 MHz, CDCl3): 169.3 (C1a’), 158.8 (C2”), 154.4 (C9), 149.4 (C6”), 141.0 (C2’), 
136.5 (C4”), 132.0 (C1’), 131.2 (C4’), 130.0 (C3’), 129.9 (C6’), 128.5 (C5’), 122.9 (C3”), 122.2 (C5”), 
101.4 (C10), 71.3 (C1a), 62.5 (C2), 60.5 (C4), 52.1 (C3a), 41.9 (C5), 40.6 (C1), 36.2 (C8), 34.1 (C6), 
21.5 (C7), 12.7 (C3b) LRMS (EI): m/z = 376 (M+·, < 10), 200 (25), 182 (45), 177 (100),  
HRMS (EI): 376.2147 (M+·, C24H28N2O2 gives 376.2151) 
The general procedure for Suzuki coupling was applied to 2-bromopyridine  
(103a, 150 mg, 949 μmol) to yield the ester (97a) as a colourless oil (12 mg, 14%) with 
spectroscopic properties identical to those reported above. 
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The general procedure for Steglich esterification was applied to 2-(3-pyridyl)benzoic acid  
(100b, 160 mg, 804 μmol) in dichloromethane to yield the ester (97b) as a pale  
yellow oil (98 mg, 51%) IR (NaCl): 1722 (C=O, ester), 1285, 1248 (C–O, C–N)  
1H-NMR (δ, 400 MHz, CDCl3): 8.57-8.61 (2H, m, H2”, H6”), 7.95 (1H, d, J = 7.6 Hz, H6’),  
7.65 (1H, dm, J = 8.0 Hz, H4”), 7.59 (1H, t, J = 7.6 Hz, H4’), 7.49 (1H, t, J = 7.6 Hz, H5’),  
7.31-7.37 (2H, m, H3’, H5”), 4.66 (1H, s, H10a), 4.33 (1H, s, H10b), 4.09 (1H, d, J = 10.8 Hz, H1a), 
4.02 (1H, d, J = 10.8 Hz, H1a), 2.94 (1H, d, J = 10.4 Hz, H4eq), 2.59-2.73 (2H, m, H2eq, H7ax),  
2.35 (1H, s, br, H5), 2.08-2.27 (3H, m, H3a, H4ax), 1.83 (1H, m, H6eq),  
1.74 (1H, d, J = 10.4 Hz, H2ax), 1.59-1.70 (2H, m, H6ax, H8eq), 1.37 (1H, m, H7eq),  
1.25 (1H, m, H8ax), 1.00 (3H, t, J = 7.2 Hz, H3b) 13C-NMR (δ, 100 MHz, CDCl3): 168.1 (C1a’), 
154.2 (C9), 149.2 (C2”), 148.6 (C6”), 139.2 (C2’), 137.4 (C3”), 135.8 (C4”), 131.8 (C4’), 131.2 (C3’), 
130.9 (C1’), 130.7 (C6’), 128.2 (C5’), 123.1 (C5”), 101.5 (C10), 71.3 (C1a), 62.6 (C2), 60.4 (C4),  
52.1 (C3a), 41.9 (C5), 40.7 (C1), 36.2 (C8), 34.0 (C6), 21.5 (C7), 12.7 (C3b) LRMS (EI): m/z = 376 
(M+·, 20), 200 (85), 176 (100), 127 (30) HRMS (EI): 376.2153 (M+·, C24H28N2O2 gives 376.2151) 
The general procedure for Suzuki coupling was applied to 3-bromopyridine  
(103b, 150 mg, 949 μmol) to yield the ester (97b) as a colourless oil (19 mg, 22%) with 
spectroscopic properties identical to those reported above. 
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The general procedure for Steglich esterification was applied to 2-(4-pyridyl)benzoic acid  
(100c, 160 mg, 804 μmol) in dichloromethane to yield the ester (97c) as a pale  
yellow oil (109 mg, 57%) IR (NaCl): 1723 (C=O, ester), 1285, 1248 (C–O, C–N)  
1H-NMR (δ, 400 MHz, CDCl3): 8.63 (2H, m, H2”), 7.92 (1H, dd, J = 7.6 Hz, 1.2 Hz, H6’),  
7.58 (1H, td, J = 7.6 Hz, 1.2 Hz, H4’), 7.50 (1H, td, J = 7.6 Hz, 1.2 Hz, H5’),  
7.33 (1H, dd, J = 7.6 Hz, 0.8 Hz, H3’), 7.25 (2H, m, H3”), 4.65 (1H, s, H10a), 4.31 (1H, s, H10b),  
4.06 (1H, d, J = 10.8 Hz, H1a), 4.00 (1H, d, J = 10.8 Hz, H1a), 2.94 (1H, d, J = 10.4 Hz, H4eq),  
2.59-2.72 (2H, m, H2eq, H7ax), 2.34 (1H, m, H5), 2.06-2.27 (3H, m, H3a, H4ax), 1.82 (1H, m, H6eq),  
1.57-1.73 (3H, m, H2ax, H6ax, H8eq), 1.36 (1H, m, H7eq), 1.22 (1H, m, H8ax),  
1.00 (3H, t, J = 7.2 Hz, H3b) 13C-NMR (δ, 100 MHz, CDCl3): 168.2 (C1a’), 154.2 (C9), 149.7 (C2”), 
149.6 (C4”), 140.0 (C2’), 131.8 (C4’), 130.8 (C1’), 130.5 (C3’, C6’), 128.6 (C5’), 123.5 (C3”),  
101.5 (C10), 71.4 (C1a), 62.5 (C2), 60.4 (C4), 52.1 (C3a), 41.8 (C5), 40.7 (C1), 36.1 (C8), 34.0 (C6), 
21.5 (C7), 12.8 (C3b) LRMS (EI): m/z = 376 (M+·, < 10), 200 (100), 182 (35), 177 (85),  
HRMS (EI): 376.2157 (M+·, C24H28N2O2 gives 376.2151) 
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The general procedure for Steglich esterification was applied to 2-(3-acetamidophenyl)benzoic acid  
(101a, 160 mg, 627 μmol) in dichloromethane to yield the ester (98a) as a yellow oil (74 mg, 42%).  
IR (NaCl): 3307 (N–H) 1716 (C=O, ester), 1669 (C=O, amide) 1287, 1245 (C–O, C–N)  
1H-NMR (δ, 400 MHz, CDCl3): 7.83 (1H, d, J = 7.6 Hz, H6’), 7.57 (1H, d, J = 8.0 Hz, H6”),  
7.51 (1H, t, J = 7.6 Hz, H4’), 7.39-7.44 (2H, m, H2”, H5’), 7.29-7.36 (3H, m, H3’, H5”, H1a”),  
7.04 (1H, d, J = 7.6 Hz, H4”), 4.64 (1H, s, H10a), 4.32 (1H, s, H10b), 4.06 (1H, d, J = 10.8 Hz, H1a), 
3.98 (1H, d, J = 10.8 Hz, H1a), 2.93 (1H, d, J = 10.4 Hz, H4eq), 2.57-2.71 (2H, m, H2eq, H7ax),  
2.33 (1H, m, H5), 2.06-2.26 (6H, m, H3a, H4ax, H1c”), 1.82 (1H, m, H6eq),  
1.59-1.73 (3H, m, H2ax, H6ax, H8eq), 1.34 (1H, m, H7eq) 1.22 (1H, m, H8ax),  
0.99 (3H, t, J = 7.2 Hz, H3b) 13C-NMR (δ, 100 MHz, CDCl3): 169.0 (C1a’), 168.3 (C1b”),  
154.4 (C9), 142.4 (C3”), 142.0 (C2’), 138.1 (C1”), 131.4 (C4’), 131.2 (C1’), 131.0 (C3’),  
130.0 (C6’), 129.0 (C5”), 127.5 (C5’), 124.5 (C4”), 119.7 (C2”), 118.8 (C6”), 101.4 (C10),  
71.3 (C1a), 62.6 (C2), 60.4 (C4), 52.1 (C3a), 41.9 (C5), 40.7 (C1), 36.1 (C8), 34.1 (C6),  
24.8 (C1c”), 21.5 (C7), 12.7 (C3b) LRMS (EI): m/z = 432 (M+·, 15), 417 ([M–CH3]+·, 20), 281 (20),  
196 (25), 178 (100) HRMS (EI): 432.2414 (M+·, C27H32N2O3 gives 432.2413) 
The general procedure for Suzuki coupling was applied to 3-bromoacetanilide  
(104a, 200 mg, 935 μmol) to yield the ester (98a) as a colourless oil (18 mg, 18%) with 
spectroscopic properties identical to those reported above. 
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The general procedure for Steglich esterification was applied to 2-(4-acetamidophenyl)benzoic acid  
(101b, 160 mg, 627 μmol) in dichloromethane to yield the ester (98b) as a yellow  
oil (88 mg, 50%). IR (NaCl): 3306 (N–H) 1714 (C=O, ester), 1669 (C=O, amide)  
1284 (C–O, C–N) 1H-NMR (δ, 400 MHz, CDCl3): 7.81 (1H, dd, J = 7.6 Hz, 0.8 Hz, H6’),  
7.49-7.55 (3H, m, H4’, H2”), 7.43 (1H, s, br, H1a’’), 7.40 (1H, td, J = 7.6 Hz, 0.8 Hz, H5’),  
7.35 (1H, dd, J = 7.6 Hz, 0.8 Hz, H3’), 7.27 (2H, m, H3”,), 4.65 (1H, s, H10a), 4.33 (1H, s, H10b), 4.07 
(1H, d, J = 10.8 Hz, H1a), 3.99 (1H, d, J = 10.8 Hz, H1a), 2.94 (1H, d, J = 10.4 Hz, H4eq),  
2.58-2.72 (2H, m, H2eq, H7ax), 2.34 (1H, m, H5), 2.07-2.24 (6H, m, H3a, H4ax, H1c”),  
1.83 (1H, m, H6eq), 1.59-1.76 (3H, m, H2ax, H6ax, H8eq), 1.35 (1H, m, H7eq), 1.25 (1H, m, H8ax),  
1.00 (3H, t, J = 7.2 Hz, H3b) 13C-NMR (δ, 100 MHz, CDCl3): 169.3 (C1a’), 168.4 (C1b”),  
154.3 (C9), 141.9 (C1”), 137.5 (C2’), 137.3 (C4”), 131.4 (C4’), 131.2 (C1’), 130.9 (C3’),  
130.0 (C6’), 129.1 (C3”), 127.2 (C5’), 119.6 (C2”), 101.5 (C10), 71.3 (C1a), 62.6 (C2), 60.4 (C4),  
52.1 (C3a), 41.9 (C5), 40.7 (C1), 36.2 (C8), 34.1 (C6), 24.8 (C1c”), 21.5 (C7), 12.8 (C3b)  
LRMS (EI): m/z = 432 (M+·, 15), 417 ([M–CH3] +·, 25), 178 (100) HRMS (EI): 432.2411  
(M+·, C27H32N2O3 gives 432.2413) 
The general procedure for Suzuki coupling was applied to 4-bromoacetanilide  
(104a, 200 mg, 935 μmol) to yield the ester (98a) as a colourless oil (16 mg, 16%) with 
spectroscopic properties identical to those reported above.  
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The general procedure for Steglich esterification was applied to 2-(4-acetamido-2-pyridyl)benzoic 
acid (99a, 80 mg, 313 μmol) in DMF to yield the ester (96a) as a pale yellow oil (21 mg, 24%).  
IR (NaCl): 3325 (N–H) 1721 (C=O, ester) 1707 (C=O, amide) 1285, 1261 (C–O, C–N)  
1H-NMR (δ, 400 MHz, CDCl3): 8.43 (1H, d, J = 5.6 Hz, H6”), 7.92 (1H, s, br, H4a”),  
7.81 (1H, dd, J = 7.6 Hz, 0.8 Hz, H6’), 7.63 (1H, d, J = 1.6 Hz, H3”),  
7.43-7.55 (3H, m, H3’, H4’, H5’), 7.35 (1H, dd, J = 5.6 Hz, 2.0 Hz, H5”), 4.68 (1H, s, H10a),  
4.39 (1H, s, H10b), 4.12 (1H, d, J = 10.8 Hz, H1a), 4.06 (1H, d, J = 10.8 Hz, H1a),  
2.95 (1H, d, J = 10.4 Hz, H4eq), 2.77 (1H, d, J = 10.4 Hz, H2eq), 2.68 (1H, m, H7ax),  
2.36 (1H, m, H5), 2.08-2.26 (6H, m, H3a, H4ax, H4c”), 1.73-1.87 (3H, m, H2ax, H6eq, H8eq),  
1.66 (1H, m, H6ax), 1.25-1.41 (2H, m, H7eq, H8ax), 0.99 (3H, t, J = 7.2 Hz, H3b)  
13C-NMR (δ, 100 MHz, CDCl3): 169.4 (C1a’), 169.1 (C4b”), 159.7 (C2”), 154.4 (C9), 150.1 (C6”), 
145.7 (C4”), 141.0 (C2’), 131.8 (C1’), 131.3 (C4’), 130.0 (C3’), 129.8 (C6’), 128.5 (C5’), 112.5 (C3”), 
112.1 (C5”), 101.5 (C10), 71.4 (C1a), 62.7 (C2), 60.5 (C4), 52.2 (C3a), 41.9 (C5), 40.8 (C1), 36.3 (C8), 
34.1 (C6), 24.8 (C4c”), 21.5 (C7), 12.8 (C3b) LRMS (EI): m/z = 433 (M+·, < 10), 347 (50), 277 (30), 
257 (20), 229 (50), 223 (65), 211 (85), 201 (50), 177 (100), 169 (45), 168 (25), 79 (20), 69 (30),  
58 (25) HRMS (ESI): 434.2446 ([M+H]+, C26H32N3O3 gives 434.2444) 
The general procedure for Suzuki coupling was applied to 4-acetamido-2-bromopyridine  
(102a, 200 mg, 930 μmol) to yield the ester (96a) as a colourless oil (8 mg, 8%) with spectroscopic 
properties identical to those reported above.  
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The general procedure for Steglich esterification was applied to 2-(4-acetamido-2-pyridyl)benzoic 
acid (99b, 80 mg, 313 μmol) in DMF to yield the ester (96b) as a pale yellow  
oil (25 mg, 28%). IR (NaCl): 3308 (N–H) 1721 (C=O, ester) 1697 (C=O, amide)  
1285, 1250 (C–O, C–N) 1H-NMR (δ, 400 MHz, CDCl3): 8.51 (1H, d, J = 2.4 Hz, H6”),  
8.34 (1H, dd, J = 8.4 Hz, 2.4 Hz, H4”), 7.83 (1H, s, br, H5a”), 7.78 (1H, d, J = 7.6 Hz, H6’),  
7.53-7.57 (2H, m, H3’, H4’), 7.42-7.51 (2H, m, H5’, H3”), 4.65 (1H, s, H10a), 4.33 (1H, s, H10b),  
4.09 (1H, d, J = 10.8 Hz, H1a), 4.03 (1H, d, J = 10.8 Hz, H1a), 2.93 (1H, d, J = 10.4 Hz, H4eq),  
2.58-2.72 (2H, m, H2eq, H7ax), 2.34 (1H, m, H5), 2.05-2.22 (6H, m, H3a, H4ax, H5c”),  
1.82 (1H, m, H6eq), 1.58-1.74 (3H, m, H2ax, H6ax, H8eq), 1.21-1.39 (2H, m, H7eq, H8ax),  
0.97 (3H, t, J = 7.2 Hz, H3b) 13C-NMR (δ, 100 MHz, CDCl3): 170.0 (C1a’), 168.9 (C5b”),  
154.3 (C9), 153.7 (C2”), 140.4 (C6”), 140.3 (C2’), 134.1 (C5”), 132.0 (C1’), 131.2 (C4’), 129.8 (C3’), 
129.7 (C6’), 128.3 (C5’), 127.4 (C4”), 122.6 (C3”), 101.5 (C10), 71.4 (C1a), 62.6 (C2), 60.4 (C4),  
52.1 (C3a), 41.9 (C5), 40.7 (C1), 36.3 (C8), 34.1 (C6), 24.6 (C5c”), 21.5 (C7), 12.8 (C3b)  
LRMS (ESI): m/z = 456 ([M+Na]+, 20), 434 ([M+H]+, 100) HRMS (ESI): 434.2444 
([M+H]+, C26H32N3O3 gives 434.2444) 
The general procedure for Suzuki coupling was applied to 2-acetamido-5-bromopyridine  
(102b, 200 mg, 930 μmol) to yield the ester (96b) as a colourless oil (10 mg, 10%) with 
spectroscopic properties identical to those reported above. 
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The general procedure for Steglich esterification was applied to 2-(4-acetamido-2-pyridyl)benzoic 
acid (99c, 80 mg, 313 μmol) in DMF to yield the ester (96c) as a pale yellow oil (28 mg, 32%).  
IR (NaCl): 3306 (N–H) 1723 (C=O, ester) 1699 (C=O, amide) 1290, 1252 (C–O, C–N)  
1H-NMR (δ, 400 MHz, CDCl3): 8.17 (1H, d, J = 8.0 Hz, H5”), 7.97 (1H, s, br, H6a”),  
7.82 (1H, dd, J = 7.6 Hz, 0.8 Hz, H6’), 7.76 (1H, t, J = 8.0 Hz, H4”), 7.46-7.59 (3H, m, H3’, H4’, H5’), 
7.35 (1H, dd, J = 7.6 Hz, 0.4 Hz, H3”), 4.63 (1H, s, H10a), 4.31 (1H, s, H10b),  
4.04 (1H, d, J = 10.8 Hz, H1a), 3.96 (1H, d, J = 10.8 Hz, H1a), 2.92 (1H, d, J = 10.4 Hz, H4eq),  
2.56-2.69 (2H, m, H2eq, H7ax), 2.33 (1H, m, H5), 2.05-2.20 (6H, m, H3a, H4ax, H6c”),  
1.81 (1H, m, H6eq), 1.57-1.68 (3H, m, H2ax, H6ax, H8eq), 1.32 (1H, m, H7eq), 1.19 (1H, m, H8ax),  
0.97 (3H, t, J = 7.2 Hz, H3b) 13C-NMR (δ, 100 MHz, CDCl3): 169.3 (C1a’), 168.7 (C6b”),  
157.2 (C2”), 154.4 (C9), 150.9 (C6”), 140.2 (C2’), 139.0 (C4”), 131.8 (C1’), 131.3 (C4’), 130.0 (C6’), 
129.9 (C3’), 128.7 (C5’), 118.8 (C3”), 112.3 (C5”), 101.4 (C10), 71.5 (C1a), 62.6 (C2), 60.4 (C4),  
52.1 (C3a), 41.9 (C5), 40.6 (C1), 36.2 (C8), 34.0 (C6), 24.9 (C6c”), 21.4 (C7), 12.7 (C3b)  
LRMS (EI): m/z = 433 (M+·, < 10), 257 (40), 239 (20), 223 (35), 197 (45), 178 (100), 177 (85),  
176 (30), 93 (20), 79 (30), 58 (35) HRMS (EI): 433.2366 (M+·, C26H31N3O3 gives 433.2365) 
The general procedure for Suzuki coupling was applied to 2-acetamido-5-bromopyridine  
(102c, 200 mg, 930 μmol) to yield the ester (96c) as a colourless oil (19 mg, 19%) with 
spectroscopic properties identical to those reported above.  
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[3-ethyl-9-methylidene-3-azabicyclo[3.3.1]non-1-yl]methyl 2-(5-acetamido-3-pyridyl)benzoate 
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The general procedure for Suzuki coupling was applied to 3-acetamido-5-bromopyridine  
(102d, 200 mg, 930 μmol) to yield the ester (96d) as a colourless oil (11 mg, 11%).  
IR (NaCl): 3301 (N–H) 1721 (C=O, ester) 1704 (C=O, amide) 1285, 1250 (C–O, C–N)  
1H-NMR (δ, 400 MHz, CDCl3): 8.53 (1H, d, J = 2.0 Hz, H6”), 8.28 (1H, d, J = 1.6 Hz, H2”),  
8.15 (1H, m, H4”), 7.95 (1H, dd, J = 7.6 Hz, 0.8 Hz, H6’), 7.71 (1H, s, br, H5a”),  
7.58 (1H, td, J = 7.6 Hz, 1.2 Hz, H4’), 7.49 (1H, td, J = 7.6 Hz, 0.8 Hz, H5’),  
7.35 (1H, dd, J = 7.6 Hz, 0.8 Hz, H3’), 4.67 (1H, s, H10a), 4.35 (1H, s, H10b),  
4.12 (1H, d, J = 10.8 Hz, H1a), 4.05 (1H, d, J = 10.8 Hz, H1a), 2.96 (1H, d, J = 10.4 Hz, H4eq),  
2.76 (1H, d, J = 10.4 Hz, H2eq), 2.69 (1H, m, H7ax), 2.36 (1H, m, H5),  
2.08-2.29 (6H, m, H3a, H4ax, H5c”), 1.78-1.87 (2H, m, H2ax, H6eq), 1.60-1.75 (3H, m, H6ax, H8eq),  
1.24-1.43 (2H, m, H7eq, H8ax), 1.01 (3H, t, J = 7.2 Hz, H3b) 13C-NMR (δ, 100 MHz, CDCl3):  
168.8 (C5b”), 167.9 (C1a’), 154.2 (C9), 144.5 (C2”), 139.6 (C6”), 138.9 (C2’), 137.6 (C3”),  
134.6 (C5”), 131.9 (C4’), 131.4 (C3’), 130.7 (C6’), 128.4 (C5’), 126.9 (C4”), 101.6 (C10),  
71.3 (C1a), 62.7 (C2),  60.4 (C4), 52.2 (C3a), 41.9 (C5), 40.8 (C1), 36.3 (C8), 34.0 (C6),  
24.6 (C5c”), 21.5 (C7), 12.7 (C3b) LRMS (EI): m/z = 433 (M+·, 10), 297 (20), 257 (60), 197 (20), 
178 (90), 176 (100), 164 (25), 105 (20), 93 (20), 91 (35), 79 (25), 77 (20) HRMS (EI): 433.2368  
(M+·, C26H31N3O3 gives 433.2365) 
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[3-ethyl-9-methylidene-3-azabicyclo[3.3.1]non-1-yl]methyl 2-(6-acetamido-3-pyridyl)benzoate 
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The general procedure for Suzuki coupling was applied to 3-acetamido-6-bromopyridine  
(102e, 200 mg, 930 μmol) to yield the ester (96e) as a colourless oil  
(14 mg, 14%). IR (NaCl): 3245 (N–H) 1717 (C=O, ester) 1702 (C=O, amide)  
1301, 1247 (C–O, C–N) 1H-NMR (δ, 400 MHz, CDCl3): 8.20-8.29 (3H, m, H2”, H5”, H6a”),  
7.93 (1H, dd, J = 7.6 Hz, 1.2 Hz, H6’), 7.67 (1H, dd, J = 8.4 Hz, 2.4 Hz, H4”),  
7.57 (1H, td, J = 7.6 Hz, 1.2 Hz, H4’), 7.47 (1H, td, J = 7.6 Hz, 1.2 Hz, H4’),  
7.33 (1H, dd, J = 7.6 Hz, 0.8 Hz, H3’), 4.67 (1H, s, H10a), 4.34 (1H, s, H10b),  
4.10 (1H, d, J = 10.8 Hz, H1a), 4.04 (1H, d, J = 10.8 Hz, H1a), 2.95 (1H, d, J = 10.4 Hz, H4eq),  
2.61-2.74 (2H, m, H2eq, H7ax), 2.35 (1H, m, H5), 2.07-2.25 (6H, m, H3a, H4ax, H6c”),  
1.83 (1H, m, H6eq), 1.77 (1H, dd, J = 10.4 Hz, 2.0 Hz, H2ax) 1.60-1.71 (2H, m, H6ax, H8eq),  
1.37 (1H, m, H7eq), 1.28 (1H, m, H8ax), 1.01 (3H, t, J = 7.2 Hz, H3b) 
13C-NMR (δ, 100 MHz, CDCl3): 168.6 (C6b”), 168.2 (C1a’), 154.2 (C9), 150.6 (C2”),  
146.9 (C6”), 138.8 (C2’), 138.4 (C4”), 133.5 (C5”), 131.8 (C4’), 131.2 (C3’), 130.9 (C1’),  
130.7 (C6’), 128.0 (C5’), 113.3 (C3”), 101.6 (C10), 71.3 (C1a), 62.7 (C2), 60.4 (C4),  
52.1 (C3a), 41.9 (C5), 40.8 (C1), 36.3 (C8), 34.0 (C6), 24.9 (C6c”), 21.5 (C7), 12.8 (C3b)  
LRMS (EI): m/z = 433 (M+·, 20), 376 (20), 258 (25), 257 (85), 197 (20), 179 (25), 178 (100),  
176 (40), 93 (20), 79 (30), 58 (25)  HRMS (EI): 433.2363 (M+·, C26H31N3O3 gives 433.2363) 
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[3-ethyl-9-methylidene-3-azabicyclo[3.3.1]non-1-yl]methyl 2-(2-acetamido-4-pyridyl)benzoate 
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The general procedure for Suzuki coupling was applied to 2-acetamido-4-bromopyridine  
(102f, 200 mg, 930 μmol) to yield the ester (96f) as a colourless oil (22 mg, 22%).  
IR (NaCl): 3266 (N–H) 1721 (C=O, ester) 1701 (C=O, amide) 1286, 1265 (C–O, C–N)  
1H-NMR (δ, 400 MHz, CDCl3): 8.45 (1H, s, br, H2a”), 8.21-8.26 (2H, m, H3”, H6”),  
7.93 (1H, dd, J = 7.6 Hz, 0.8 Hz, H6’), 7.57 (1H, td, J = 7.6 Hz, 1.2 Hz, H4’),  
7.49 (1H, td, J = 7.6 Hz, 0.8 Hz, H5’), 7.36 (1H, dd, J = 7.6 Hz, 0.8 Hz, H3’),  
6.98 (1H, dd, J = 5.2 Hz, 1.2 Hz, H5”), 4.66 (1H, s, H10a), 4.34 (1H, s, H10b),  
4.09 (1H, d, J = 10.8 Hz, H1a), 4.02 (1H, d, J = 10.8 Hz, H1a), 2.95 (1H, d, J = 10.4 Hz, H4eq),  
2.60-2.73 (2H, m, H2eq, H7ax), 2.34 (1H, m, H5), 2.07-2.27 (6H, m, H3a, H4ax, H2c”),  
1.83 (1H, m, H6eq), 1.75 (1H, dd, J = 10.4 Hz, 1.6 Hz, H2ax), 1.59-1.70 (2H, m, H6ax, H8eq),  
1.36 (1H, m, H7eq), 1.25 (1H, m, H8ax), 1.00 (3H, t, J = 7.2 Hz, H3b) 
13C-NMR (δ, 100 MHz, CDCl3): 168.6 (C2b”), 167.9 (C1a’), 154.2 (C9), 152.3 (C4”),  
151.6 (C2”), 147.2 (C6”), 140.3 (C2’), 131.8 (C4’), 130.6 (C3’), 130.5 (C6’, C1’), 128.6 (C5’),  
120.0 (C5”), 113.7 (C3”), 101.5 (C10), 71.3 (C1a), 62.7 (C2), 60.4 (C4), 52.1 (C3a),  
41.9 (C5), 40.8 (C1), 36.2 (C8), 34.0 (C6), 24.9 (C2c”), 21.5 (C7), 12.8 (C3b)  
LRMS (EI): m/z = 433 (M+·, < 10), 258 (20), 257 (100), 197 (20), 178 (95), 176 (40), 79 (20) 
HRMS (EI): 433.2351 (M+·, C26H31N3O3 gives 433.2365) 
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[3-ethyl-9-methylidene-3-azabicyclo[3.3.1]non-1-yl]methyl 2-phenylbenzoate 
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The general procedure for Suzuki coupling was applied to bromobenzene  
(144, 150 mg, 955 μmol) to yield the ester (143) as a colourless oil (11 mg, 12%)  
IR (NaCl): 1720 (C=O, ester), 1279, 1243 (C–O, C–N) 1H-NMR (δ, 400 MHz, CDCl3):  
7.83 (1H, dd, J = 7.6 Hz, 1.2 Hz, H6’), 7.53 (1H, td, J = 7.6 Hz, 1.2 Hz, H4’),  
7.31-7.45 (7H, m, H3’, H5’, H2”, H3”, H4”), 4.63 (1H, s, H10a), 4.31 (1H, s, H10b),  
4.04 (1H, d, J = 10.8 Hz, H1a), 3.96 (1H, d, J = 10.8 Hz, H1a), 2.92 (1H, d, J = 10.4 Hz, H4eq),  
2.55-2.69 (2H, m, H2eq, H7ax), 2.33 (1H, m, H5), 2.07-2.24 (3H, m, H3a, H4ax), 1.81 (1H, m, H6eq),  
1.55-1.68 (3H, m, H2ax, H6ax, H8eq), 1.33 (1H, m, H7eq), 1.18 (1H, m, H8ax),  
1.00 (3H, t, J = 7.2 Hz, H3b) 13C-NMR (δ, 100 MHz, CDCl3): 169.3 (C1a’), 154.4 (C9),  
142.4 (C2’), 141.6 (C1”), 131.5 (C1’), 131.3 (C4’), 130.9 (C3’), 130.0 (C6’), 128.5 (C3”),  
128.4 (C2”), 127.4 (C4”), 127.3 (C5’), 101.4 (C10), 71.3 (C1a), 62.5 (C2), 60.5 (C4), 52.1 (C3a),  
41.9 (C5), 40.6 (C1), 36.1 (C8), 34.1 (C6), 21.5 (C7), 12.7 (C3b) LRMS (EI): m/z = 375 (M+·, 10), 
360 ([M–CH3]+·, 20), 194 (25), 179 (25), 178 (100), 152 (20), 79 (20), 58 (25)  
HRMS (EI): 375.2190 (M+·, C25H29NO2 gives 375.2198) 
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Appendix A: Kinetics Data 
A1: Codeinone 
Table A1: Calibration curve of the correlation between the area of  
the peak corresponding to codeinone (36) and the concentration 
Concentration 
Peak Area 
1st  2nd  3rd  Average 
1.25 μM 61784 65644 64847 64092 
2.50 μM 122975 124181 133956 127037 
5.00 μM 253188 253365 253891 253481 10.00 μM 477843 485895 511079 491606 20.00 μM 897666 939863 946870 928133 40.00 μM 1715962 1674627 1733661 1708083 
  
Figure A1: Calibration curve of the correlation between the area of  
the peak corresponding to codeinone (36) and the concentration 
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Table A2: Concentration of codeinone (36) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 25 μM 
Reaction 
Time 
Codeinone 
Peak Area Concentration 108 s 934878 21.33 μM 356 s 578631 13.20 μM 603 s 367415 8.38 μM 853 s 247934 5.66 μM 1102 s 166711 3.80 μM 1347 s 123410 2.82 μM 1596 s 81411 1.86 μM 1841 s 68435 1.56 μM 2088 s 59995 1.37 μM 2336 s 48315 1.10 μM 
  
Figure A2: Concentration of codeinone (36) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 25 μM 
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Table A3: Concentration of codeinone (36) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 25 μM 
Reaction 
Time 
Codeinone 
Peak Area Concentration 115 s 1030177 23.51 μM 365 s 629648 14.37 μM 611 s 431014 9.84 μM 858 s 287998 6.57 μM 1107 s 215692 4.92 μM 1354 s 147649 3.37 μM 1603 s 109473 2.50 μM 1853 s 84629 1.93 μM 2099 s 71737 1.64 μM 2346 s 66150 1.51 μM 
  
Figure A3: Concentration of codeinone (36) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 25 μM 
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Table A4: Concentration of codeinone (36) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 25 μM 
Reaction 
Time 
Codeinone 
Peak Area Concentration 110 s 943373 21.53 μM 358 s 589377 13.45 μM 603 s 390669 8.91 μM 849 s 271791 6.20 μM 1097 s 198851 4.54 μM 1343 s 140228 3.20 μM 1589 s 114580 2.61 μM 1838 s 98784 2.25 μM 2087 s 77970 1.78 μM 2334 s 71688 1.64 μM 
  
Figure A4: Concentration of codeinone (36) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 25 μM 
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Table A5: Concentration of codeinone (36) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 20 μM 
Reaction 
Time 
Codeinone 
Peak Area Concentration 115 s 890869 20.33 μM 365 s 546525 12.47 μM 613 s 393136 8.97 μM 861 s 274675 6.27 μM 1110 s 207026 4.72 μM 1357 s 158719 3.62 μM 1605 s 126597 2.89 μM 1854 s 105222 2.40 μM 2101 s 94513 2.16 μM 2351 s 84487 1.93 μM 
  
Figure A5: Concentration of codeinone (36) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 20 μM 
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Table A6: Concentration of codeinone (36) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 20 μM 
Reaction 
Time 
Codeinone 
Peak Area Concentration 115 s 805937 18.39 μM 365 s 543300 12.40 μM 613 s 386688 8.82 μM 861 s 293006 6.69 μM 1110 s 220237 5.03 μM 1357 s 181704 4.15 μM 1605 s 126415 2.88 μM 1854 s 110810 2.53 μM 2101 s 94119 2.15 μM 2351 s 80648 1.84 μM 
  
Figure A6: Concentration of codeinone (36) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 20 μM  
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A2: Morphinone 
Table A7: Calibration curve of the correlation between the area of  
the peak corresponding to morphinone (37) and the concentration 
Concentration 
Peak Area 
1st  2nd  3rd  Average 1.88 μM 23139 22452 21636 22409 3.75 μM 47929 44524 43954 45469 7.50 μM 92828 86823 86294 88648 15.00 μM 166847 162636 161455 163646 30.00 μM 297091 290367 289464 292307 
  
Figure A7: Calibration curve of the correlation between the area of  
the peak corresponding to morphinone (37) and the concentration 
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Table A8: Concentration of morphinone (37) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 25 μM 
Reaction 
Time 
Morphinone 
Peak Area Concentration 107 s 196343 19.45 μM 286 s 137091 13.58 μM 465 s 111970 11.09 μM 643 s 82431 8.17 μM 822 s 67957 6.73 μM 1001 s 51440 5.10 μM 1179 s 41485 4.11 μM 1357 s 33739 3.34 μM 1537 s 27259 2.70 μM 1716 s 25759 2.55 μM 
  
Figure A8: Concentration of morphinone (37) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 25 μM 
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Table A9: Concentration of morphinone (37) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 25 μM 
Reaction 
Time 
Morphinone 
Peak Area Concentration 110 s 180522 17.88 μM 289 s 130314 12.91 μM 468 s 102652 10.17 μM 646 s 75332 7.46 μM 825 s 58819 5.83 μM 1003 s 46549 4.61 μM 1182 s 36801 3.65 μM 1360 s 30137 2.99 μM 1539 s 25989 2.57 μM 1717 s 20761 2.06 μM 
  
Figure A9: Concentration of morphinone (37) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 25 μM 
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Table A10: Concentration of morphinone (37) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 25 μM 
Reaction 
Time 
Morphinone 
Peak Area Concentration 126 s 182410 18.07 μM 305 s 136492 13.52 μM 484 s 107178 10.62 μM 664 s 78377 7.76 μM 843 s 63167 6.26 μM 1022 s 49041 4.86 μM 1200 s 37087 3.67 μM 1380 s 31997 3.17 μM 1559 s 27145 2.69 μM 1737 s 24686 2.45 μM 
  
Figure A10: Concentration of morphinone (37) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 25 μM 
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Table A11: Concentration of morphinone (37) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 20 μM 
Reaction 
Time 
Morphinone 
Peak Area Concentration 106 s 157395 15.59 μM 286 s 118273 11.72 μM 465 s 96082 9.52 μM 644 s 77124 7.64 μM 823 s 60075 5.95 μM 1002 s 49269 4.88 μM 1181 s 39566 3.92 μM 1359 s 31412 3.11 μM 1538 s 26302 2.61 μM 1717 s 22846 2.26 μM 
  
Figure A11: Concentration of morphinone (37) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 20 μM 
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Table A12: Concentration of morphinone (37) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 20 μM 
Reaction 
Time 
Morphinone 
Peak Area Concentration 107 s 167054 16.55 μM 285 s 130702 12.95 μM 464 s 101927 10.10 μM 643 s 78116 7.74 μM 823 s 66443 6.58 μM 1001 s 54555 5.40 μM 1180 s 40419 4.00 μM 1358 s 35889 3.56 μM 1537 s 31298 3.10 μM 1715 s 27050 2.68 μM 
  
Figure A12: Concentration of morphinone (37) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 20 μM 
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A3: Narwedine 
Table A13: Concentration of narwedine (30) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 10 mM 
Reaction 
Time 
Narwedine 
Integral (Total H12α) Concentration 600 s 1.31 7.63 mM 1140 s 1.45 6.90 mM 2280 s 1.93 5.18 mM 2880 s 2.23 4.48 mM 3480 s 2.44 4.09 mM 4080 s 2.77 3.61 mM 4680 s 3.22 3.10 mM 5280 s 3.80 2.63 mM 5880 s 4.44 2.25 mM 6480 s 5.04 1.98 mM 7080 s 5.61 1.78 mM 7680 s 6.55 1.53 mM 8280 s 7.50 1.33 mM 8880 s 8.58 1.17 mM 
  
Figure A13: Concentration of narwedine (30) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 10 mM 
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Table A14: Concentration of narwedine (30) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 10 mM 
Reaction 
Time 
Narwedine 
Integral (Total H12α) Concentration 600 s 1.13 8.58 mM 1440 s 1.38 7.03 mM 2400 s 1.73 5.61 mM 3540 s 2.09 4.64 mM 4140 s 2.63 3.69 mM 5040 s 3.18 3.05 mM 5940 s 3.91 2.48 mM 6840 s 4.71 2.06 mM 7740 s 5.61 1.73 mM 8580 s 6.86 1.41 mM 
  
Figure A14: Concentration of narwedine (30) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 10 mM 
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Table A15: Concentration of narwedine (30) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 10 mM 
Reaction 
Time 
Narwedine 
Integral (Total H12α) Concentration 420 s 1.33 7.52 mM 900 s 1.52 6.58 mM 1500 s 1.70 5.88 mM 2100 s 1.99 5.03 mM 2700 s 2.28 4.39 mM 3300 s 2.60 3.85 mM 3900 s 2.98 3.36 mM 4500 s 3.37 2.97 mM 5100 s 3.95 2.53 mM 5700 s 4.58 2.18 mM 6300 s 4.99 2.00 mM 6900 s 5.99 1.67 mM 
  
Figure A15: Concentration of narwedine (30) over time during the reaction with  
N-acetyl-L-cysteine methyl ester (66) with a starting concentration of 10 mM
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Appendix B: Selected NMR Spectra 
B1: Codeinone – N-acetyl-L-cysteine methyl ester adduct (71) 
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B2: Narwedine – N-acetyl-L-cysteine methyl ester adducts (73a and 73b) 
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* Denotes cross-peaks arising from traces of the other adduct (73a) in the sample 
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B3: Azabicyclo Aryl Iodide (106) 
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